rnai agents and compositions for inhibiting the expression of angiopoietin type 3 (angptl3), and met

专利摘要:
The present invention relates to RNAi agents, for example, double-stranded RNAi agents, capable of inhibiting the expression of the type 3 angiopoietin gene (also called ANGPTL3, ANGPL3, type 3 angiopoietin protein), and compositions that include agents of ANGPTL3 RNAi. Methods of using ANGPTL3 RNAi agents and compositions are also described. The ANG-PTL3 RNAi agents described here can be conjugated to the targeting ligands to facilitate delivery to cells, including hepatocytes. Pharmaceutical compositions that include one or more ANGPTL3 RNAi agents, optionally with one or more additional therapies, are described. The release of AN-GTL3 RNAi agents in vivo provides inhibition of ANGPTL3 gene expression, and may result in lower triglyceride and / or cholesterol levels in the individual. RNAi agents can be used in methods of treating ANGPTL3-related diseases and disorders, including cardiometabolic diseases such as hypertriglyceridemia and hyperlipidemia.
公开号:BR112020003126A2
申请号:R112020003126-7
申请日:2018-09-13
公开日:2020-10-13
发明作者:Zhen Li；Rui Zhu；So Wong
申请人:Arrowhead Pharmaceuticals, Inc.；
IPC主号:

专利说明:

[0001] [0001] This application claims priority for United States Provisional Patent Application serial number 62 / 694,976, filed on July 7, 2018, United States Provisional Patent Application serial number 62 / 651,284, filed on April 2 of 2018, United States Provisional Patent Application Serial Number 62 / 583,919, filed on November 9, 2017, and United States Provisional Patent Application Serial Number 62 / 558,819, filed on September 14, 2017, the contents of which are incorporated herein by reference in their entirety. SEQUENCE LISTING
[0002] [0002] This request contains a Sequence Listing that was sent in ASCII format and is hereby incorporated by reference in its entirety. The ASCII copy is called 30658 SequencelListing and is 111 kb in size. FIELD OF THE INVENTION
[0003] [0003] The present invention relates to RNA interference agents (RNAi), for example, double-stranded RNAi agents, for inhibiting angiopoietin type 3 gene expression, compositions that include angiopoietin type 3 RNAi agents, and methods of using them. BACKGROUND
[0004] [0004] Angiopoietin type 3 (also called ANGPTL3, ANGPL3, ANG3, or type 3 angiopoietin protein) is an angiopoietin protein encoded by the type 3 angioietin gene that is reported to be involved in the regulation of lipid metabolism. ANGPTL3 is a 460 amino acid polypeptide that consists of a signal peptide,
[0005] [0005] An effective therapeutic targeting ANGPTL3 would provide a beneficial impact on the treatment (including prophylactic treatment) of cardiometabolic diseases such as hypertriglyceridemia, obesity, hyperlipidemia, abnormal cholesterol and / or lipid metabolism, atherosclerosis, type II diabetes mellitus, cardiovascular disease, coronary artery disease, non-alcoholic steatohepatitis, non-alcoholic fatty liver disease, homozygous and heterozygous familial hypercholesterolemia, statin-resistant hypercholesterolemia and other related metabolic disorders and diseases. While certain double-stranded RNA-based compounds have been identified as being able to inhibit the expression of an ANGPTL3 gene (see, for example, International Patent Application Publications No. * WO 2012/177784, WO 2016/168286, and WO 2016 / 154127), the ANGPTL3 RNAi agents described herein have not been previously described or known, and provide specific inhibition of ANGPTL3 highly potent and highly efficient expression of an ANGTPL3 gene. SUMMARY
[0006] [0006] There is a need for new ANGPTL3-specific RNA interference agents (RNAi) (also called here RNAi agent, RNAi trigger, or trigger), for example, double-stranded RNAi agents, which are capable of selective and efficiently inhibit the expression of an ANGPTL3 gene. In addition, there is a need for compositions that include new ANGPTL3-specific RNAi agents for the treatment of diseases associated with, among other things, high triglyceride (TG) levels.
[0007] [0007] In general, the present invention features ANGPTL3 gene-specific RNAi agents, compositions that include ANGPTL3 RNAi agents, and methods for inhibiting expression of an ANGPTL3 gene in vitro and / or in vivo using RNAi agents from ANGPTL3 and compositions that include ANGPTL3 RNAi agents described here. The ANGPTL3 RNAi agents described herein can selectively and efficiently decrease or inhibit the expression of an ANGPTLS3 gene, and thereby reduce the levels of TG and / or cholesterol levels in an individual, for example, a human or animal individual.
[0008] [0008] The ANGPTL3 RNAi agents described can be used in methods for therapeutic treatment (including prophylactic and preventive treatment) of symptoms and diseases associated with elevated TG levels and / or elevated cholesterol levels, including, but not limited to hypertriglyceridemia, obesity, hyperlipidemia, cholesterol metabolism | and / or abnormal lipid, atherosclerosis, type 1 diabetes mellitus, cardiovascular disease, coronary artery disease, non-alcoholic steatohepatitis, non-alcoholic fatty liver disease, hypercholesterolemia - familial - homozygous = e - heterozygous, statin-resistant hypercholesterolemia and other disorders and related metabolic diseases. The ANGPTL3 RNAi agents described here can selectively reduce the expression of the ANGPTL3 gene, which can induce a reduction, among other things, in TG levels and / or cholesterol levels, in an individual. The methods described herein include administering one or more ANGPTL3 RNAi agents to an individual, for example, a human or animal individual, using any suitable methods known in the art, such as subcutaneous injection or intravenous administration.
[0009] [0009] In one aspect, the invention features RNAi agents for inhibiting expression of the human ANGPTL3 gene, wherein the RNAi agent includes a sense strand and an antisense strand. Also described here are compositions that include or consist of an RNAi agent capable of inhibiting the expression of an ANGPTL3 gene, wherein the RNAi agent includes or consists of a sense strand and an antisense strand, and the composition also comprises at least one pharmaceutically acceptable excipient. The compositions described herein that include one or more of the described ANGPTL3 RNAi agents are capable of selectively and efficiently decreasing expression of an ANGPTL3 gene. Compositions that include one or more ANGPTL3 RNAi agents can be administered to an individual, such as a human or animal individual, for the treatment (including prophylactic treatment or inhibition) of symptoms and diseases associated with high TG, chlorester | elevated, and / or enhanced ANGPTL3 expression.
[0010] [0010] An ANGPTL3 RNAi agent described here includes a sense tape (also referred to as a passing tape), and an antisense tape (also referred to as a guide tape). The sense tape and the antisense tape can be partially, substantially, or totally complementary to each other. The length of the RNAi agent sense and antisensor strips described here each can be 16 to 30 nucleotides in length. In some embodiments, the sense and antisense strips are independently 17 to 26 nucleotides in length. Sense and antisense tapes can be of equal length or different length. In some embodiments, the sense and antisense strips are independently 21 to 26 nucleotides in length. In some embodiments, the sense or antisense strips are independently 21 to 24 nucleotides in length. In some embodiments, both the sense tape and the antisense tape are 21 nucleotides in length. In some embodiments, the sense and / or antisense strips are independently 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides in length. The RNAi agents described here, upon release to a cell expressing ANGPTL3, inhibit the expression of one or more ANGPTLS3 genes in vivo or in vitro.
[0011] [0011] A sense strand of the ANGTL3 RNAi agents described here includes at least 16 consecutive nucleotides that have at least 85% identity to a nucleus elongation sequence (also referred to herein as a "nucleus elongation" or "nucleus sequence" ) of the same number of nucleotides in an ANGPLT3 mRNA. In some embodiments, this sense strand core length is 16, 17, 18, 19, 20, 21, 22, or 23 nucleotides in length. In some embodiments, this sense strand core length is 17 nucleotides in length. In some embodiments, this sense strand core length is 19 nucleotides in length.
[0012] [0012] An antisense strand of an ANGPTL3 RNAi agent described here includes at least 16 consecutive nucleotides that have at least 85% complementarity to a core elongation of the same number of nucleotides in an ANGPLT3 mRNA and to a core elongation of the same number of nucleotides in the corresponding sense strand. In some embodiments, this antisense tape core elongation is 16, 17, 18, 19, 20, 21, 22, or 23 nucleotides in length. In some embodiments, this antisense tape core elongation is 19 nucleotides in length. In some embodiments, this antisense tape core length is 17 nucleotides in length
[0013] [0013] In some embodiments, the ANGPTL3 RNAi agents described here target the portion of an ANGPTL3 gene having the sequence of any of the sequences described in Table 1.
[0014] [0014] Examples of ANGPTL3 RNAi agent sense tapes and antisense tapes that can be included in the ANGPTL3 RNAi agents described here are provided in Table 3 and Table 4. Examples of ANGPTL3 RNAi agent duplicates are provided in the Table 5. Examples of 19-nucleotide core elongation sequences that consist of or are included in the sense strips and antisense strands of ANGPTL3 RNAi agents described here, are provided in Table 2.
[0015] [0015] In another aspect, the invention features methods for delivering ANGPTL3 RNAi agents to liver cells in an individual, such as a mammal, in vivo. Compositions for use in such methods are also described here. The one or more ANGPTL3 RNAi agents can be released to target cells or tissues using any oligonucleotide delivery technology known in the art. Methods of nucleic acid release include, but are not limited to, by encapsulation in liposomes, by iontophoresis, or by incorporation into other vehicles, such as hydrogels, cyclodextrins, - nanocapsules - biodegradable, and bioadhesive microspheres, proteinaceous vectors, or Dynamic Polyconjugates '"Y (DPCs) (see, for example, WO 2000/053722, WO 2008/0022309, WO 2011/104169, and WO 2012/083185, each of which is incorporated herein by reference).
[0016] [0016] In some embodiments, an ANGPTL3 RNAi agent is released to target cells or tissues covalently linking or conjugating the RNAi agent to a targeting group, such as an asialoglycoprotein receptor ligand (i.e., a ligand that includes a compound that has an affinity for the receptor for an asymoglycoprotein). In some embodiments, an asialoglycoprotein receptor ligand includes, consists of, or consists essentially of, a galactose or cluster derived from galactose. In some embodiments, an ANGPTL3 RNAi agent is linked to a targeting linker that comprises the galactose derivative N-acetyl-galactosamine. In some embodiments, a galactose-derived cluster includes an N-acetyl-galactosamine trimer or an N-acetyl-galactosamine tetramer. In some embodiments, a galactose-derived cluster is an N-acetyl-galactosamine trimer or an N-acetyl-galactosamine tetramer. In some embodiments, ANGPTL3 RNAi agents that are conjugated to targeting ligands that include N-acetyl-galactosamine are selectively internalized by liver cells, and hepatocytes in particular, or via receptor-mediated endocytosis or by other means. Examples of targeting groups useful for releasing RNAi agents are described, for example, in International Patent Application Publications No. WO 2018/044350 and WO 2017/156012, which are incorporated by reference in their entirety.
[0017] [0017] A targeting group can be attached to the 3 'or 5' end of a sense strand or an antisense strand of an ANGPTL3 RNAi agent. In some embodiments, a targeting group is attached to the 3 'or 5' end of the sense tape. In some embodiments, a targeting group is attached to the end of the sense tape. In some embodiments, a targeting group is internally linked to a nucleotide on the sense strand and / or the antisense strand of the RNAi agent. In some embodiments, a targeting group is linked to the RNAi agent via a linker.
[0018] [0018] A targeting group, with or without a linker, can be attached to the 5 'or 3' end of any of the sense and / or antisense tapes described in tables 2, 3, and 4. A linker, with or without a targeting group, can be attached to the 5 'or 3' end of any of the sense and / or antisense tapes described in tables 2, 3.04.
[0019] [0019] In some embodiments, described here are compositions that include one or more ANGPTL3 RNAi agents that have the duplicate structures described in Table 5.
[0020] [0020] In another aspect, pharmaceutical compositions are described here that include one or more described ANGPTL3 RNAi agents, optionally combined with one or more additional therapeutics (i.e., second, third, etc.). In some embodiments, pharmaceutical compositions that include one or more described ANGPTL3 RNAi agents, optionally combined with one or more additional therapeutics (i.e., second, third, etc.), can be formulated in a pharmaceutically acceptable carrier or diluent. In some embodiments, these compositions can be administered to an individual, such as a mammal. In some embodiments, the mammal is a human.
[0021] [0021] In some embodiments, compositions are described here that include a combination or cocktail of at least two ANGPTL3 RNAi agents having different nucleotide sequences. In some embodiments, the two or more different ANGPTL3 RNAi agents are each separately and independently linked to targeting groups. In some embodiments, the two or more different ANGPTL3 RNAi agents are each linked to targeting groups that include or consist of targeting ligands that include one or more portions that target the asialoglycoprotein receptor. In some embodiments, the two or more different ANGPTL3 RNAi agents are each linked to targeting groups that include or consist of targeting ligands that include one or more galactose-derivatives. In some embodiments, the two or more different ANGPTL3 RNAi agents are each linked to targeting groups that include or consist of targeting linkers that include one or more N-acetyl-galactosamines.
[0022] [0022] In another aspect, the invention provides methods for inhibiting expression of an ANGPTL3 gene, wherein the methods include administering to an individual or a cell of an individual an amount of an ANGPTL3 RNAi agent capable of inhibiting expression of an ANGPTL3 gene, where the ANGPTL3 RNAi agent comprises a sense strand and an antisense strand, and where the antisense strand includes the sequence of any of the antisense strand nucleotide sequences in Table 2 or Table 3. In some embodiments, methods of inhibiting expression of an ANGPTL3 gene are described herein, wherein the methods include administering to an individual or a cell an amount of an ANGPTL3 RNAi agent capable of inhibiting the expression of an ANGPTL3 gene, wherein the ANGPTL3 RNAi agent comprises a sense strand and an antisense strand, wherein the sense strand includes the sequence of any of the sense strand nucleotide sequences in Tables 2 or 4. Also described here are compositions. for use in such methods.
[0023] [0023] In another aspect, the invention features methods of treatment (including preventive or prophylactic treatment) of diseases or symptoms caused by elevated TG levels and / or elevated cholesterol levels, wherein the methods include administering to an individual in need there is an ANGPTL3 RNAi agent having an antisense tape that includes the sequence of any of the sequences in tables 2 or 3. In some embodiments, treatment methods (including preventive treatment) are described here
[0024] [0024] Also described are methods of treating a human individual having a pathological state (such as a condition or disease), or being at risk of developing a pathological state, which is mediated at least in part by the expression of the ANGPTL3 gene , the methods comprising the step of administering to the individual a therapeutically effective amount of an ANGPTL3 RNAi agent and / or composition containing ANGPTL3 RNAi agent. The method of treating an individual with an ANGPTL3 RNAi agent and / or composition containing ANGPTL3 RNAi agent can optionally be combined with one or more steps of administering one or more additional therapies (i.e., second, third, etc. .) or treatments. An additional therapy may be another ANGPTL3 RNAi agent (for example, an ANGPTL3 RNAi agent that targets a different sequence within the ANGPTL3 gene). An additional therapeutic can also be a small molecule drug, antibody, antibody fragment, and / or aptamer. In some embodiments, the one or more additional therapies is a statin, such as atorvastatin, fluvastatin, pravastatin, pitavastatin, rosuvastatin, or simvastatin.
[0025] [0025] In some embodiments, the ANGPTL3 RNAi agents described are optionally combined with one or more additional therapies. The ANGPTL3 RNAi agent and additional therapeutic (s) can be administered in a simple composition or they can be administered separately. In some embodiments, the one or more additional therapies are administered separately in dosage forms separate from the RNAi agent (for example, the ANGPTL3 RNAi agent is administered by subcutaneous injection, while the additional therapy involved in the dosing regimen method treatment is administered orally). In some embodiments, the described ANGPTL3 RNAi agents are administered to an individual in need of them via subcutaneous injection, and the one or more additional optional therapies are administered orally, which together provide for a treatment regimen for diseases and conditions associated with elevated TG and / or cholesterol levels. In some embodiments, the described ANGPTL3 RNAi agents are administered to an individual in need thereof by means of subcutaneous injection, and the one or more additional optional therapies are administered by means of a separate subcutaneous injection. In some embodiments, the ANGPTL3 RNAi agent and one or more additional therapies are combined in a single dosage form (for example, a "cocktail" formulated into a single composition for subcutaneous injection). ANGPTL3 RNAi agents, with or without the one or more additional therapies, can be combined with one or more excipients to form pharmaceutical compositions.
[0026] [0026] In some embodiments, methods for inhibiting expression of an ANGPTL3 gene in a cell or an individual are described herein, wherein the methods include administering to the cell or individual an ANGPTL3 RNAi agent having a sense strand comprising the sequence of any of the sequences in Table 4, and an antisense tape comprising the sequence of any of the sequences in Table 3.
[0027] [0027] In some embodiments, compositions for releasing an ANGPTL3 RNAi agent to a liver cell,
[0028] [0028] In some embodiments, methods for inhibiting expression of an ANGPTL3 gene in a cell are described here, methods comprising administering one or more ANGPTL3 RNAi agents having the duplex structure of a duplex mentioned in Table 5.
[0029] [0029] In some embodiments, methods of treatment (including prophylactic or preventive treatment) for diseases, disorders or symptoms caused by high TG levels and / or high cholesterol levels are described here, in which the methods include administering to an individual in they need a therapeutically effective amount of an ANGPTL3 RNAi agent that includes an antisense strand that is at least partially complementary to the portion of the ANGPTL3 mMRNA having the sequence in Table 1. In some embodiments, treatment methods (including prophylactic or preventive treatment) of diseases or symptoms caused by elevated TG levels and / or elevated cholesterol levels, wherein the methods include administering to a subject in need of them a therapeutically effective amount of an ANGPTL3 RNAi agent that includes a antisense tape that comprises the sequence of any of the sequences in tables 2 or 3, and a sense tape that c it does not include any of the strings in tables 2 or 4 that are at least partially complementary to the antisense tape. In some embodiments, methods of treatment (including prophylactic or preventive treatment) for diseases or symptoms caused by elevated TG levels and / or elevated cholesterol levels are described here, in which the methods include administering to an individual in need of them a quantity therapeutically effective effect of an ANGPTL3 RNAi agent which includes a sense strand comprising any of the sequences in tables 2 or 4, and an antisense strand comprising the sequence of any of the sequences in tables 2 or 3 which is at least partially complementary to the sense tape.
[0030] [0030] In some embodiments, methods for inhibiting expression of an ANGPTL3 gene in a cell are described here, wherein the methods include administering to the cell an ANGPTL3 RNAi agent that includes an antisense strip that is at least partially complementary to the portion of the ANGPTL3 MRNA having the sequence in Table 1. In some embodiments, methods of inhibiting expression of an ANGPTL3 gene in a cell are described here, wherein the methods include administering to a cell an ANGPTL3 RNAi agent that includes a strand antisense which comprises the sequence of any of the sequences in tables 2 or 3, and a sense tape comprising any of the sequences in tables 2 or 4 which is at least partially complementary to the antisense tape. In some embodiments, methods of inhibiting expression of an ANGPTL3 gene in a cell are described here, wherein the methods include administering an ANGPTL3 RNAi agent that includes a sense strand comprising any of the sequences in Tables 2 or 4, and an antisense tape that includes the sequence of any of the sequences in tables 2 or 3 that is at least partially complementary to the sense tape.
[0031] [0031] In some embodiments, compositions for inhibiting the expression of an ANGPTL3 gene in a cell are described here, wherein the methods include administering a composition comprising an ANGPTL3 RNAi agent having the duplex structure of a duplex mentioned in Table 5 .
[0032] [0032] In some embodiments, compositions for delivering an ANGPTL3 RNAi agent to a liver cell in vivo are described here, the composition including an ANGPTL3 RNAi agent conjugated or linked to a targeting group. In some embodiments, the targeting group is an asialoglycoprotein receptor ligand. In some embodiments, compositions for releasing an ANGPTL3 RNAi agent to a liver cell in vivo are described, the composition including an ANGPTL3 RNAi agent attached to an N-acetyl-galactosamine targeting ligand.
[0033] [0033] ANGPTL3 RNAi agents are described herein designed to target specific positions in an ANGPTL3 gene (SEQ ID NO: 1). As defined here, an antisense strand sequence is designed to target an ANGPTL3 gene at a given position in the gene when the 5 'terminal nucleobase of the antisense strand is aligned with a position that is 19 nucleotides downstream (towards the 3' end ) of the position in the gene when pairing the base to the gene. For example, as illustrated in Tables 1 and 2 here, an antisense strand sequence designed to target an ANGPTL3 gene at position 304 requires that when pairing the base to the gene, the 5 'terminal nucleobase of the antisense tape is aligned with position 322 of the ANGPTL3 gene.
[0034] [0034] As provided here, an ANGPTL3 RNAi agent does not require that the nucleobase at position 1 (5 '> 3') of the antisense strand be complementary to the gene, as long as there is at least 85% complementarity (for example, by minus 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% complementarity) of the antisense tape and the gene through a core stretch sequence of at least 16 consecutive nucleotides. For example, for an ANGPTL3 RNAi agent described here that is designed to target the position 304 of an ANGPTL3 gene, the terminal nucleobase
[0035] [0035] The use of ANGPTL3 RNAi agents provides methods for therapeutic treatment (including prophylactic) of diseases / disorders associated with elevated TG and / or cholesterol levels and / or enhanced or elevated ANGPTL3 expression. The ANGPTL3 RNAi agents described mediate RNA interference to inhibit the expression of one or more genes necessary for the production of ANGPTL3. ANGPTL3 RNAi agents can also be used to treat or prevent various diseases or disorders, including hypertriglyceridemia, obesity, hyperlipidemia, abnormal cholesterol and / or lipid metabolism, atherosclerosis, diabetes, cardiovascular disease, coronary artery disease, and other disorders and related metabolic diseases. In addition, compositions for releasing ANGPTL3 RNAi agents to liver cells in vivo are described
[0036] [0036] Pharmaceutical compositions including one or more ANGPTL3 RNAi agents can be administered in a variety of ways depending on whether local or systemic treatment is desired. Administration can be, but is not limited to, intravenous, intraarterial, subcutaneous, intraperitoneal, subdermal (for example, by means of an implanted device) and intraparenchymal administration. In some embodiments, the pharmaceutical compositions are described here, administered by subcutaneous injection.
[0037] [0037] In some embodiments, compositions for releasing an ANGPTL3 RNAi agent to a liver cell in vivo are described here, wherein the composition includes an ANGPTL3 RNAi agent conjugated or linked to a targeting group. In some embodiments, the targeting group is an asialoglycoprotein receptor ligand. In some embodiments, compositions for delivering an ANGPTL3 RNAi agent to a liver cell in vivo are described, wherein the composition includes an ANGPTL3 RNAi agent attached to a targeting linker that includes N-acetyl-galactosamine.
[0038] [0038] In some embodiments, the ANGPTL3 RNAi agents described here may include one or more targeting groups having the structure of (NAG25), (NAG25) s, (NAG26), (NAG26) s, (NAG27), ( NAG27) s, (NAG28), (NAG28) s, (NAG29), (NAG29) s, (NAG30), (NAG30) s, (NAG31), (NAG31) s, (NAG32), (NAG32) s, ( NAG33), (NAG33) s, (NAG34), (NAG34) s, (NAG35), (NAG35) s, (NAG36), (NAG36) s, (NAG37), (NAG37) s, (NAG38), (NAG38) ) s, (NAG39), (NAG39) s, each as defined here in Table 6.
[0039] [0039] In some embodiments, the ANGPTL3 RNAi agents described here include a targeting group at the 5 'end of the sense strand having the structure of (NAG25), (NAG25) s, (NAG26), (NAG26) s, ( NAG27), (NAG27) s, (NAG28), (NAG28) s, (NAG29), (NAG29) s, (NAG30), (NAG30) s, (NAG31), (NAG31) s, (NAG32), (NAG32) ) s, (NAG33), (NAG33) s, (NAG34), (NAG34) s, (NAG35),
[0040] The described ANGPTL3 RNAi agents and / or compositions that include ANGPTL3 RNAi agents can be used in methods for the therapeutic treatment of diseases or conditions caused by elevated TG and / or cholesterol levels. Such methods include administering an ANGPTL3 RNAi agent as described herein to an individual, for example, a human or animal individual.
[0041] [0041] In some embodiments, an ANGPTL3 RNAi agent described here includes an antisense strip that consists of, consists essentially of, or comprises a nucleobase sequence differing in O or 1 nucleobase from the nucleotide sequence (5 '> 3') UACUGAUCAAAUAUGUUGAGC (SEQ ID NO: 3) In some embodiments, an ANGPTL3 RNAi agent described here includes an antisense strand that consists of, consists essentially of, or comprises a nucleotide sequence differing by no more than 1 nucleotide from the nucleotide sequence (5 '> 3) UACUGAUCAAAUAUGUUGAGC (SEQ ID NO: 3), where all or substantially all nucleotides are modified nucleotides. In some embodiments, an ANGPTL3 RNAi agent described herein includes an antisense strand that consists of, consists essentially of, or comprises a nucleobase sequence differing in O or 1 nucleobase from the nucleotide sequence (5 '> 3') UACUGAUCAAAUAUGUUGAGC (SEQ ID NO: 3), where SEQ ID NO: 3 is located in positions 1 to 21 (5 '> 3') of the antisense tape.
[0042] [0042] In some embodiments, an ANGPTL3 RNAi agent described here includes an antisense strip that consists of, consists essentially of, or comprises a modified nucleotide sequence differing by no more than 1 nucleotide from the nucleotide sequence (5 '> 3 ') usAfscsUfgAfuCfaAfaUfaUfgUufuGfaGfsc (SEQ ID NO: 2), where a, c, 9, eu represent 2'-O-methyl adenosine, cytidine, guanosine, or uridine, respectively; Af, Cf, Gf, and Uf represent 2 "- fluorine adenosine, cytidine, guanosine, or uridine, respectively; es represent a phosphorothioate bond, and in which the sense tape is at least substantially complementary to the antisense tape. in the art would clearly understand, the inclusion of a phosphorothioate bond, as shown in the modified nucleotide sequences described here, replaces the phosphodiester bond typically present in oligonucleotides (see, for example, Figs. 5A to 5K showing all internucleoside bonds) In In some embodiments, an ANGPTL3 RNAi agent described here includes an antisense strand that consists of, consists essentially of, or comprises the nucleotide sequence (58> 3) usAfscsUfgAfuCfaAfaUfaUfgUufuGfaGfsc (SEQ ID NO: 2), where a, c, g , eu represent 2'-O-methyl adenosine, cytidine, guanosine, or uridine, respectively; Af, Cf, Gf, and Uf represent 2'-fluorine adenosine, cytidine, guanosine, or uridine, respectively ; and s represents a phosphorothiocate bond, and wherein the sense tape is at least substantially complementary to the antisense tape.
[0043] [0043] In some embodiments, an ANGPTL3 RNAi agent described here includes an antisense strip that consists of, consists essentially of, or comprises a modified nucleotide sequence differing by no more than 1 nucleotide from the nucleotide sequence (5 '> 3 ') usAfscUfgAfuCfaAfaUfaUfgUfuGfasGfsc (SEQ ID NO: 4), wherein a, c, g, and urepresent 2'-O-methyl adenosine, cytidine, guanosine, or uridine, respectively; Af, Cf, Gf, and Uf represent 2 "- fluorine adenosine, cytidine, guanosine, or uridine, respectively; es represent a phosphorothioate bond, and in which the sense tape is at least substantially complementary to the antisense tape. in the art would clearly understand, the inclusion of a phosphorothioate bond, as shown in the modified nucleotide sequences described here, replaces the phosphodiester bond typically present in oligonucleotides (see, for example, Figs. 5A to 5K showing all internucleoside bonds) In In some embodiments, an ANGPTL3 RNAi agent described here includes an antisense strand that consists of, consists essentially of, or comprises the nucleotide sequence (5 '> 3) usAfscUfgAfuCfaAfaUfaUfgUfuGfasGfsc (SEQ ID NO4), where a, c, g, eu represent 2'-O-methyl adenosine, cytidine, guanosine, or uridine, respectively; Af, Cf, Gf, and Uf represent 2'-fluorine adenosine, cytidine, guanosine, or uridine, respectively; and s represents a phosphorothioate bond, and wherein the sense tape is at least substantially complementary to the antisense tape.
[0044] [0044] In some embodiments, an ANGPTL3 RNAi agent described here includes an antisense strip that consists of, consists essentially of, or comprises a nucleobase sequence differing in O or 1 nucleobase from the nucleotide sequence (5 '> 3') UACUGAUCAAAUAUGUUGAGU (SEQ I | D NO: 6) In some embodiments, an ANGPTL3 RNAi agent described here includes an antisense strand that consists of, essentially consists of, or comprises a nucleotide sequence differing by no more than 1 nucleotide from the sequence nucleotide (5 '> 3) UACUGAUCAAAUAUGUUGAGU (SEQ ID NO: 6), where all or substantially all nucleotides are modified nucleotides. In some embodiments, an ANGPTL3 RNAi agent described herein includes an antisense strand that consists of, consists essentially of, or comprises a nucleobase sequence differing in O or 1 nucleobase from the nucleotide sequence (5 '> 3')
[0045] [0045] In some embodiments, an ANGPTL3 RNAi agent described here includes an antisense strip that consists of, consists essentially of, or comprises a modified nucleotide sequence differing by no more than 1 nucleotide from the nucleotide sequence (5 '> 3 ') usAfscsUfgAfuCfaAfaUfaUfgUufuGfaGfsu (SEQ ID NO: 5), where a, c, 9, eu represent 2'-O-methyl adenosine, cytidine, guanosine, or uridine, respectively; Af, Cf, Gf, and Uf represent 2 ”- fluorine adenosine, cytidine, guanosine, or uridine, respectively; and s represents a phosphorothioate bond, and wherein the sense tape is at least substantially complementary to the antisense tape. As the person skilled in the art would clearly understand, the inclusion of a phosphorothioate bond, as shown in the modified nucleotide sequences described here, replaces the phosphodiester bond typically present in oligonucleotides (see, for example, Figs. 5A to 5K showing all the internucleoside bonds). In some embodiments, an ANGPTL3 RNAi agent described here includes an antisense strip that consists of, consists essentially of, or comprises the nucleotide sequence (58> 3) usAfscsUfgAfuCfaAfaUfaUfgUfuGfaGfsu (SEQ ID NO: 5), where a, c, g, eu represent 2'-O-methyl adenosine, cytidine, guanosine, or uridine, respectively; Af, Cf, Gf, and Uf represent 2'-fluorine adenosine, cytidine, guanosine, or uridine, respectively; and s represents a phosphorothioate bond, and wherein the sense tape is at least substantially complementary to the antisense tape.
[0046] [0046] In some embodiments, an ANGPTL3 RNAi agent described herein includes an antisense strip that consists of, consists essentially of, or comprises a nucleobase sequence differing in O or 1 nucleobase from the nucleotide sequence (5 '> 3')
[0047] [0047] In some embodiments, an ANGPTL3 RNAi agent described here includes an antisense strip that consists of, consists essentially of, or comprises a modified nucleotide sequence differing by no more than 1 nucleotide from the nucleotide sequence (5 '> 3 ') usUfsusGfaAfuUfaAfuGfuCfcAfuGfggsc (SEQ ID NO: 7), where a, c, g, eu represent 2'-O-methyl adenosine, cytidine, guanosine, or uridine, respectively; Af, Cf, Gf, and Uf represent 2 "- fluorine adenosine, cytidine, guanosine, or uridine, respectively; es represent a phosphorothioate bond, and in which the sense tape is at least substantially complementary to the antisense tape. In some embodiments, an ANGPTL3 RNAi agent described herein includes an antisense tape that consists of, essentially consists of, or comprises the nucleotide sequence (58> 3) usUfsusGfaAfuUfaAfuGfuCfcAfuGfggsc (SEQ ID NO: 7), where a, c, g, i represent 2'-O-methyl adenosine, cytidine, guanosine, or uridine, respectively; Af, Cf, Gf, and Uf represent 2'-fluorine adenosine, cytidine, guanosine, or uridine, respectively; es represent a phosphoroticate bond, and in that the sense tape is at least substantially complementary to the antisense tape.
[0048] [0048] In some embodiments, an ANGPTL3 RNAi agent described here includes an antisense strip that consists of, consists essentially of, or comprises a nucleobase sequence differing in O or 1 nucleobase from the nucleotide sequence (5 '> 3') UUUGAAUUAAUGUCCAUGGGU (SEQ ID NO: 10) In some embodiments, an ANGPTL3 RNAi agent described here includes an antisense strand that consists of, essentially consists of, or comprises a nucleotide sequence differing by no more than 1 nucleotide from the nucleotide sequence (5 '> 3) UUUGAAUUAAUGUCCAUGGGU (SEQ ID NO: 10), where all or substantially all nucleotides are modified nucleotides. In some embodiments, an ANGPTL3 RNAi agent described here includes an antisense strip that consists of, consists essentially of, or comprises a nucleobase sequence differing in O or 1 nucleobase from the nucleotide sequence (5 '> 3') UUUGAAUUAAUGUCCAUGGGU (SEQ ID NO: 10), where SEQ ID NO: 10 is located in positions 1 to 21 (5 '> 3') of the antisense tape.
[0049] [0049] In some embodiments, an ANGPTL3 RNAi agent described here includes an antisense strip that consists of, consists essentially of, or comprises a modified nucleotide sequence differing by no more than 1 nucleotide from the nucleotide sequence (5 '> 3 ') usUfsusGfaAfuUfaAfuGfuCfcAfuGfgGfsu (SEQ ID NO: 9), where a, c, g, and urepresent 2'-O-methyl adenosine, cytidine, guanosine, or uridine, respectively; Af, Cf, Gf, and Uf represent 2 "- fluorine adenosine, cytidine, guanosine, or uridine, respectively; es represent a phosphorothioate bond, and in which the sense tape is at least substantially complementary to the antisense tape. In some embodiments, an ANGPTL3 RNAi agent described herein includes an antisense tape that consists of, consists essentially of, or comprises the nucleotide sequence (5 '> 3) usUfsusGfaAfuUfaAfuGfuCfcAfuGfgGfsu (SEQ ID NO: 9), where a, c, g, i represent 2'-O-methyl adenosine, cytidine, guanosine, or uridine, respectively; Af, Cf, Gf, and Uf represent 2'-fluorine adenosine, cytidine, guanosine, or uridine, respectively; es represent a phosphorothioate bond, and wherein the sense tape is at least substantially complementary to the antisense tape.
[0050] [0050] In some embodiments, an ANGPTL3 RNAi agent described here includes an antisense strip that consists of, consists essentially of, or comprises a nucleobase sequence differing in O or 1 nucleobase from the nucleotide sequence (5 '> 3') UGUUGAAUUAAUGUCCAUGGA (SEQ ID NO: 12) In some embodiments, an ANGPTL3 RNAi agent described here includes an antisense strand that consists of, essentially consists of, or comprises a nucleotide sequence differing by no more than 1 nucleotide from the nucleotide sequence (5 '> 3) UGUUGAAUUAAUGUCCAUGGA (SEQ | D NO: 12), where all or substantially all nucleotides are modified nucleotides. In some embodiments, an ANGPTL3 RNAi agent described here includes an antisense strip that consists of, consists essentially of, or comprises a nucleobase sequence differing in O or 1 nucleobase from the nucleotide sequence (5 '> 3') UGUUGAAUUAAUGUCCAUGGA (SEQ ID NO: 12), where SEQ ID NO: 12 is located in positions 1 to 21 (5 '> 3') of the antisense tape.
[0051] [0051] In some embodiments, an ANGPTL3 RNAi agent described here includes an antisense strip that consists of, consists essentially of, or comprises a modified nucleotide sequence differing by no more than 1 nucleotide from the nucleotide sequence (5 '> 3 ') usGfsusugaauuaaUfgUfcCfaUfgGisa (SEQ ID
[0052] [0052] In some embodiments, an ANGPTL3 RNAi agent described herein includes an antisense strip that consists of, consists essentially of, or comprises a modified nucleotide sequence differing by no more than 1 nucleotide from the nucleotide sequence (5 '> 3 ') usGfsusUfgAfaUfuAfaUfgUfcCfaUfgGisa (SEQ ID NO: 13), where a, c, 9, eu represent 2'-O-methyl adenosine, cytidine, guanosine, or uridine, respectively; Af, Cf, Gf, and Uf represent 2 "fluorine adenosine, cytidine, guanosine, or uridine, respectively; es represent a phosphorothioate bond, and where the sense tape is at least substantially complementary to the antisense tape. In some embodiments, a ANGPTLS3 RNAi agent described herein includes an antisense tape which consists of, consists essentially of, or comprises the nucleotide sequence (5 '> 3 ") usGfsusUfgAfaUfuAfaUfgUufcCfaUfgGfsa (SEQ ID NO: 13), where a, c, 9, i represent 2'-O-methyl adenosine, cytidine, guanosine, or uridine, respectively; Af, Cf, Gf, and Uf represent 2 "-
[0053] [0053] In some embodiments, an ANGPTL3 RNAi agent described herein includes an antisense strip that consists of, consists essentially of, or comprises a nucleobase sequence differing in O or 1 nucleobase from the nucleotide sequence (5 '> 3') ACAUCGUCUAACAUAGCAACC (SEQ ID NO: 15) In some embodiments, an ANGPTL3 RNAi agent described here includes an antisense strand that consists of, consists essentially of, or comprises a nucleotide sequence differing by no more than 1 nucleotide from the nucleotide sequence (5 '> 3) ACAUCGUCUAACAUAGCAACC (SEQ ID NO: 15), where all or substantially all nucleotides are modified nucleotides. In some embodiments, an ANGPTL3 RNAi agent described here includes an antisense strip that consists of, consists essentially of, or comprises a nucleobase sequence differing in O or 1 nucleobase from the nucleotide sequence (5 '> 3') ACAUCGUCUAACAUAGCAACC (SEQ ID NO: 15), where SEQ ID NO: 14 is located in positions 1 to 21 (5 '> 3') of the antisense tape.
[0054] [0054] In some embodiments, an ANGPTL3 RNAi agent described here includes an antisense strip that consists of, consists essentially of, or comprises a modified nucleotide sequence differing by no more than 1 nucleotide from the nucleotide sequence (5 '> 3 ') asCfsasUfcGfucuaaCfaUfaGfcAfaCfsc (SEQ ID NO: 14), where a, c, g, eu represent 2 "-O-methyl adenosine, cytidine, guanosine, or uridine, respectively; Af, Cf, Gf, and Uf represent 2" - fluorine adenosine, cytidine, guanosine, or uridine, respectively; and s represents a phosphorothioate bond, and wherein the sense tape is at least substantially complementary to the antisense tape. In some embodiments, an ANGPTL3 RNAi agent described here includes an antisense tape that consists of, consists essentially of, or comprises the nucleotide sequence (5 '> 323) asCfsasUfcGfucuaaCfaUfaGfcAfaCfsc (SEQ ID NO: 14), where a, c , 9, eu represent 2'-O-methyl adenosine, cytidine, guanosine, or uridine, respectively; Af, Cf, Gf, and Uf represent 2'-fluorine adenosine, cytidine, guanosine, or uridine, respectively; and s represents a phosphorotic bond, and wherein the sense tape is at least substantially complementary to the antisense tape.
[0055] [0055] In some embodiments, an ANGPTL3 RNAi agent described here includes an antisense strip that consists of, consists essentially of, or comprises a nucleobase sequence differing in O or 1 nucleobase from the nucleotide sequence (5 '> 3') UACUGAUCAAAUAUGUUGAGC (SEQ ID NO: 3) and a sense strand consisting of, consists essentially of, or comprises a nucleobase sequence differing in O or 1 nucleobase from the nucleotide sequence (5 '> 3) GCUCAACAUAUUUGAUCAGUA (SEQ ID NO: 17) . In some embodiments, an ANGPTL3 RNAi agent described herein includes an antisense strand that consists of, consists essentially of, or comprises a nucleotide sequence differing by no more than 1 nucleotide from the nucleotide sequence (5 '> 3 ") UACUGAUCAAAUAUGUUGAGC (SEQ ID NO: 3), where all or substantially all nucleotides are modified nucleotides, and a sense strand consisting of, consists essentially of, or comprises a nucleotide sequence differing by no more than 1 nucleotide from the nucleotide sequence (5 '> 3) GCUCAACAUAUUUGAUCAGUA (SEQ ID NO: 17), where all or substantially all nucleotides are modified nucleotides.
[0056] [0056] In some embodiments, an ANGPTL3 RNAi agent described here includes an antisense strip that consists of, consists essentially of, or comprises a nucleobase sequence differing in O or 1 nucleobase from the nucleotide sequence (5 '> 3') UACUGAUCAAAUAUGUUGAGC (SEQ ID NO: 3) and a sense strand consisting of, essentially consists of, or comprises a nucleobase sequence differing in O or 1 nucleobase from the nucleotide sequence (5 '> 3) GCUCAACAU (A NJUUUGAUCAGUA (SEQ ID NO: 19), where (AºY) represents a 2-aminoadenine nucleotide.In some embodiments, an ANGPTL3 RNAi agent described here includes an antisense strand that consists of, consists essentially of, or comprises a nucleotide sequence differing in no more than 1 nucleotide of the nucleotide sequence (5 '> 3 ") UACUGAUCAAAUAUGUUGAGC (SEQ ID NO: 3), where all or substantially all nucleotides are modified nucleotides, and a sense strand consisting of, consists of in, or comprises a nucleotide sequence deferred by no more than 1 nucleotide from the nucleotide sequence (5 '> 3') GCUCAACAU (A NJUUUGAUCAGUA (SEQ ID NO: 19), where (A YN) represents a 2-aminoadenine nucleotide, and wherein all or substantially all of the nucleotides are modified nucleotides.
[0057] [0057] In some embodiments, an ANGPTL3 RNAi agent described here includes an antisense strip that consists of, consists essentially of, or comprises a nucleobase sequence differing in O or 1 nucleobase from the nucleotide sequence (5 '> 3') UACUGAUCAAAUAUGUUGAGC (SEQ ID NO: 3) and a sense strand consisting of, consists essentially of, or comprises a nucleobase sequence differing in O or 1 nucleobase from the nucleotide (5 '> 3 ") sequence GCUCAAC (A N) JU (A NJUUUGAUCAGUA (SEQ ID NO: 21), where (AºY) represents a 2-aminoadenine nucleotide.
[0058] [0058] In some embodiments, an ANGPTL3 RNAi agent described here includes an antisense strip that consists of, consists essentially of, or comprises a nucleobase sequence differing in O or 1 nucleobase from the nucleotide sequence (5 '> 3') UACUGAUCAAAUAUGUUGAGU (SEQ ID NO: 6) and a sense strand consisting of, consists essentially of, or comprises a nucleobase sequence differing in O or 1 nucleobase from the nucleotide sequence (5 '> 3') ACUCAACAUAUUUGAUCAGUA (SEQ ID NO: 24 ). In some embodiments, an ANGPTL3 RNAi agent described here includes an antisense strand that consists of, consists essentially of, or comprises a nucleotide sequence differing by no more than 1 nucleotide from the nucleotide sequence (5 '> 3) UACUGAUCAAAUAUGUUGAGU ( SEQ ID NO: 6), where all or substantially all nucleotides are modified nucleotides, and a sense strand consisting of, consists essentially of, or comprises a nucleotide sequence differing by no more than 1 nucleotide from the nucleotide sequence ( 5 '> 3 ") ACUCAACAUAUUUGAUCAGUA (SEQ ID NO: 24), where all or substantially all nucleotides are modified nucleotides.
[0059] [0059] In some embodiments, an ANGPTL3 RNAi agent described here includes an antisense strip that consists of, consists essentially of, or comprises a nucleobase sequence differing in O or 1 nucleobase from the nucleotide sequence (5 '> 3') UUUGAAUUAAUGUCCAUGGGC (SEQ ID NO: 8) and a sense strand consisting of, essentially consists of, or comprises a nucleobase sequence differing in O or 1 nucleobase from the nucleotide sequence (5 '> 3) GCCCAUGGACAUUAAUUCAAA (SEQ | D NO: 26 ). In some embodiments, an ANGPTL3 RNAi agent described herein includes an antisense strand that consists of, consists essentially of, or comprises a nucleotide sequence differing by no more than 1 nucleotide from the nucleotide sequence (5 '> 3 ") UUUGAAUUAAUGUCCAUGGGC (SEQ ID NO: 8), where all or substantially all nucleotides are modified nucleotides, and a sense strand consisting of, consists essentially of, or comprises a nucleotide sequence differing by no more than 1 nucleotide from the nucleotide sequence (5 '> 3) GCCCAUGGACAUUAAUUCAAA (SEQ ID NO: 26), where all or substantially all nucleotides are modified nucleotides.
[0060] [0060] In some embodiments, an ANGPTL3 RNAi agent described here includes an antisense strip that consists of, consists essentially of, or comprises a nucleobase sequence differing in O or 1 nucleobase from the nucleotide sequence (5 '> 3') UUUGAAUUAAUGUCCAUGGGU (SEQ ID NO: 10) and a sense strand consisting of, consists essentially of, or comprises a nucleobase sequence differing in O or 1 nucleobase from the nucleotide sequence (5 '> 3') ACCCAUGGACAUUAAUUCAAA (SEQ | D NO: 28). In some embodiments, an ANGPTL3 RNAi agent described herein includes an antisense strand that consists of, consists essentially of, or comprises a nucleotide sequence differing by no more than 1 nucleotide from the nucleotide sequence (5 '> 3) UUUGAAUUAAUGUCCAUGGGU ( SEQ ID NO: 10), where all or substantially all nucleotides are modified nucleotides, and a sense strand consisting of, consists essentially of, or comprises a nucleotide sequence differing by no more than 1 nucleotide from the nucleotide sequence ( 5 '> 3) ACCCAUGGACAUUAAUUCAAA (SEQ ID NO: 28), where all or substantially all nucleotides are modified nucleotides.
[0061] [0061] In some embodiments, an ANGPTL3 RNAi agent described here includes an antisense strip that consists of, consists essentially of, or comprises a nucleobase sequence differing in O or 1 nucleobase from the nucleotide sequence (5 '> 3') UGUUGAAUUAAUGUCCAUGGA (SEQ ID NO: 12) and a sense strand consisting of, consists essentially of, or comprises a nucleobase sequence differing in O or 1 nucleobase from the nucleotide sequence (5 '> 3') UCCAUGGACAUUAAUUCAACA (SEQ ID NO: 30 ). In some embodiments, an ANGPTL3 RNAi agent described herein includes an antisense strand that consists of, consists essentially of, or comprises a nucleotide sequence differing by no more than 1 nucleotide from the nucleotide sequence (5 '> 3) UGUUGAAUUAAUGUCCAUGGA ( SEQ ID NO: 12), where all or substantially all nucleotides are modified nucleotides, and a sense strand consisting of, consists essentially of, or comprises a nucleotide sequence differing by no more than 1 nucleotide from the nucleotide sequence ( 5 '> 3) UCCAUGGACAUUAAUUCAACA (SEQ ID NO: 30), where all or substantially all nucleotides are modified nucleotides.
[0062] [0062] In some embodiments, an ANGPTL3 RNAi agent described here includes an antisense strip that consists of, consists essentially of, or comprises a nucleobase sequence differing in O or 1 nucleobase from the nucleotide sequence (5 '> 3') ACAUCGUCUAACAUAGCAACC (SEQ ID NO: 15) and a sense strand consisting of, consists essentially of, or comprises a nucleobase sequence differing in O or 1 nucleobase from the nucleotide sequence (5 '> 3) GGUUGCUAUGUUAGACGAUGU (SEQ ID NO: 32) . In some embodiments, an ANGPTL3 RNAi agent described herein includes an antisense strand that consists of, consists essentially of, or comprises a nucleotide sequence differing by no more than 1 nucleotide from the nucleotide sequence (5 '> 3) ACAUCGUCUAACAUAGCAACC ( SEQ ID NO: 15), where all or substantially all nucleotides are modified nucleotides, and a sense strand consisting of, consists essentially of, or comprises a nucleotide sequence differing by no more than 1 nucleotide from the nucleotide sequence ( 5 '> 3) GGUUGCUAUGUUAGACGAUGU (SEQ ID NO: 32), where all or substantially all nucleotides are modified nucleotides.
[0063] [0063] In some embodiments, an ANGPTL3 RNAi agent described here includes an antisense strip that consists of, consists essentially of, or comprises the modified nucleotide sequence (5 '> 3') usAfscsUfgAfuCfaAfaUfaUfgufuGfaGfsc (SEQ ID NO: 2), and a sense strand consisting of, consists essentially of, or comprises the modified nucleotide sequence (5 '> 3') gcucaacaUfAfUfuugaucagua (SEQ ID NO: 16), where a, c, gy i represent 2'-O-methyl adenosine, cytidine, guanosine, or uridine, respectively; Af, Cf, Gf, and Uf represent 2'-fluorine adenosine, cytidine, guanosine, or uridine, respectively; and s represents a phosphorothioate bond. In some embodiments, an ANGPTL3 RNAi agent described here includes an antisense strand that consists of, consists essentially of, or comprises the modified nucleotide sequence (5 '> 3) usAfscsUfgAfuCfaAfaUfaUfgUfuGfaGfsc (SEQ ID NO: 2), and a sense tape which consists of, consists essentially of, or comprises the modified nucleotide sequence (5 '> 3) gcucaacaUfAfUfuugaucagua (SEQ ID NO: 16), and where the sense stripe also includes inverted abasic residues at the 3' and 5 'end 'of the nucleotide sequence, and the sense strand also includes a targeting linker that is covalently linked to the 5' endpoint, where the targeting linker includes N-acetyl-galactosamine.
[0064] [0064] In some embodiments, an ANGPTL3 RNAi agent described here includes an antisense strip that consists of, consists essentially of, or comprises the modified nucleotide sequence (5 '> 3') usAfscsUfgAfuCfaAfaUfaUfgufuGfaGfsc (SEQ ID NO: 2), and a sense strand consisting of, consists essentially of, or comprises the modified nucleotide sequence (5 '> 3') gcucaacaUfa 2NUfuugaucagua (SEQ ID NO: 18), where a, c, g, i represent 2'-O -methyl adenosine, cytidine, guanosine, or uridine, respectively; 2N represents 2'-O-methyl-2-aminoadenosine (see Table 6); Af, Cf, Gf, and Uf represent 2'-fluorine adenosine, cytidine, guanosine, or uridine, respectively; and s represents a phosphorothiocate bond. In some embodiments, an ANGPTL3 RNAi agent described here includes an antisense strip that consists of, essentially consists of, or comprises the modified nucleotide sequence (5 '= 3 ") usAfscsUfgAfuCfaAfaUfaUfgUfuGfaGfsc (SEQ ID NO: 2), and a strip sense which consists of, consists essentially of, or comprises the modified nucleotide sequence (5 '> 3) gcucaacaUfa 2NUfuugaucagua (SEQ ID NO: 18), and in which the sense tape also includes abasic residues inverted at the 3' terminal end and the 5 'end of the nucleotide sequence, and the sense strand also includes a targeting linker that is covalently linked to the 5' endpoint, where the targeting linker includes N-acetyl-galactosamine.
[0065] [0065] In some embodiments, an ANGPTL3 RNAi agent described here includes an antisense strand that consists of, consists essentially of, or comprises the modified nucleotide sequence (5 '> 3') usAfscUfgAfuCfaAfaUfaUfgUufuGfasGfsc (SEQ ID NO: 4), and a sense strand consisting of, consists essentially of, or comprises the modified nucleotide sequence (5 '> 3') gcucaacaUfAfUfuugaucagua (SEQ ID NO: 16), where a, c, gy, eu represent 2'-O- methyl adenosine, cytidine, guanosine, or uridine, respectively; Af, Cf, Gf, and Uf represent 2'-fluorine adenosine, cytidine, guanosine, or uridine, respectively; and s represents a phosphorothioate bond. In some embodiments, an ANGPTL3 RNAi agent described here includes an antisense strand that consists of, consists essentially of, or comprises the modified nucleotide sequence (5 '> 3) usAfscUfgAfuCfaAfaUfaUfgUfuGfasGfsc (SEQ ID NO4), and a sense tape that consists em, consists essentially of, or comprises the modified nucleotide sequence (5 '> 3) gcucaacaUfAfUfuugaucagua (SEQ ID NO: 16), and where the sense stripe also includes inverted abasic residues at the 3' end and 5 'end of nucleotide sequence, and the sense strand also includes a targeting linker that is covalently attached to the 5 'end end, where the targeting linker includes N-acetyl-galactosamine.
[0066] [0066] In some embodiments, an ANGPTL3 RNAi agent described here includes an antisense strip that consists of, consists essentially of, or comprises the modified nucleotide sequence (5 '> 3') usAfscsUfgAfuCfaAfaUfaUfgufuGfaGfsc (SEQ ID NO: 2), and a sense strand consisting of, consists essentially of, or comprises the modified nucleotide sequence (5 '> 3) gcucaaca 2NUfa 2NUfuugaucagua (SEQ ID NO: 20), where a, c, g, eu represent 2'-O -methyl adenosine, cytidine, guanosine, or uridine, respectively; 2N represents 2'-O-methyl-2-aminoadenosine (see Table 6); Af, Cf, Gf, and Uf represent 2'-fluorine adenosine, cytidine, guanosine, or uridine, respectively; and s represents a phosphoroticate bond. In some embodiments, an ANGPTLS3 RNAi agent described here includes an antisense strand that consists of, consists essentially of, or comprises the modified nucleotide sequence (5 '> 3) usAfscsUfgAfuCfaAfaUfaUfgUfuGfaGfsc (SEQ ID NO: 2), and a sense tape which consists of, consists essentially of, or comprises the modified nucleotide sequence (5 '> 3) gcucaaca 2NUfa 2NUfuugaucagua (SEQ ID NO: 20), and in which the sense tape also includes inverted abasic residues at the 3' terminal end and 5th end of the nucleotide sequence, and the sense stripe also includes a targeting linker that is covalently linked to the 5 'endpoint, where the targeting linker includes N-acetyl-galactosamine.
[0067] [0067] In some embodiments, an ANGPTL3 RNAi agent described here includes an antisense tape that consists of, consists essentially of, or comprises the modified nucleotide sequence (5 '> 3 ") usAfscsUfgAfuCfaAfaUfaUfgufuGfaGfsc (SEQ ID NO: 2), and a sense strand consisting of, consists essentially of, or comprises the modified nucleotide sequence (5 '> 3') gcUfcAfaCfaUfAfUfuugaucagua (SEQ ID NO: 22), where a, c, g, eu represent 2'-O- methyl adenosine, cytidine, guanosine, or uridine, respectively; 2N represents 2'-O-methyl-2-aminoadenosine (see Table 6); Af, Cf, Gf, and Uf represent 2'-fluorine adenosine, cytidine, guanosine , or uridine, respectively; es represent a phosphoroticate bond. In some embodiments, an ANGPTL3 RNAi agent described here includes an antisense strand that consists of, consists essentially of, or comprises the modified nucleotide sequence (5 '= 3 " ) usAfscsUfgAfuCfaAfaUfaUfgUfuGfaGfsc (SEQ ID NO: 2), and a ribbon sense which consists of, consists essentially of, or comprises the modified nucleotide sequence (5 '> 3) gecUfcAfaCfaUfAfUfuugaucagua (SEQ ID NO: 22), and where the sense tape also includes inverted abasic residues at the 3' terminal end and at the end 5 'of the nucleotide sequence, and the sense strand also includes a targeting linker that is covalently attached to the 5' endpoint, where the targeting linker includes N-acetyl-galactosamine.
[0068] [0068] In some embodiments, an ANGPTL3 RNAi agent described here includes an antisense tape that consists of, consists essentially of, or comprises the modified nucleotide sequence (5 '> 3') usAfscsUfgAfuCfaAfaUfaUfgUufuGfaGfsu (SEQ ID NO: 5), and a sense strand consisting of, consists essentially of, or comprises the modified nucleotide sequence (5 '> 3') acucaacaUfAfUfuugaucagua (SEQ ID NO: 23), where a, c, g, eu represent 2'-O- methyl adenosine, cytidine, guanosine, or uridine, respectively; Af, Cf, Gf, and Uf represent 2'-fluorine adenosine,
[0069] [0069] In some embodiments, an ANGPTL3 RNAi agent described here includes an antisense strip that consists of, consists essentially of, or comprises the modified nucleotide sequence (5 '> 3') usUfsusGfaAfuUfaAfuGfuCfcAfuGfggsc (SEQ ID NO: 7), and a sense strand consisting of, consists essentially of, or comprises the modified nucleotide sequence (5 '> 3') gccecauggAfCfAfuuaauucaaa (SEQ ID NO: 25), where a, c, gy, eu represent 2'-O- methyl adenosine, cytidine, guanosine, or uridine, respectively; Af, Cf, Gf, and Uf represent 2'-fluorine adenosine, cytidine, guanosine, or uridine, respectively; and s represents a phosphorothioate bond. In some embodiments, an ANGPTL3 RNAi agent described here includes an antisense strand that consists of, consists essentially of, or comprises the modified nucleotide sequence (5 '> 3) usUfsusGfaAfuUfaAfuGfuCfcAfuGfCgc (SEQ ID NO: 7), and a sense strand which consists of, consists essentially of, or comprises the modified nucleotide sequence (5 '> 3) gccecauggAfCfAfuuaauucaaa (SEQ ID NO: 25), and where the sense stripe also includes inverted abasic residues at the 3' and 5 'end 'of the nucleotide sequence, and the sense strand also includes a targeting linker that is covalently linked to the 5' endpoint, where the targeting linker includes N-acetyl-galactosamine.
[0070] [0070] In some embodiments, an ANGPTL3 RNAi agent described here includes an antisense strand that consists of, essentially consists of, or comprises the modified nucleotide sequence (5 '> 3') usUfsusGfaAfuUfaAfuGfuCfcAfuGfgGfsu (SEQ ID NO: 9), and a sense strand consisting of, consists essentially of, or comprises the modified nucleotide sequence (5 '> 3) acccauggAfCfAfuuaauucaaa (SEQ ID NO: 27), where a, c, g, eu represent 2'-O-methyl adenosine, cytidine, guanosine, or uridine, respectively; Af, Cf, Gf, and Uf represent 2'-fluorine adenosine, cytidine, guanosine, or uridine, respectively; and s represents a phosphorothioate bond. In some embodiments, an ANGPTL3 RNAi agent described here includes an antisense strand that consists of, consists essentially of, or comprises the modified nucleotide sequence (5 '- 3) usUfsusGfaAfuUfaAfuGfuCfcAfuGfgGfsu (SEQ ID NO: 9), and a sense tape which consists of, consists essentially of, or comprises the modified nucleotide sequence (5 '> 3) acccauggAfCfAfuuaauucaaa (SEQ ID NO: 27), and where the sense stripe also includes inverted abasic residues at the 3' terminal end and the 5 end 'of the nucleotide sequence, and the sense strand also includes a targeting linker that is covalently linked to the 5' endpoint, where the targeting linker includes N-acetyl-galactosamine.
[0071] [0071] In some embodiments, an ANGPTL3 RNAi agent described here includes an antisense strip that consists of, consists essentially of, or comprises the modified nucleotide sequence (5 '> 3') usGfsusugaauuaaUfgUufcCfaUfgGisa (SEQ ID NO: 11), and a sense strand consisting of, consists essentially of, or comprises the modified nucleotide sequence (5 '> 3') uccauggaCfAfUfuaauucaaca (SEQ ID NO: 29), where a, c, g, eu represent 2'-O- methyl adenosine, cytidine, guanosine, or uridine, respectively; Af, Cf, Gf, and Uf represent 2'-fluorine adenosine, cytidine, guanosine, or uridine, respectively; and s represents a phosphorothioate bond. In some embodiments, an ANGPTL3 RNAi agent described here includes an antisense ribbon that consists of, consists essentially of, or comprises the modified nucleotide sequence (5 '> 3') usGfsusugaauuaaUfgUfcCfaUufgGfisa (SEQ ID NO: 11), and a ribbon sense that consists of, consists essentially of, or comprises the modified nucleotide sequence (5 '> 3') uccauggaCfAfUfuaauucaaca (SEQ ID NO: 29), and in which the sense tape also includes inverted abasic residues at the 3 'terminal end and the 5 'end of the nucleotide sequence, and the sense strand also includes a targeting linker that is covalently linked to the 5' endpoint, where the targeting linker includes N-acetyl-galactosamine.
[0072] [0072] In some embodiments, an ANGPTL3 RNAi agent described here includes an antisense tape that consists of, consists essentially of, or comprises the modified nucleotide sequence (5 '> 3') usGfsusUfgAfaUfuAfaUfgUfcCfaUfgGisa (SEQ ID NO: 13), and a sense strand consisting of, consists essentially of, or comprises the modified nucleotide sequence (5 '> 3') uccauggaCfAfUfuaauucaaca (SEQ ID NO: 29), where a, c, g, eu represent 2'-O- methyl adenosine, cytidine, guanosine, or uridine,
[0073] [0073] In some embodiments, an ANGPTL3 RNAi agent described here includes an antisense strand that consists of, consists essentially of, or comprises the modified nucleotide sequence (5 '> 3') asCfsasUfcGfucuaaCfaUfaGfcAfaCfsc (SEQ ID NO: 14), and a sense strand consisting of, consists essentially of, or comprises the modified nucleotide sequence (5 '> 3') gguugcuaUfGfUfuagacgaugu (SEQ ID NO: 31), where a, c, g, eu represent 2'-O- methyl adenosine, cytidine, guanosine, or uridine, respectively; Af, Cf, Gf, and Uf represent 2'-fluorine adenosine, cytidine, guanosine, or uridine, respectively; and s represents a phosphorothioate bond. In some embodiments, an ANGPTL3 RNAi agent described here includes an antisense strip that consists of, consists essentially of, or comprises the modified nucleotide sequence (5 '> 3') asCfsasUfcGfucuaaCfaUfaGfcAfaCfsc (SEQ ID NO: 14), and a strip sense that consists of, essentially consists of, or comprises the modified nucleotide sequence (5 '> 3') cccuaaaaGfGfGfacaguauucu (SEQ ID NO: 31), and in which the sense tape also includes abasic residues at the 3 'endpoint and the 5 'end of the nucleotide sequence, and the sense strand also includes a targeting linker that is covalently linked to the 5' endpoint, where the targeting linker includes N-acetyl-galactosamine.
[0074] [0074] In some embodiments, an ANGPTL3 RNAi agent described here includes an antisense strand that consists of, consists essentially of, or comprises a nucleotide sequence that differs in O or 1 nucleotide from one of the following nucleotide sequences (5 ' 3 '): UACUGAUCAAAUAUGUUGAGC (SEQ ID NO: 3); UACUGAUCAAAUAUGUUGAGU (SEQ ID NO: 6); UUUGAAUUAAUGUCCAUGGGC (SEQ ID NO: 8); UUUGAAUUAAUGUCCAUGGGU (SEQ ID NO: 10); UGUUGAAUUAAUGUCCAUGGA (SEQ ID NO: 12); or ACAUCGUCUAACAUAGCAACC (SEQ ID NO: 15); wherein the ANGPTL3 RNAi agent also includes a sense strand that is at least partially complementary to the antisense strand; and wherein all or substantially all of the nucleotides on both the antisense and sense strips are modified nucleotides.
[0075] [0075] In some embodiments, an ANGPTL3 RNAi agent described herein includes an antisense strip that consists of, consists essentially of, or comprises a nucleotide sequence that differs in O or 1 nucleotide from one of the following nucleotide sequences (5 ' > 3 '): UACUGAUCAAAUAUGUUGAGC (SEQ ID NO: 3); UACUGAUCAAAUAUGUUGAGU (SEQ ID NO: 6); UUUGAAUUAAUGUCCAUGGGC (SEQ ID NO: 8);
[0076] [0076] In some embodiments, an ANGPTL3 RNAi agent described here includes an antisense strip that consists of, consists essentially of, or comprises a nucleotide sequence that differs in O or 1 nucleotide from one of the following nucleotide sequences (5 ' 3 '): UACUGAUCAAAUAUGUUGAGC (SEQ ID NO: 3); UACUGAUCAAAUAUGUUGAGU (SEQ ID NO: 6); UUUGAAUUAAUGUCCAUGGGC (SEQ ID NO: 8); UUUGAAUUAAUGUCCAUGGGU (SEQ ID NO: 10); UGUUGAAUUAAUGUCCAUGGA (SEQ | D NO: 12); or ACAUCGUCUAACAUAGCAACC (SEQ ID NO: 15); wherein the ANGPTL3 RNAi agent also includes a sense strand that is at least partially complementary to the antisense strand; wherein all or substantially all of the nucleotides on both the antisense and sense strips are modified nucleotides; and wherein the sense strand also includes abasic residues inverted at the 3 'end and 5 ° end of the nucleotide sequence, and the sense strand also includes a targeting linker that is covalently linked to the 5' end end, where the targeting includes N-acetyl-galactosamine; and wherein the respective antisense tape sequence is located at positions 1 to 21 of the antisense tape.
[0077] [0077] In some embodiments, an ANGPTL3 RNAi agent described here includes an antisense and sense strips, wherein the antisense and sense strips consist of, consist essentially of, or comprise nucleotide sequences that differ in O or 1 nucleotide from one of the following nucleotide sequence pairs (5 '> 3) UACUGAUCAAAUAUGUUGAGC (SEQ ID NO: 3) and GCUCAACAUAUUUGAUCAGUA (SEQ ID NO: 17); UACUGAUCAAAUAUGUUGAGC (SEQ ID NO: 3) and GCUCAACAU (A PNJUUUGAUCAGUA (SEQ ID NO: 19), where (A YN) represents a 2-aminoadenine nucleotide; UACUGAUCAAAUAUGUUGAGC (SEQ ID NO: 3) and GC N) JU (A NJUUUGAUCAGUA (SEQ ID NO: 21), where (AN) represents a 2-aminoadenine nucleotide; UACUGAUCAAAUAUGUUGAGU (SEQ ID NO: 6) and ACUCAACAUAUUUGAUCAGUA (SEQ ID NO: 24); UUUGAAGUA NO: 8) and GCCCAUGGACAUUAAUUCAAA (SEQ ID NO: 26); UUUGAAUUAAUGUCCAUGGGU (SEQ ID NO: 10) and ACCCAUGGACAUUAAUUCAAA (SEQ ID NO: 28); UGUUGAAUUAAUGUCCAUGA (SEA ID: NO; or ACAUCGUCUAACAUAGCAACC (SEQ ID NO: 15) and GGUUGCUAUGUUAGACGAUGU (SEQ | D NO: 32), where all or substantially all nucleotides on both the antisense and sense strips are modified nucleotides.
[0078] [0078] In some embodiments, an ANGPTL3 RNAi agent described here includes an antisense tape and a sense tape, wherein the antisense tape and the sense tape consist of, consist essentially of, or comprise nucleotide sequences that differ in O or 1 nucleotide from one of the following nucleotide sequences (5 '> 3') pairs: UACUGAUCAAAUAUGUUGAGC (SEQ ID NO: 3) and GCUCAACAUAUUUGAUCAGUA (SEQ ID NO: 17); UACUGAUCAAAUAUGUUGAGC (SEQ ID NO: 3) and GCUCAACAU (A PNJUUUGAUCAGUA (SEQ ID NO: 19), where (A ºYN) represents a 2-aminoadenine nucleotide; UACUGAUCAAAUAUGUUGAGC (SEQ ID NO: 3) and GC N) JU (A NJUUUGAUCAGUA (SEQ ID NO: 21), where (AY) represents a 2-aminoadenine nucleotide; UACUGAUCAAAUAUGUUGAGU (SEQ ID NO: 6) and ACUCAACAUAUUUGAUCAGUA (SEQ | D NO: 24); UUUGAGUA ID NO: 8) and GCCCAUGGACAUUAAUUCAAA (SEQ ID NO: 26); UUUGAAUUAAUGUCCAUGGGU (SEQ ID NO: 10) and ACCCAUGGACAUUAAUUCAAA (SEQ ID NO: 28); UGUUGAAUUAAAAAAAAAAAAAA ; or ACAUCGUCUAACAUAGCAACC (SEQ ID NO: 15) and GGUUGCUAUGUUAGACGAUGU (SEQ | D NO: 32); where all or substantially all nucleotides on both the antisense and sense strips are modified nucleotides; and where the sense stripe also includes residues inverted abasics at the 3 'terminal end and the 5' end of the nucleotide sequence, and the sense tape also includes a targeting ligand which is covalently attached to the 5 'terminal end, where the targeting linker includes N-acetyl-galactosamine.
[0079] [0079] In some embodiments, an ANGPTL3 RNAi agent described here includes an antisense strip that consists of, consists essentially of, or comprises a modified nucleotide sequence that differs in O or 1 nucleotide from one of the following nucleotide sequences (5 "3 3"): usAfscsUfgAfuCfaAfaUfaUfgUufuGfaGfsc (SEQ ID NO: 2); usAfscUfgAfuCfaAfaUfaUfgufuGfasGfsc (SEQ ID NO: 4); usAfscsUfgAfuCfaAfaUfaUfgUufuGfaGfsu (SEQ ID NO: 5); usUfsusGfaAfuUfaAfuGfuCfcAfuGfggsc (SEQ ID NO: 7); usUfsusGfaAfuUfaAfuGfuCfcAfuGfgGfsu (SEQ ID NO: 9) ; usGfsusugaauuaaUfgufcCfaUfgGfsa (SEQ ID NO: 11); usGfsusUfgAfaUfuAfaUfgUfcCfaUfgGfsa (SEQ ID NO: 13); asCfsasUfcGfucuaaCfaUfaGfcA, which represent, c; or uridine, respectively; Af, Cf, Gf, and Uf represent 2 "- fluorine adenosine, cytidine, guanosine, or uridine, respectively; s represents a phosphorothioate bond; and wherein the ANGPTL3 RNAi agent also includes the sense strand which is at least partially complementary to the antisense strand; and wherein all or substantially all of the nucleotides in the sense strand are modified nucleotides.
[0080] [0080] In some embodiments, an ANGPTL3 RNAi agent described here includes an antisense strip that consists of, consists essentially of, or comprises a modified nucleotide sequence that differs in O or 1 nucleotide from one of the following nucleotide sequences (5 '3 3 "): usAfscsUfgAfuCfaAfaUfaUfgUufuGfaGfsc (SEQ ID NO: 2); usAfscUfgAfuCfaAfaUfaUufgUfuGfasGfsc (SEQ ID NO: 4); usAfscsUfgAfuCfaAfg
[0081] [0081] In some embodiments, an ANGPTL3 RNAi agent described here includes an antisense strip and a sense strip that consist of, consist essentially of, or comprise modified nucleotide sequences that differ in O or 1 nucleotide from one of the following pairs of nucleotide sequence (5 '> 3'): usAfscsUfgAfuCfaAfaUfaUfgUfuGfaGfsc (SEQ ID NO: 2) and gcecucaacaUfAfufuugaucagua (SEQ ID NO: 16); usAfscsUfgAfuCfaAfaUfaUfgUufuGfaGfsc (SEQ ID NO: 2) and gcucaacaUfa 2NUfuugaucagua (SEQ ID NO: 18); usAfscUfgAfuCfaAfaUfaUufgUfuGfasGfsc ( SEQ ID NO: 4) and gcucaacaUfAfUfuugaucagua (SEQ ID NO: 16); usAfscsUfgAfuCfaAfaUfaUfgUfuGfaGfsc (SEQ ID NO: 2) and gcucaaca 2NUfa 2NUfuugaucagua (SEQ ID NO: 20); : 22); usAfscsUfgAfuCfaAfaUfaUfgUufuGfaGfsu (SEQ ID NO: 5) and acucaacaUfAfUfuugaucagua (SEQ ID NO: 23); usUfsusGfaAfuUfaAfuGfuCfcAfuGfggg (SEQ ID NO: 7) and gefa fuGfuCfcAfuGfgGfsu (SEQ ID NO: 9) and acccauggAfCfAfuuaauucaaa (SEQ ID NO: 27); usGfsusugaauuaaUfgUufcCfaUfgGfsa (SEQ ID NO: 11) and uccauggaCfAfUfuaauucaaca (SEQ ID NO: 29); usGfsusUfgAfaUfuAfaUfgUfcCfaUfgGfsa (SEQ ID NO: 13) and uccauggaCfAfUfuaauucaaca (SEQ ID NO: 29); or asCfsasUfcGfucuaaCfaUfaGfcAfaCfsc (SEQ ID NO: 14) and gguugcuaUufGfUfuagacgaugu (SEQ ID NO: 31); wherein a, c, g, and u represent 2'-O-methyl adenosine, cytidine, guanosine, or uridine, respectively; Af, Cf, Gf, and Uf represent 2 "- fluorine adenosine, cytidine, guanosine, or uridine, respectively; 2N represents 2'-O-methyl-2-aminoadenosine (see Table 6); es represents a phosphorothioate bond .
[0082] [0082] In some embodiments, an ANGPTL3 RNAi agent described here includes an antisense tape and a sense tape that consist of, essentially consist of, or comprise one of the nucleotide sequence pairs (5 '3 3'): usAfscsUfgAfuCfaAfaUfaUfgUufuGfaGfsc ( SEQ ID NO: 2) and gcucaacaUfAfUfuugaucagua (SEQ ID NO: 16); usAfscsUfgAfuCfaAfaUfaUfgUufuGfaGfsc (SEQ ID NO: 2) and gcucaacaUfa 2NUfuugaucagua (SEQ ID NO: 18); usAfscUfgAfuCfaAfaUfaUfgufuGfasGfsc (SEQ ID NO: 4) and gcucaacaUfAfUfuugaucagua (SEQ ID NO: 16); usAfscsUfgAfuCfaAfaUfaUfgUufuGfaGfsc (SEQ ID NO: 2) and gcucaaca 2NUfa 2NUfuugaucagua (SEQ ID NO: 20); usAfscsUfgAfuCfaAfaUfaUfgUufuGfaGfsc (SEQ ID NO: 2) and gcUufcAfaCfaUfAfUfuugaucagua (SEQ ID NO: 22);
[0083] [0083] In some embodiments, an ANGPTL3 RNAi agent described here includes an antisense strand that includes a nucleobase sequence that differs in O or 1 nucleobase from the nucleotide sequence selected from the group consisting of (5 '> 3'): UACUGAUCAAAUAUGUUGA (SEQ ID NO: 50); UGUUGAAUUAAUGUCCAUG (SEQ ID NO: 55); UUUGAAUUAAUGUCCAUGG (SEQ ID NO: 60); or ACAUCGUCUAACAUAGCAA (SEQ ID NO: 64).
[0084] [0084] In some embodiments, an ANGPTL3 RNAi agent described here includes an antisense strand that includes a nucleobase sequence that differs in O or 1 nucleobase from the nucleotide sequence selected from the group consisting of (5 '> 3 "): UACUGAUCAAAUAUGUUGA (SEQ ID NO: 50); UGUUGAAUUAAUGUCCAUG (SEQ ID NO: 55); UUUGAAUUAAUGUCCAUGG (SEQ ID NO: 60); or ACAUCGUCUAACAUAGCAA (SEQ ID NO: 64); and in which all nucleotides are substantially all or substantially all.
[0085] [0085] In some embodiments, an ANGPTL3 RNAi agent described here includes an antisense strip that includes a nucleobase sequence that differs in O or 1 nucleobase from the nucleotide sequence selected from the group consisting of (5 '> 3 "): UACUGAUCAAAUAUGUUGA (SEQ ID NO: 50); UGUUGAAUUAAUGUCCAUG (SEQ ID NO: 55); UUUGAAUUAAUGUCCAUGG (SEQ ID NO: 60); or ACAUCGUCUAACAUAGCAA (SEQ ID NO: 64); and where SEQ ID NO: 50, SEQ ID NO: 55, SEQ ID NO: 60, or SEQ ID NO: 64, respectively, are located at nucleotide positions 1 to 19 (5 '> 3') of the antisense tape .
[0086] [0086] In some embodiments, an ANGPTL3 RNAi agent described here includes an antisense ribbon and a sense ribbon, each of which includes nucleobase sequences that differ in O or 1 nucleobase from the selected nucleotide sequence pairs from the group consisting of (5 '> 3): UACUGAUCAAAUAUGUUGA (SEQ ID NO: 50) and UCAACAUAUUUGAUCAGUA (SEQ ID NO: 130); UACUGAUCAAAUAUGUUGA (SEQ ID NO: 50) and
[0087] [0087] In some embodiments, an ANGPTL3 RNAi agent described here includes an antisense and sense strips, each of which includes nucleobase sequences that differ in O or 1 nucleobase from the selected nucleotide sequence pairs from the group consisting of (5 '> 3): UACUGAUCAAAUAUGUUGA (SEQ ID NO: 50) and UCAACAUAUUUGAUCAGUA (SEQ ID NO: 130); UACUGAUCAAAUAUGUUGA (SEQ ID NO: 50) and UCAACAU (A PNJUUUGAUCAGUA (SEQ ID NO: 131), where (AN) represents a 2-aminoadenine nucleotide; UACUGAUCAAAUAUGUUGA (SEQ ID NO: 50) and UCAAC (A N) JU (APN) JUUUGAUCAGUA (SEQ ID NO: 132), where (AN) represents a 2-aminoadenine nucleotide; UGUUGAAUUVUAAUGUCCAUG (SEQ ID NO: 55) and CAUGGACAUUAAUUCAACA (SEQ ID NO: 145); UUUGAUCAUA 60) and CCAUGGACAUUAAUUCAAA (SEQ ID NO: 150); ACAUCGUCUAACAUAGCAA (SEQ ID NO: 64) and UUGCUAUGUUAGACGAUGU (SEQ ID NO: 154); and where all or substantially all nucleotides are modified nucleotides.
[0088] [0088] In some embodiments, the compositions described here that comprise one or more ANGPTL3 RNAi agents are packaged in a Kit, container, packaging, applicator, pre-filled syringes, or vials. In some embodiments, the compositions described here are administered parenterally.
[0089] [0089] As used herein, the terms "oligonucleotide" and "polynucleotide" mean a polymer of linked nucleosides, each of which can be independently modified or unmodified.
[0090] [0090] As used herein, an "RNAi agent" (also referred to as an "RNAi trigger") means a composition that contains an RNA oligonucleotide molecule or similar to RNA (for example, chemically modified RNA) that is capable to degrade or inhibit (e.g., degrade or inhibit under appropriate conditions) the translation of messenger RNA (mMRNA) transcripts from a target mRNA in a sequence specific manner. As used here, RNAi agents can operate through the RNA interference mechanism (that is, induction of RNA interference through interaction with the RNA interference reaction pathway machinery (RNA-induced silencing complex or RISC) mammalian cells), or by any alternative mechanism (s) or alternative reaction path (s). While it is believed that RNAi agents, since such a term is used here, operate primarily through the RNA interference mechanism, the RNAi agents described are not bound by or limited to any reaction pathway or mechanism of action. RNAi agents are described here comprised of a sense strand and an antisense strand, and include, but are not limited to: short (or small) interference RNAs (sIiRNAs), double-stranded RNAs (dsSsRNA), micro RNAs
[0091] [0091] As used here, the terms "mute," "reduce," "inhibit," "sub-regular," or "block" when referring to the expression of a particular gene, mean that the expression of the gene, when measured by the level of RNA transcribed from the gene or the level of polypeptide, protein, or subunit of protein translated from the MRNA in a cell, group of cells, tissue, organ, or individual into which the gene is transcribed, is reduced when the cell, group of cells, tissue, organ, or individual is treated with the RNAi agents described herein as compared to a second cell, group of cells, tissue, organ, or individual that is not being or has not been treated in this way.
[0092] [0092] As used herein, the terms "sequence" and "nucleotide sequence" mean a sequence or order of nucleobases or nucleotides, described with a sequence of letters using standard nomenclature.
[0093] [0093] As used herein, a "base," "nucleotide base," or "nucleobase," is a heterocyclic purine or pyrimidine compound that is a component of a nucleotide, and includes the primary purine bases, adenine and guanine , and the primary pyrimidine bases, cytosine, thymine, and uracil. The nucleobase can also be modified to include, without limitation, universal bases, hydrophobic bases, promiscuous bases, expanded size bases, and fluorinated bases. (See, for example, Modified Nucleosides in Biochemistry, Biotechnology and Medicine, Herdewijn, P. ed. Wiley-VCH, 2008). The synthesis of such modified nucleobases (including phosphoramidite compounds that include modified nucleobases) is known in the art.
[0094] [0094] As used herein, and unless otherwise indicated, the term "complementary," when used to describe a first nucleobase or nucleotide sequence (e.g., targeted RNAi agent strand or targeted mRNA) in relation to a second nucleotide or nucleotide sequence (for example, single antisense strand oligonucleotide or RNAi agent antisense strand), means the ability of an oligonucleotide or polynucleotide including the first nucleotide sequence to hybridize (form pair hydrogen bonds) base under mammalian physiological conditions (or similar conditions in vitro)) and form a duplex or double helical structure under certain standard conditions with an oligonucleotide or polynucleotide including the second nucleotide sequence. Complementary sequences include Watson-Crick base pairs or non-Watson-Crick base pairs and include natural or modified nucleotides or nucleotide mimics, at least to the extent that the hybridization requirements above are met. Complementarity and sequence identity are independent of modification. For example, a and Af, as defined here, are complementary to U (or T) and identical to A for purposes of determining identity or complementarity.
[0095] [0095] As used here, "perfectly complementary" or "fully complementary" means that in a hybridized pair of nucleobase or nucleotide sequence molecules, all (100%) the bases in a contiguous sequence of a first oligonucleotide will hybridize with the same number of bases in a contiguous sequence of a second oligonucleotide. The contiguous sequence can comprise all or part of a first or second nucleotide sequence.
[0096] [0096] As used here, "partially complementary" means that in a hybridized pair of nucleobase or nucleotide sequence molecules, at least 70%, but not all, of the bases in a contiguous sequence of a first oligonucleotide will hybridize with the same number of bases in a contiguous sequence of a second oligonucleotide. The contiguous sequence can comprise all or part of a first or second nucleotide sequence.
[0097] [0097] As used here, "substantially complementary" means that in a hybridized pair of nucleobase or nucleotide sequence molecules, at least 85%, but not all, the bases in a contiguous sequence of a first oligonucleotide will hybridize with the same number of bases in a contiguous sequence of a second oligonucleotide. The contiguous sequence can comprise all or part of a first or second nucleotide sequence.
[0098] [0098] As used herein, the terms "complementary," "fully complementary," "partially complementary," and "substantially complementary" are used with respect to the pairing of a nucleobase or nucleotide between the sense tape and the antisense tape of an agent RNAi, or between the antisense strand of an RNAi agent and a sequence of an ANGPTL3 mRNA.
[0099] [0099] As used herein, the term "substantially identical" or "substantial identity," as applied to a nucleic acid sequence means the nucleotide sequence (or a portion of the nucleotide sequence) has at least about 85% identity of sequence or more, for example, at least 90%, at least 95%, or at least 99% identity, compared to a reference sequence. The percentage of sequence identity is determined by comparing the two sequences ideally aligned over a comparison window. The percentage is calculated by determining the number of positions in which the same type of nucleic acid base occurs and both sequences to produce the number of paired positions, dividing the number of paired positions by the total number of positions in the comparison window and multiplying the result per 100 to produce the sequence identity percentage. The inventions described here encompass nucleotide sequences substantially identical to those described here.
[00100] [00100] As used herein, the terms "treat," "treatment," and the like, mean the methods or steps adopted to provide mitigation of or alleviation of the number, severity, and / or frequency of one or more symptoms of a disease in an individual. As used herein, "treating" and "treatment" may include preventive treatment, control, prophylactic treatment, and / or inhibiting or reducing the number, severity, and / or frequency of one or more symptoms of a disease in an individual.
[00101] [00101] As used here, the phrase "introduce into a cell," when referring to an RNAi agent, means functionally to release the RNAi agent into a cell. The phrase "functional release," means the release of the RNAi agent to the cell in a way that allows the RNAi agent to have the expected biological activity, for example, specific gene expression sequence inhibition.
[00102] [00102] Unless otherwise stated, the use of the symbol É: as used here means that any group or groups can be linked to it, which is in accordance with the scope of the inventions described here.
[00103] [00103] As used here, the term "isomers" refers to compounds that have identical molecular formulas, but that differ in nature or in the binding sequence of their atoms or in the arrangement of their atoms in space. Isomers that differ in the arrangement of their atoms in space are called
[00104] [00104] “As used here, unless specifically identified in a structure as having a particular conformation, for each structure in which asymmetric centers are present and thereby give rise to enantiomers, or other stereoisomeric configurations, and the structure described here is intended to represent all such possible isomers, including their optically pure and racemic forms. For example, structures are described to cover mixtures of diastereomers, as well as simple stereoisomers.
[00105] [00105] As used in a claim here, the phrase "consisting of" excludes any element, step or ingredient not claimed in the claim. When used in a claim here, the phrase "which essentially consists of" limits the scope of a claim to the specified materials or steps and those that do not materially affect the basic and new feature (s) of the claim. claimed invention.
[00106] [00106] The person skilled in the art would easily understand or appreciate that the compounds and compositions described here may have certain atoms (for example, N, O, or S atoms) in a protonated or deprotonated state depending on the environment in which the compound or composition is placed. Consequently, as used herein, the structures described here consider that certain functional groups, such as, for example, OH, SH, or NH, can be protonated or deprotonated. The invention herein is intended to encompass the described compositions compounds regardless of their protonation state based on the environment (such as pH), as would be easily understood by the person skilled in the art.
[00107] [00107] As used here, the term "attached" or "conjugated" when referring to the connection between two compounds or molecules means that two compounds or molecules are connected by a covalent bond. Unless stated, the terms "attached" and "conjugated" as used herein may refer to the connection between a first compound and a second compound with or without any intervening atoms or groups of atoms.
[00108] [00108] As used here, the term "including" is used here to mean, and is used interchangeably with, the phrase "including, but not limited to." The term "or" is used here to mean, and is used interchangeably with, the term "and / or," unless the context clearly indicates otherwise.
[00109] [00109] Unless otherwise defined, all technical and specific terms used here have the same meaning as commonly understood by someone skilled in the art. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods are described below. All publications, patent applications, patents, and other references mentioned here are incorporated by reference in their entirety. In the event of a conflict, this specification, including definitions, will control. In addition, the materials, methods and examples are illustrative only and are not intended to be limiting.
[00110] [00110] Other objectives, characteristics, aspects and advantages of the invention will be evident from the following detailed description, accompanying figures and from the claims. BRIEF DESCRIPTION OF THE DRAWINGS
[00111] [00111] FIG 1Aa1D. Representation of the chemical structure of ANGPTL3 RNAi agent ADO5488, conjugated to an N-acetyl-galactosamine tridentate ligand having the structure of (NAG37) s (see Table 6) at the 5 'end of the sense strand, shown in a form of sodium salt.
[00112] [00112] FIG. 2A to 2D. Representation of the chemical structure of ANGPTL3 ADOS5488 RNAi agent, conjugated to an N-acetyl-galactosamine tridentate ligand having the (NAG37) s structure (see Table 6) at the 5 'terminal end of the sense strip, shown in a free acid form.
[00113] [00113] FIG. 3A to 3D. Representation of the chemical structure of the ANGPTL3 ADOS5775 RNAi agent, conjugated to an N-acetyl-galactosamine tridentate ligand having the (NAG37) s structure (see Table 6) at the 5 'end of the sense strand, shown in a form of sodium salt.
[00114] [00114] FIG. 4A to 4D. Representation of the chemical structure of the ANGPTL3 ADOS5775 RNAi agent, conjugated to an N-acetyl-galactosamine tridentate ligand having the (NAG37) s structure (see Table 6) at the 5 'end of the sense strand, shown in a free acid form.
[00115] [00115] FIG.5A. Schematic diagram of the modified sense and antisense strands of ANGPTL3 ADOS5488 RNAi agent (see Tables 3 to 5), conjugated to an N-acetyl-galactosamine tridentate ligand having the (NAG37) s structure (see Table 6) . Fig. SA describes SEQ ID NOs: 2 and 300.
[00116] [00116] The following abbreviations are used in Figures 3A to 3B: a, c, g, and u are modified 2'-O-methyl nucleotides; Af, Cf, Gf, and Uf are modified 2'-fluorine nucleotides; p is a phosphodiester bond; s is a phosphorothioate bond; invAb is an inverted abasic residue; 2N is a 2'-O-methyl-2- nucleotide
[00117] [00117] FIG.5B. Schematic diagram of the modified antisepense and sense strips of ANGPTL3 ADO5775 RNAi agent (see Tables 3 to 5), conjugated to an N-acetyl-galactosamine tridentate ligand having the (NAG37) structure s (see Table 6). Fig. 5B describes SEQ ID NOs: 2 and 334.
[00118] [00118] FIG.5C.Schematic diagram of the modified antisepense and sense strips of ANGPTL3 RNAi agent ADO5791 (see Tables 3 to 5), conjugated to an N-acetyl-galactosamine tridentate ligand having the structure of (NAG37) s (see Table 6). Fig. SC describes SEQ ID NOs: 4 and 300.
[00119] [00119] FIG.5D. Schematic diagram of the modified antisepense and sense strips of ANGPTL3 ADO5777 RNAi agent (see Tables 3 to 5), conjugated to an N-acetyl-galactosamine tridentate ligand having the structure of (NAG37) s (see Table 6). Fig. 5D describes SEQ ID NOs: 2 and 336.
[00120] [00120] FIG.5E. Schematic diagram of the modified antisepense and sense strips of ANGPTL3 ADO5743 RNAi agent (see Tables 3 to 5), conjugated to an N-acetyl-galactosamine tridentate ligand having the (NAG37) structure s (see Table 6). Fig. SE describes SEQ ID NOs: 2 and 326.
[00121] [00121] FIG.5F. Schematic diagram of the modified antisepense and sense strips of ANGPTL3 ADOS5487 RNAi agent (see Tables 3 to 5), conjugated to an N-acetyl-galactosamine tridentate ligand having the (NAG37) s structure (see Table 6) . Fig. 5F describes SEQ ID NOs: 5 and 299.
[00122] [00122] —FIG.5G. Schematic diagram of the modified ANGPTL3 ADO5307 RNAi antisense and sense strips (see
[00123] [00123] FIG.5H. Schematic diagram of the modified antisepense and sense strips of ANGPTL3 ADO5418 RNAi agent (see Tables 3 to 5), conjugated to an N-acetyl-galactosamine tridentate ligand having the (NAG37) s structure (see Table 6) . Fig. 5SH describes SEQ ID NOs: 9 and 292.
[00124] [00124] FIG.5I. Schematic diagram of the modified antisepense and sense strips of ANGPTL3 ADO5577 RNAi agent (see Tables 3 to 5), conjugated to an N-acetyl-galactosamine tridentate ligand having the (NAG37) s structure (see Table 6) . Fig. 51 describes SEQ ID NOs: 11 and 279.
[00125] [00125] FIG.5J. Schematic diagram of the modified antisepense and sense strips of ANGPTL3 ADO5308 RNAi agent (see Tables 3 to 5), conjugated to an N-acetyl-galactosamine tridentate ligand having the (NAG37) s structure (see Table 6) . Fig. 5J describes SEQ ID NOs: 13 and 279.
[00126] [00126] FIG.5K. Schematic diagram of the modified antisepense and sense strips of ANGPTL3 ADOS5840 RNAi agent (see Tables 3 to 5), conjugated to an N-acetyl-galactosamine tridentate ligand having the (NAG37) structure s (see Table 6). Fig. 5SK describes SEQ ID NOs: 15 and 357.
[00127] [00127] RNAi agents for inhibiting the expression of an ANGPTL3 gene (referred to herein as ANGPTL3 RNAi agents or ANGPTL3 RNAi triggers) are described herein. Each ANGPTL3 RNAi agent comprises a sense strip and an antisense strip. The sense tape and the antisense tape each can be 16 to 30 nucleotides in length. Sense or antisense tapes can be of the same length or can be of different lengths. In some embodiments, the sense or antisense strips are each 17 to 27 nucleotides in length. In some embodiments, the sense or antisense strips are each 17 to 21 nucleotides in length. In some embodiments, both sense or antisense strands are each 21 to 26 nucleotides in length. In some embodiments, the sense or antisense strips are each 21 to 24 nucleotides in length. In some embodiments, the sense tape is about 19 nucleotides in length while the antisense tape is about 21 nucleotides in length. In some embodiments, the sense tape is about 21 nucleotides in length while the antisense tape is about 23 nucleotides in length. In some embodiments, a sense tape is 23 nucleotides in length and an antisense tape is 21 nucleotides in length. In some embodiments, both sense or antisense tapes are each 21 nucleotides in length. In some embodiments, the antisense strips and sense of RNAi agent each have 16, 17, 18, 19, 20, 21, 22,23, 24, 25, 26, or 27 nucleotides in length. In some embodiments, a double-stranded RNAi agent has a duplex length of about 16, 17, 18, 19, 20, 21, 22, 23 or 24 nucleotides.
[00128] [00128] In some modalities, the region of perfect, substantial or partial complementarity between the sense tape and the antisense tape is 16 to 26 (for example, 16, 17, 18, 19, 20, 21, 22, 23, 24 , 25, or 26) nucleotides in length and occurs at or near the 5 'end of the antisense tape (for example, this region can be separated from the 5' end of the antisense tape by O, 1, 2, 3, or 4 nucleotides that are not perfect, substantially or partially complementary).
[00129] [00129] The sense tape and antisense tape each contains a core stretch (also referred to here as a "core sequence" or a "core stretch sequence") that is 16 to 23 nucleotides in length. An antisense ribbon core elongation is 100% (perfectly) complementary or at least about 85% (substantially) complementary to the nucleotide sequence (sometimes referred to, for example, as a target sequence) present in the target ANGPTL3 MRNA. A sense tape core stretch sequence is 100% (perfectly) complementary or at least about 85% (substantially) complementary to a core stretch sequence on the antisense tape, and so the sense tape core stretch sequence is typically perfectly fine. identical or at least about 85% identical to the nucleotide sequence (target sequence) present in the target ANGPTL3 MRNA. A sense strand core sequence may be of the same length with a corresponding antisense core sequence or it may be of a different length. In some embodiments, the antisense tape core stretching sequence is 16, 17, 18, 19, 20, 21, 22, or 23 nucleotides in length. In some embodiments, the sense core stretch sequence is 16, 17, 18, 19, 20, 21, 22, or 23 nucleotides in length.
[00130] [00130] Examples of nucleotide sequences used in the formation of ANGPTL3 RNAi agents are provided in tables 2,3, and 4. Examples of RNAi agent duplexes, which include the sense and antisense tape sequences in tables 2, 3, and 4, are shown in Table 5.
[00131] [00131] ANGPTL3 RNAi agent sense and antisense asphytes ring to form a duplex. A sense tape and an antisense tape from an ANGPTL3 RNAi agent can be partial, substantial or totally complementary to each other. Within the complementary duplex region, the sense tape core stretching sequence is at least 85% complementary or 100% complementary to the antisense core stretching sequence. In some embodiments, the sense core stretch sequence contains a sequence of at least 16, at least 17, at least 18, at least 20, at least 21, at least 22, or at least 23 nucleotides that is at least 85% or 100% complementary to a sequence of 16, 17, 18, 19, 20, 21, 22, or 23 corresponding nucleotides from the antisense ribbon core stretching sequence (i.e., the sense core stretching sequences and antisense of an ANGPTL3 RNAi agent have a region of at least 16, at least 17, at least 18, at least 20, at least 20, at least 21, at least 22, or at least 23 nucleotides which is at least 85 % paired base or 100% paired base.)
[00132] [00132] In some embodiments, the antisense strand of an ANGPTL3 RNAi agent described here differs by 0, 1, 2, or 3 nucleotides from any of the antisense strings in Table 2 or Table
[00133] [00133] The sense tape and / or the antisense tape can optionally and independently contain an additional 1, 2, 3, 4, 5, or 6 nucleotides (extension) at the 3 'end, at the 5' end, or both at the ends 3 'and 5' of the core stretching sequences. Additional antisense strand nucleotides, if present, may or may not be complementary to the corresponding sequence in the ANGPTL3 MRNA. Additional sense strand nucleotides, if present, may or may not be identical to the corresponding sequence in the ANGPTL3 mRNA. Additional antisense tape nucleotides, if present,
[00134] [00134] As used herein, an extension comprises 1, 2,3,4,5, or 6 nucleotides at the 5 'end and / or 3' end of the sense core strand sequence and / or core strand sequence antisense. Extension nucleotides on a sense tape may or may not be complementary to the nucleotides, or nucleotides of the nucleus lengthening sequence or extension nucleotides, on the corresponding antisense tape. Conversely, the extension nucleotides on an antisense strip may or may not be complementary to the nucleotides, or extension nucleotides or extension nucleotides, on the corresponding sense strip. In some embodiments, both the sense strand and the antisense strand of an RNAi agent contain 3 'and 5 "extensions. In some embodiments, one or more of the 3' extension nucleotides of a strand base pair with one or more 5 'nucleotides from the other strand In other embodiments, one or more 3' nucleotides from one strand base do not match one or more 5 'nucleotides from the other strand. In some embodiments, an ANGPTL3 RNAi has an antisense strand having a 3 'extension and a sense strand having a 5' extension. In some embodiments, the extension nucleotides are unpaired and form a lump. As used here, a "lump" refers to an extension of one or more unpaired nucleotides located at one end of the antisense strip that is not part of the hybridized or duplexed portion of an RNAi agent described herein.
[00135] [00135] In some embodiments, an ANGPTL3 RNAi agent comprises an antisense strip having a 3 'extension of 1,2,3, 4, 5, or 6 nucleotides in length. In other embodiments, an ANGPTL3 RNAi agent comprises an antisense strip having a 3 'extension of 1, 2, or 3 nucleotides in length. In some embodiments, one or more of the antisense tape extension nucleotides comprise uracil or thymidine nucleotides or nucleotides that are complementary to the corresponding ANGPTL3 mMRNA sequence.
[00136] [00136] In some embodiments, the 3 'end of the antisense tape may include abasic residues (Ab), which can also be referred to as an "abasic site" or "abasic nucleotide." An abasic residue (Ab) is a nucleotide or nucleoside that does not have a nucleobase at the 1st position of the sugar portion. (See, for example, United States Patent No. 5,998,203). In some embodiments, Ab or AbAb can be added to the 3 'end of the antisense tape.
[00137] [00137] In some embodiments, the sense tape or the antisense tape may include a "terminal plug," which as used here is a non-nucleotide compound or other portion that can be incorporated into one or more terminals of an agent tape of RNAi described here, and may provide the RNAi agent, in some cases, with certain beneficial properties, such as, for example, protection against exonuclease degradation. In some embodiments, inverted abasic residues (invAb) are added as terminal buffers (see Table 6). (See, for example, F. Czauderna, Nucleic Acids Res., 2003, 31 (11), 2705-16). End buffers are generally known in the art, and include, for example, inverted abasic residues as well as carbon chains such as terminal C3, C6, or C12 groups. In some embodiments, a terminal plug is present at the 5 'terminal end, the 3' terminal end, or both the 5 'and 3' terminal ends of the sense tape.
[00138] [00138] In some embodiments, an ANGPTL3 RNAi agent comprises a sense strand having a 3 'span of 1,2, 3,4, or 5 nucleotides in length. In some embodiments, one or more of the nucleotide extension strand comprises adenosine, uracil nucleotides, or thymidine, AT dinucleotide, or nucleotides that correspond to the nucleotides in the ANGPTL3 mMRNA sequence. In some embodiments, the 3 'sense tape extension includes or consists of one of the following strings, but is not limited to: T, UT, TT, UU, UUT, TTT, or TTTT (each listed from 5'to 3') .
[00139] [00139] In some embodiments, the 3 'end of the sense tape may include abasic residues or additional inverted abasic terminal plugs. In some embodiments, UUAb, UAb, or Ab are added to the 3 'end of the sense tape.
[00140] [00140] In some embodiments, one or more inverted abasic residues (invAb) are added to the 3 'end of the sense tape. In some embodiments, one or more inverted abasic residues (invAb) are added to the 5 'end of the sense tape. In some embodiments, one or more inverted abasic residues or inverted abasic sites are inserted between the targeting ligand and the nucleobase sequence of the RNAi agent sense strand. In some embodiments, the inclusion of one or more inverted abasic residues or inverted abasic sites at or near the terminal end or terminal ends of an RNAi agent's sense strand allows enhanced activity or other desired properties of an RNAi agent.
[00141] [00141] In some embodiments, an ANGPTL3 RNAi agent comprises a sense strand having a 5 'extension of 1, 2, 3,4,5, or 6 nucleotides in length. In some embodiments, one or more of the sense strand nucleotides comprise uracil or adenosine nuceotides or nucleotides that correspond to the nucleotides in the ANGPTL3 mMRNA sequence. In some embodiments, the 5 'extension of sense tape is one of the following strings, but is not limited to: CA, AUAGGC, AUAGG, AUAG, AUA, A, AA, AC, GCA, GGCA, GGC, UAUCA, UAUC, UCA , UAU, U, UU (each listed from 5 'to 3'). A sense tape can have a 3 'extension and / or a 5' extension.
[00142] [00142] In some embodiments, the 5 'end of the sense tape may include one or more additional abasic residues (for example, (Ab) or (AbAb)). In some embodiments, one or more inverted abasic residues (invAb) are added to the 5 'end of the sense tape. In some embodiments, one or more inverted abasic residues can be inserted between the targeting ligand and the nucleobase sequence of the RNAi agent sense strand. In some embodiments, the inclusion of one or more abasic residues inverted at or near the terminal end or end ends of the sense strand of an RNAi agent may allow enhanced activity or other desired properties of an RNAi agent. In some embodiments, an abasic residue (deoxyribose) can be replaced with a ribitol residue (abasic ribose).
[00143] [00143] In some embodiments, the 3 'end of the antisense tape core stretching sequence, or the 3' end of the antisense tape sequence, may include an inverted abasic residue (invAb (see Table 6)).
[00144] [00144] Examples of sequences used in the formation of ANGPTL3 RNAi agents are provided in Tables 2, 3, and 4. In some embodiments, an ANGPTL3 RNAi antiserum strand agent includes a sequence of any of the sequences in Tables 2 or 3. In certain embodiments, an ANGPTL3 RNAi agent antisense strand comprises or consists of any of the modified sequences in Table 3. In some embodiments, an ANGPTL3 RNAi agent antisense strand includes the nucleotide (end) sequence 5 '> end 3') 1 to 17, 2a 15, 2a 17, 1a 18,2a18,
[00145] [00145] In some embodiments, the sense or antisense strands of the RNAi agents described here contain the same number of nucleotides. In some embodiments, the sense or antisense strands of the RNAi agents described here contain different nucleotides. In some embodiments, the 5 'end of sense tape and the 3' end of antisense tape of an RNAi agent form a blunt end. In some embodiments, the 3 'end of sense tape and the 5' end of antisense tape of an RNAi agent form a blunt end. In some embodiments, both ends of an RNAi agent form blunt ends. In some embodiments, no end of an RNAi agent is a blunt end. As used herein, a "blunt end" refers to an end of a double stranded RNA agent in which the terminal nucleotides of the two ringed strands are complementary (form a complementary base pair).
[00146] [00146] In some embodiments, the 5 'end of sense tape and the 3' end of antisense tape of an RNAi agent form a worn end. In some embodiments, the 3 'end of sense tape and the 5' end of antisense tape of an RNAi agent form a worn end. In some embodiments, both ends of an RNAi agent form a worn end. In some embodiments, neither end of an RNAi agent is a worn end. As used here, a worn end refers to an end of a double-stranded RNAi agent on which the nucleotides of the two ringed strands of a pair (that is, they do not form a lump), but are not complementary (that is, they form a non-complementary pair). In some embodiments, one or more unpaired nucleotides at the end of a strand of a double stranded RNAi agent forms a bulge. Unpaired nucleotides can be on the sense or antisense tape, creating 3 'or 5 "bumps. In some embodiments, the RNAi agent contains: a blunt end and a worn end, a blunt end and a 5' lump end. , a blunt end and a 3 'hump end, a worn end and a 5' hump end, a worn end and a 3 'hump end, two 5' hump ends, two 3 'hump ends, a protrusion 5 'and one end of protrusion 3', two worn ends, or two blunt ends. Typically, when present, the protrusions are located at the 3 'terminal ends of the sense tape, the antisense tape, or both the sense tape and the tape antisense.
[00147] [00147] - "Modified nucleotides, when used in various polynucleotide or oligonucleotide constructions, can conserve the activity of the compound in cells, while at the same time increasing the stability of the serum of these compounds, and can also minimize the possibility of activating the activity of interferon in humans in administering the polynucleotide or oligonucleotide construct.
[00148] [00148] In some embodiments, an ANGPTL3 RNAi agent is prepared or supplied as a salt, mixed salt or a filter acid. In some embodiments, an ANGPTL3 RNAi agent is prepared as a sodium salt. Such forms that are well known in the art are within the scope of the inventions described here. Modified Nucleotides
[00149] [00149] In some embodiments, an ANGPTL3 RNAi agent contains one or more modified nucleotides. As used here, a "modified nucleotide" is a nucleotide other than a ribonucleotide (2'-hydroxyl nucleotide). In some embodiments, at least 50% (for example, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99 %, or 100%) of the nucleotides are modified nucleotides. As used herein, modified nucleotides may include, but are not limited to, deoxyribonucleotides, nucleotide mimics, abasic nucleotides (represented here as Ab), modified 2'-nucleotides, 3 'to 3' (reversed) nucleotides (represented here such as invdN, invN, invn), nucleotides comprising modified nuceobase, bridged nucleotides, peptide nucleic acids (PNAs), 2 ', 3-dry nucleotide mimics (unblocked nucleobase analogs, represented here as Nuna or NUNA), blocked nucleotides (represented here as Nina or NLNA), 3'-O-methoxy nucleotides (2 'linked internucleoside) (represented here as 3'-OMen), 2'-F-Arabino nucleotides (represented here as NfANA or Nfana ), 5'-Me, 2'-fluorine nucleotide (represented here as 5Me-Nf), morpholino nucleotides, vinyl phosphonate deoxyribonucleotides (represented here as vpdN), nucleotides containing vinyl phosphonate, and nucleotides “containing cyclopropyl phosphonate (CPrpN). 2 "modified nucleotides (ie, a nucleotide with a group other than a hydroxyl group at the 2 'position of the five-membered sugar ring) include, but are not limited to, 2'-O-methyl nucleotides (represented here as a lowercase letter no in the nucleotide sequence), 2'-deoxy-2'-fluorine nucleotides (also referred to here as 2'-fluorine nucleotide, and represented here as Nf), 2'-deoxy nucleotides (represented here as dN) , 2'-methoxyethyl (2-O0-2-methoxyethyl) nucleotides (also referred to herein as 2 "- MOE, and represented here as NM), 2'-amino nucleotides, and 2'-alkyl nucleotides. It is not necessary for all positions in a given compound to be uniformly modified. Conversely, more than one modification can be incorporated into a single ANGPTL3 RNAi agent or even a single nucleotide thereof. ANGPTL3 RNAi agent antisense tapes and sense tapes can be synthesized and / or modified by methods known in the art. The change in one nucleotide is independent of the change in another nucleotide.
[00150] [00150] Modified nucleobases include synthetic and natural nucleobases, such as 5-substituted pyrimidines, 6-azapyrimidines and purines - substituted by N-2, N-6 and O6 (for example, 2-aminopropyladenine, 5-propynyluracil, or 5- propynylcytosine), 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, inosine, xanthine, hypoxanthine, 2-aminoadenine, 6-alkyl derivatives (for example, 6-methyl, 6-ethyl, 6-isopropyl, or 6-n-butyl) of adenine and guanine, 2-alkyl (for example, 2-methyl, 2-ethyl, 2-isopropyl, or 2-n-butyl) and other adenine and guanine alkyl derivatives, 2- thiouracil, 2-thiotimine, 2-thiocytosine, 5-halouracil, cytosine, 5-propynyl uracil, 5-propynyl cytosine,
[00151] [00151] In some embodiments, all or substantially all of the nucleotides of an RNAi agent are modified nucleotides. As used herein, an RNAi agent, in which substantially all of the nucleotides present are modified nucleotides, is an RNAi agent having four or less (i.e., O, 1, 2, 3, or 4) nucleotides on both the sense and on the antisense tape being ribonucleotides (ie, unmodified). As used herein, a sense strand, in which substantially all of the nucleotides present are modified nucleotides, is a sense strand having two or less (i.e., O, 1, or 2) nucleotides on the sense strand being unmodified ribonucleotides. As used here, an antisense strand, sense in which substantially all of the nucleotides present are modified nucleotides, is an antisense strand having two or less (i.e., O, 1, or 2) nucleotides on the sense strand being unmodified ribonucleotides. In some embodiments, one or more nucleotides of an RNAi agent are an unmodified ribonucleotide. Modified Internucleoside Links
[00152] [00152] In some embodiments, one or more nucleotides of an ANGPTL3 RNAi agent are linked by non-standard bonds or structures (i.e., modified internucleoside bonds or modified structures). Modified internucleoside structures and bonds include, but are not limited to, phosphorothioate groups (represented here as a lower case "s"), chiral phosphorothioates, thiophosphates, phosphorodithioates, phosphotriesteres, "aminoalkylphosphotriesters, alkyl phosphonates (for example, phosphonates of alkylsates methyl or 3 "-alkenylene phosphonates) chiral phosphonates, phosphinates, phosphoramidates (eg 3 '” - amino phosphoramidate, aminoalkylphosphoramidates, or thionophosphoramidates), thionoalkylphosphonates, thionalkylphosphotriesteres, 5-boron phosphate bonds normal, linked 2 "-5 'analogs of boranophosphates, or boranophosphates having inverted polarity, where adjacent pairs of nucleoside units are linked 3'-5' to 5-3 'or 2-5' to 5-2 ' . In some embodiments, a modified internucleoside structure or bond does not have a phosphorus atom. Modified internucleoside bonds that do not have a phosphorus atom include, but are not limited to, short chain alkyl or cycloalkyl inter-sugar bonds, mixed heteroatom and alkyl or cycloalkyl inter-sugar bonds, or one or more short chain heteroatomic or heterocyclic inter-sugar bonds . In some embodiments, modified internucleoside structures include, but are not limited to, siloxane structures, sulfide structures, sulfoxide structures, sulfone structures, formacetyl and thioformacetyl structures, methylene formacetyl and thioformacetyl structures, wavy structures, structures sulfamate, methyleneimine and methylene hydrazine structures, sulfonate and sulfonamide structures, amide structures, and other structures having mixed components of N, O, S, and CH>.
[00153] [00153] In some embodiments, an ANGPTL3 RNAi sense strand may contain 1, 2, 3, 4, 5, or 6 phosphorothioate bonds, an ANGPTL3 RNAi agent antisense strand may contain 1, 2 , 3, 4, 5, or 6 phosphorothioate bonds, or both the sense tape and the antisense tape independently can contain 1, 2, 3, 4, 5, or 6 phosphorothioate bonds. In some embodiments, an ANGPTL3 RNAi agent sense strand may contain 1, 2, 3, or 4 phosphorothioate bonds, an ANGPTL3 RNAi agent antisense strand may contain 1, 2, 3, or 4 phosphorothioate, or both sense tape and antisense tape can independently contain 1, 2, 3, or 4 phosphorothioate bonds.
[00154] [00154] In some embodiments, an ANGPTL3 RNAi sense strand contains at least two phosphorothioate internucleoside bonds. In some embodiments, the at least two internucleoside phosphorothioate bonds are between the nucleotides at positions 1 to 3 of the 3 'end of the sense strand. In some embodiments, an internucleoside phosphorothioate bond is at the 5 'end of the sense strand, and the other phosphorothioate bond is at the 3' end of the sense strand. In some embodiments, two internucleoside phosphorothioate bonds are located at the 5 'end of the sense strand, and the other phosphorothioate bond is at the end of the sense strand. In some embodiments, the sense tape dose does not include any phosphoroticate internucleoside bonds between the nucleotides, but does contain one, two or three phosphorothioate bonds between the terminal nucleotides at both the 5 'and 3' ends and the inverted abasic terminal plug. optionally present. In some embodiments, the targeting ligand is attached to the sense tape via a phosphorothioate bond.
[00155] [00155] In some embodiments, an ANGPTL3 RNAi antisense tape contains four phosphoroticate internucleoside bonds. In some embodiments, the four phosphorothioate internucleoside bonds are between the nucleotides at positions 1 to 3 from the 5 'end of the antisense tape and between the nucleotides at positions 19 to 21.20 to 22.21 to 23.22 to 24.23a25 , or 24 to 26 from the 5th end. In some embodiments, three phosphorothioate internucleoside bonds are located between positions 1 to 4 from the 5 'end of the antisense tape, and a fourth phosphoroticate internucleoside bond is located between positions 20 to 21 from the 5' end of the tape antisense. In some embodiments, an ANGPTL3 RNAi agent contains at least three or four internucleoside phosphorothioate bonds on the antisense tape.
[00156] [00156] In some embodiments, an ANGPTL3 RNAi agent contains one or more modified nucleotides and one or more internucleoside - modified bonds. In some embodiments, the modified 2'-nucleoside is combined with modified internucleoside binding. ANGPTL3 RNAi AGENTS
[00157] [00157] In some embodiments, the ANGPTL3 RNAi agents described here carry an ANGPTL3 gene at or near the positions of the ANGPTL3 gene sequence shown in Table 1. In some embodiments, the antisense strand of an ANGPTL3 RNAi agent described here includes a core elongation sequence that is fully, substantially, or at least partially complementary to the target ANGPTL3 19-mer sequence described in Table 1.
[00158] [00158] Table 1. Target ANGPTL3 19-mer MRNA sequences (taken from homo sapiens type 3 angiopoietin transcription (ANGPTL3), GenBank NM 014495.3 (SEQ ID NO: 1)) ANGPTL3 19-mer sequences | Target positions corresponding in (5 '> 3 ") SEQ ID NO: 1
[00159] [00159] In some embodiments, an ANGPTL3 RNAi agent includes an antisense strip, where position 19 of the antisense strip (5 '> 23') is capable of forming a base pair with position 1 of a target sequence 19 -mer described in Table 1. In some embodiments, an ANGPTL3 RNAi agent includes an antisense strand, where position 1 of the antisense strand (5'33 ') is capable of forming a base pair with position 19 of the sequence 19-mer target described in Table 1.
[00160] [00160] In some embodiments, an ANGPTL3 RNAi agent includes an antisense strand, where position 2 of the antisense strand (5 '> 3') is able to form a base pair with position 18 of the target sequence 19- mer described in Table 1. In some embodiments, an ANGPTL3 RNAi agent includes an antisense strip, where positions 2 to 18 of the antisense strip (5 '> 3') are able to form base pairs with each of the respective complementary bases located at 18 to 2 of the 19-mer target sequence described in Table 1.
[00161] [00161] For the RNAi agents described here, the nucleotide at position 1 of the antisense strip (from the 5 'end> 3' end) may be perfectly complementary to the ANGPTL3 gene, or it may be non-complementary to the ANGPTL3 gene. In some embodiments, the nucleotide at position 1 of the antisense strip (from the 5 'end> 3' end) is a U, A, or dT. In some embodiments, the nucleotide at position 1 of the antisense tape (from the 5 'end> 3' end) forms a base pair A: U or U: A with the sense tape.
[00162] [00162] In some embodiments, an ANGPTL3 RNAi agent antisense strand comprises the nucleotide sequence (from 5 'end> 3' end) 2 to 18 or 2 to 19 of any of the antisense sequences in Table 2 or Table 3 In some embodiments, an ANGPTL3 RNAi sense strand comprises the nucleotide sequence (from the 5 'end> end 3) 1 to 17, 1 to 18, or 2 to 18 of any of the sense strand sequences in Table 2 or Table 4.
[00163] [00163] In some embodiments, an ANGPTL3 RNAi agent is comprised of (i) an antisense strand comprising the nucleotide sequence (from the 5 'end> 3 "end) 2a 18 or 2a 19 of any of the antisense sequences in the Table 2 or Table 3, and (ii) a sense strand comprising the nucleotide sequence (from the 5 'end> 3' end) 1 to 17 or 1 to 18 of any of the sense strings in Table 2 or Table 4 .
[00164] [00164] In some embodiments, the ANGPTL3 RNAi agents include 19-mer nucleotide sequences shown in the following Table 2.
[00165] [00165] The sense strips and antisense strands of ANGPTL3 RNAi agent that comprise or consist of the sequences in Table 2 can be modified nucleotides or unmodified nucleotides. In some embodiments, ANGPTL3 RNAi agents having the sense and antisense streak sequences that comprise or consist of the sequences in Table 2 are all or substantially all modified nucleotides
[00166] [00166] In some embodiments, the antisense strand of an ANGPTL3 RNAi agent described here differs by 0, 1, 2, or 3 nucleotides from any of the antisense strings in Table 2. In some embodiments, the sense tape an ANGPTL3 RNAi agent described here differs by 0, 1, 2, or 3 nucleotides from any of the sense strand sequences in Table 2.
[00167] [00167] As used here, each N listed in a sequence described in Table 2 can be independently selected from any and all nucleobases (including those found in both the modified and unmodified nucleotides) In some embodiments, an N nucleotide listed in a sequence described in Table 2 has a nucleobase that is complementary to the N nucleotide in the corresponding position on the other strand. In some embodiments, an N nucleotide listed in a sequence described in Table 2 has a nucleobase that is not complementary to the N nucleotide in the corresponding position on the other strand. In some embodiments, an N nucleotide listed in a sequence described in Table 2 has a nucleobase that is equal to the N nucleotide in the corresponding position on the other strand. In some embodiments, an N nucleotide listed in a sequence described in Table 2 has a nucleobase that is different from the N nucleotide in the corresponding position on the other strand.
[00168] [00168] Certain modified ANGPTL3 RNAi antisense strands, as well as their underlying unmodified nucleobase sequences, are provided in Table 3. Certain modified ANGPTL3 RNAi sense strands as well as their underlying unmodified nucleobase sequences, are provided in Table 4. In the formation of ANGPTL3 RNAi agents, each of the nucleotides in each of the underlying base sequences listed in Tables 3 and 4, as well as in Table 2, above, may be a modified nucleotide.
[00169] [00169] ANGPTL3 RNAi agents are described here formed by annealing an antisense tape with a sense tape. A sense tape containing a sequence listed in Table 2 or Table 4 can be hybridized to any antisense tape containing a sequence listed in Table 2 or Table 3, as long as the two sequences have a region of at least 85% more complementarity than than the continuous sequence of 16, 17.18, 19, 20, or 21 nucleotides.
[00170] [00170] In some embodiments, an ANGPTL3 RNAi antisense strand comprises the nucleotide sequence of any of the sequences in Table 2 or Table 3.
[00171] [00171] In some embodiments, an ANGPTL3 RNAi agent comprises or consists of a duplex having the sense tape and antisense tape nucleobase sequences of any of the sequences in Table 2, Table 3 or Table 4.
[00172] [00172] Examples of antisense tapes containing modified nucleotides are provided in Table 3. Examples of sense tapes containing modified nucleotides are provided in Table 4.
[00173] [00173] As used in Tables 3 and 4, the following notations are used to indicate modified nucleotides, targeting groups, and linking groups: A = adenosine-3'-phosphate; [6 = cytidine-3-phosphate;
[00174] [00174] As the person skilled in the art would easily understand, unless otherwise indicated by the sequence (such as, for example, by a phosphorothioate bond "s"), when present in an oligonucleotide, the nucleotide monomers are mutually linked by 5'-3 "-phosphodiester bonds. As the person skilled in the art would clearly understand, the inclusion of a phosphorotic bond, as shown in the modified nucleotide sequences described here, replaces the phosphodiester bond typically present in oligonucleotides (see , for example, Figs. 5A to 5K showing all internucleoside bonds.) Furthermore, the person skilled in the art would easily understand that the terminal nucleotide at the 3 'end of a given oligonucleotide sequence would typically have a hydroxyl group (-OH) in the respective 3 'position of the given monomer instead of a phosphate moiety ex vivo. Furthermore, as the knowledgeable person would easily understand and appreciate, while the chemical phosphoroticate structures described here typically show the anion in the sulfur atom, the inventions described here cover all phosphorothioate tautomers and / or diastereomers (for example, where the sulfur atom has a double bond and the anion is in an atom oxygen). Unless expressly stated otherwise herein, such understandings of the person skilled in the art are used when describing the ANGPTL3 RNAi agents and ANGPTL3 RNAi agent compositions described herein.
[00175] [00175] Certain examples of targeting groups and linking groups used with ANGPTL3 RNAi agents are described here, provided below in Table 6. More specifically, targeting groups and linking groups include the following, for which their structures chemicals are given below in Table 6: (PEACE), (NAG13), (NAG13) s, (NAG18), (NAG18) s, (NAG24), (NAG24) s, (NAG25), (NAG25) s, (NAG26 ), (NAG26) s, (NAG27), (NAG27) s, (NAG28), (NAG28) s, (NAG29), (NAG29) s, (NAG30), (NAG30) s, (NAG31), (NAG31) s, (NAG32), (NAG32) s, (NAG33), (NAG33) s, (NAG34), (NAG34) s, (NAG35), (NAG35) s, (NAG36), (NAG36) s, (NAG37) , (NAG37) s, (NAG38), (NAG38) s, (NAG39), (NAG39) s. Each sense tape and / or antisense tape can have any targeting groups or linking groups listed here, as well as other targeting or linking groups, conjugated to the 5 'and / or 3' end of the sequence.
[00176] [00176] ANGPTL3 RNAi agents are described here formed by annealing an antisense tape with a sense tape. A sense tape containing a sequence listed in Table 2 or Table 4 can be hybridized to any antisense tape containing a sequence listed in Table 2 or Table 3, as long as the two sequences have a region of at least 85% complementarity over a contiguous sequence of 16, 17, 18, 19, or 21 nucleotides.
[00177] [00177] In some embodiments, the antisense strand of an ANGPTL3 RNAi agent described here differs by 0, 1, 2, or 3 nucleotides from any of the antisense strings in Table 3. In some embodiments, the sense strand of a ANGPTL3 RNAi agent described here differs by 0, 1, 2, or 3 nucleotides from any of the sense strand sequences in Table 4.
[00178] [00178] In some embodiments, an ANGPTL3 RNAi agent antisense strand comprises the nucleotide sequence of any of the sequences in Table 2 or Table 3. In some embodiments, an ANGPTL3 RNAi agent antisense strand comprises the sequence of nucleotides (from 5 'end> 3' end) 1 to 17, 2a 17, 1a 18,2a18,1a19,2a19,1a20,2 to 20, 1a21,2a21,1a22,2a22,1a23,2a23,1a24, or out of any of the sequences in Table 2 or Table 3. In certain embodiments, an ANGPTL3 RNAi agent antisense strand comprises or consists of a modified sequence from any of the modified sequences in Table 3.
[00179] [00179] In some embodiments, an ANGPTL3 RNAi sense strand comprises the nucleotide sequence of any of the sequences in Table 2 or Table 4. In some embodiments, an ANGPTL3 RNAi sense strand comprises the nucleotide sequence (from 5 'end> 3' end) 1 to
[00180] [00180] For the ANGPTL3 RNAi agents described here, the nucleotide at position 1 of the antisense strip (from the 5th end> 3 'end) may be perfectly complementary to an ANGPTL3 gene, or it may be non-complementary to an ANGPTL3 gene. In some embodiments, the nucleotide at position 1 of the antisense strip (from the 5 'end> 3' end) is a U, A, or dT (or a modified version of it). In some embodiments, the nucleotide at position 1 of the antisense tape (from the 5 'end> 3' end) forms a base pair A: U or U: A with the sense tape.
[00181] [00181] In some embodiments, an ANGPTL3 RNAi antisense strand comprises the nucleotide sequence (from 5 'end> 3' end) 2 to 18 or 2 to 19 of any of the antisense sequences in Table 2 or Table 3 In some embodiments, an ANGPTL3 RNAi sense strand comprises the nucleotide sequence (5 'end> 3 "end) 1 to 17 or 1 to 18 of any of the sense strand sequences in Table 2 or Table 4.
[00182] [00182] In some embodiments, an ANGPTL3 RNAi agent includes (i) an antisense strand comprising the nucleotide sequence (from the 5 'end> 3' end) 2 to 18 or 2 to 19 of any of the antisense sequences in the Table 2 or Table 3, and (ii) a sense strand comprising the nucleotide sequence (from the 5 'end> 3' end) 1 to 17 or 1 to 18 of any of the sense strings in Table 2 or Table 4 .
[00183] [00183] A phytense probe containing a sequence listed in Table 2 or Table 4 can be hybridized to any antisense tape containing a sequence listed in Table 2 or Table 3, as long as the two sequences have a region of at least 85% complementarity over one contiguous sequence of 16, 17, 18, 19, or 21 nucleotides. In some embodiments, the ANGPTL3 RNAi agent has a sense strand consisting of the modified sequence of any of the modified strings in Table 4, and an antisense strand consisting of the modified sequence of any of the modified strings in Table 3. Certain pairings Representative sequence numbers are exemplified by the Duplex ID numbers shown in Table 5.
[00184] [00184] In some embodiments, an ANGPTL3 RNAi agent comprises, consists of, or consists essentially of a duplex represented by any of the Duplex ID numbers presented here. In some embodiments, an ANGPTL3 RNAi agent comprises the sense strand and antisense strand nucleotide sequence of any of the duplexes represented by any of the Duplex ID numbers presented here. In some embodiments, an ANGPTL3 RNAi agent comprises the sense strand and antisense strand nucleotide sequence of any of the duplexes represented by any of the Duplex ID numbers presented here and a targeting group and / or linking group, where the targeting group and / or linking group is covalently linked (i.e., conjugated) to the sense tape or the antisense tape. In some embodiments, an ANGPTL3 RNAi agent includes the modified sense strand and antisense strand nucleotide sequences of any of the Duplex ID numbers shown here. In some embodiments, an ANGPTL3 RNAi agent comprises the modified sense strand and antisense strand nucleotide sequences of any of the Duplex ID numbers presented here and a targeting group and / or linking group, where the targeting group and / or bonding group is covalently attached to the sense tape or the antisense tape.
[00185] [00185] In some embodiments, an ANGPTL3 RNAi agent comprises an antisense strand and a sense strand having the nucleotide sequences of any of the antisense strand / sense strand duplexes in Table 2 or Table 5, and also comprises a group of targeting. In some embodiments, an ANGPTL3 RNAi agent comprises an antisense strand and a sense strand having the nucleotide sequences of any of the antisense strand / sense strand duplexes in Table 2 or Table 5, and also comprises a ligand targeting group asialoglycoprotein receptor.
[00186] [00186] In some embodiments, an ANGPTL3 RNAi agent comprises an antisense strand and a sense strand having the nucleotide sequences of any of the antisense strand / sense strand duplexes in Table 2 or Table 5, and also comprises a group of targeting selected from the group consisting of (NAG13), (NAG13) s, (NAG18), (NAG18) s, (NAG24), (NAG24) s, (NAG25), (NAG25) s, (NAG26), (NAG26) s, (NAG27), (NAG27) s, (NAG28), (NAG28) s, (NAG29), (NAG29) s, (NAG30), (NAG30) s, (NAG31), (NAG31) s, (NAG32) , (NAG32) s, (NAG33), (NAG33) s, (NAG34), (NAG34) s, (NAG35), (NAG35) s, (NAG36), (NAG36) s, (NAG37), (NAG37) s , each as defined in Table 6. In some embodiments, the targeting group is (NAG25) or (NAG25) s as defined in Table 6. In other embodiments, the targeting group is (NAG37) or (NAG37) s, as defined in Table 6.
[00187] [00187] In some embodiments, an ANGPTL3 RNAi agent comprises an antisense strand and a sense strand having the modified nucleotide sequence of any of the antisense strand and / or sense strand nucleotide sequences in Table 3 or Table 4.
[00188] [00188] In some embodiments, an ANGPTL3 RNAi agent comprises an antisense strand and a sense strand having a modified nucleotide sequence from any of the antisense strand and / or sense strand nucleotide sequences of any of the duplexes in Table 5 , and also comprises an asialoglycoprotein receptor ligand targeting group.
[00189] [00189] In some embodiments, an ANGPTL3 RNAi agent comprises, consists of, or consists essentially of any of the duplexes in Table 5. Table 5. ANGPTL3 RNAi Agent duplexes with corresponding Senso and Antisense Tape ID Numbers
[00190] [00190] In some embodiments, an ANGPTL3 RNAi agent is prepared or supplied as a salt, mixed salt, or free acid. The RNAi agents described herein, in releasing a cell expressing an ANGPTL3 gene, inhibit or block the expression of one or more ANGPTL3 genes in vivo and / or in vitro.
[00191] [00191] In some embodiments, an ANGPTL3 RNAi agent is conjugated to one or more non-nucleotide groups including, but not limited to, a targeting group, a linking group, a release polymer, or the release vehicle. The non-nucleotide group can enhance the targeting, release or binding of the RNAi agent. Examples of targeting groups and linking groups are provided in Table 6. The non-nucleotide group can be covalently attached to the 3 'and / or 5' end of the sense tape and / or the antisense tape. In some embodiments, an ANGPTL3 RNAi agent contains a non-nucleotide group attached to the 3 'and / or 5th end of the sense strand. In some embodiments, a non-nucleotide group is attached to the 5 'end of an ANGPTL3 RNAi sense strand. A non-nucleotide group can be linked directly or indirectly to the RNAi agent via a linker / linking group. In some embodiments, a non-nucleotide group is attached to the RNAi agent via a labile, cleavable or reversible link or linker.
[00192] [00192] In some embodiments, a non-nucleotide group enhances the pharmacokinetic or biodistribution properties of an RNAi or conjugate agent to which it is attached to improve cell or tissue distribution and cell specific uptake of the RNAi or conjugate agent. In some embodiments, a non-nucleotide group enhances the endocytosis of the RNAi agent.
[00193] [00193] Targeting groups or targeting portions enhance the pharmacokinetic or biodistribution properties of a conjugate or RNAi agent to which they are attached to improve specific cell distribution (including, in some cases, organ specific) and specific uptake cell (or organ-specific) conjugate or RNAi agent. A targeting group can be monovalent, divalent, trivalent, tetravalent, or have greater value for the target to which it is directed. Representative targeting groups, without limitation, compounds with affinity for cell surface molecules, cell receptor ligands, haptens, antibodies, monoclonal antibodies, antibody fragments, and antibody mimics with affinity for cell surface molecules. In some embodiments, a targeting group is attached to an RNAi agent using a linker, such as a PEG linker or one, two or three abasic residues and / or ribitol (abasic ribose), which may, in some cases, work as binders. In some embodiments, a targeting group comprises a cluster derived from galactose.
[00194] The ANGPTL3 RNAi agents described here can be synthesized having a reactive group, such as an amino group (also referred to here as an amine), at the 5 'and / or the 3' terminal. The reactive group can be used subsequently to link a targeting portion using methods typical in the art.
[00195] [00195] In some embodiments, a targeting group comprises an asialoglycoprotein receptor ligand. As used here, an asialoglycoprotein receptor ligand is a ligand that contains a compound that has an affinity for the asiologlicoprotein receptor. As noted here, the asialoglycoprotein receptor is highly expressed in hepatocytes. In some embodiments, an asialoglycoprotein receptor ligand includes or consists of one or more galactose derivatives. As used herein, the term galactose derivative includes both galactose and galactose derivatives having an affinity for the asialoglycoprotein receptor that is equal to or greater than that of galactose. Galactose derivatives include, but are not limited to: galactose, galactosamine, N-formylgalactosamine, N-acetyl-galactosamine, N-propionyl-galactosamine, Nn-butanoyl-galactosamine, and N-iso-butanoylgalactosamine (see, for example : ST lobst and K. Drickamer, JBC, 1996, 271, 6686). Galactose derivatives, and galactose derivative clusters, which are useful for in vivo targeting of oligonucleotides and other molecules to the liver are known in the art (see, for example, Baenziger and Fiete, 1980, Cell, 22, 611- 620; Connolly et a /., 1982, J. Biol. Chem., 257, 939-945).
[00196] [00196] Galactose derivatives were used to target hepatocyte molecules in vivo through their binding to the asialoglycoprotein receptor expressed on the surface of hepatocytes. The binding of asialoglycoprotein receptor ligands to the asialoglycoprotein receptor (s) facilitates cell-specific targeting of hepatocytes and endocytosis of the molecule in hepatocytes. Asialoglycoprotein receptor ligands can be monomeric (for example, having a single galactose derivative) or multimeric (for example, having multiple galactose derivatives). The galactose derivative or galactose derivative cluster can be attached to the 3 'or 5' end of the sense or antisense strand of the RNAi agent using methods known in the art. The preparation of targeting groups, such as galactose-derived clusters, is described in, for example, International Patent Application Publication No. WO 2018/044350 by Arrowhead Pharmaceuticals, Inc., and International Patent Application Publication No. WO 2017 / 156012 by Arrowhead Pharmaceuticals, Inc., the contents of both of which are incorporated by reference in their entirety.
[00197] [00197] As used here, a galactose-derived cluster comprises a molecule having two to four terminal galactose derivatives. A terminal galactose derivative is attached to a molecule through its C-1 carbon. In some embodiments, the galactose-derived cluster is a trimer of galactose-derived (also referred to as triantenary-galactose-derived or trivalent galactose-derived). In some embodiments, the galactose-derived cluster - comprises - N-acetyl-galactosamines. In some embodiments, the galactose-derived cluster comprises three N-acetyl-galactosamines. In some embodiments, the galactose-derived cluster is a tetramer of a galactose derivative (also referred to as a tetra-antennary galactose derivative or a tetravalent galactose derivative). In some embodiments, the galactose-derived cluster comprises four N-acetyl-galactosamines.
[00198] [00198] As used here, a trimer of a galactose derivative contains three galactose derivatives, each linked to the central branching point. As used here, galactose derivative tetramer contains four galactose derivatives, each linked to the central branch point. Galactose derivatives can be linked to the central branching point using the C-1 carbons of saccharides. In some embodiments, galactose derivatives are linked to the branching point by means of ligands or spacers. In some embodiments, the linker or spacer is a flexible hydrophilic spacer, such as a PEG group (see, for example, United States Patent No. 5,885,968; Biessen et al. J. Med. Chem. 1995 Vol. 39 p. 1538-1546). In some embodiments, the PEG spacer is a PEG; z spacer. The branch point can be any small molecule that allows the binding of three galactose derivatives and also allows the branch point to be bound to the RNAi agent. An example of a branch point group is a dilisihna or diglutamate. The attachment of the branching point to the RNAi agent can occur through a linker or spacer. In some embodiments, the linker or spacer comprises a flexible hydrophilic spacer, such as, but not limited to, a PEG spacer. In some embodiments, the linker comprises a rigid linker, such as a cyclic group. In some embodiments, a galactose derivative comprises or consists of N-acetyl-galactosamine. In some embodiments, the galactose-derived cluster is comprised of a galactose-derived tetramer, which can be, for example, an N-acetyl-galactosamine tetramer.
[00199] [00199] "Modalities of the present invention include pharmaceutical compositions for delivering an ANGPTL3 RNAi agent to a liver cell in vivo. Such pharmaceutical compositions can include, for example, an ANGPTL3 RNAi agent conjugated to a galactose-derived cluster. In some embodiments, the galactose derivative cluster is comprised of a galactose derivative trimer, which can be, for example, an N-acetyl-galactosamin trimer, or galactose derivative tetramer, which can be, for example , a tetramer of N-acetyl-galactosamine.
[00200] [00200] Targeting groups include, but are not limited to, (PAZ), (NAG13), (NAG13) s, (NAG18), (NAG18) s, (NAG24), (NAG24) s, (NAG25), ( NAG25) s, (NAG26), (NAG26) s, (NAG27), (NAG27) s, (NAG28), (NAG28) s, (NAG29), (NAG29) s, (NAG30O), (NAG30) s, ( NAG31), (NAG31) s, (NAG32), (NAG32) s, (NAG33), (NAG33) s, (NAG34), (NAG34) s, (NAG35), (NAG35) s, (NAG36), (NAG36) ) s, (NAG37), (NAG37) s, (NAG38), (NAG38) s, (NAG39), and (NAG39) s as defined in Table 6. Other targeting groups, including galactose cluster targeting ligands, are known in the art.
[00201] [00201] In some embodiments, a linking group is conjugated to the RNAi agent. The linking group facilitates covalent bonding of the agent to a targeting group, release polymer, or release vehicle. The linker can be attached to the 3 'and / or 5' end of the sense strand or antisense RNAi agent strand. In some embodiments, the linker group is attached to the RNAi agent sense ribbon. In some embodiments, the linker is conjugated to the 5 'or 3' end of a sense strand of the RNAi agent. In some embodiments, a linking group is attached to the 5 'end of a sense strand of the RNAi agent. Examples of linking groups may include, but are not limited to: reactive groups such as primary and alkaline amnas, alkyl groups, abasic nucleotides, ribitol (abasic ribose), and / or PEG groups.
[00202] [00202] "A linker or linking group is a connection between two atoms that link a chemical group (such as an RNAi agent) or segment of interest to another chemical group (such as a targeting group or release polymer) or segment of interest through one or more covalent bonds. A labile linkage contains a labile bond. A bond can optionally include a spacer that increases the distance between the two bonded atoms. A spacer can also add flexibility and / or length to the connection. Spacers include, but are not limited to, alkyl groups, alkenyl groups, alkynyl groups, aryl groups, aralkyl groups, aralkyl groups and aralkyl groups; each of which may contain one or more heteroatoms, heterocycles, amino acids, nucleotides, and saccharides. Spacer groups are well known in the art and the above list is not intended to limit the scope of the invention.
[00203] [00203] In some embodiments, when two or more RNAi agents are included in a single composition, each of the RNAi agents can be linked to the same targeting group or two different targeting groups (i.e., targeting groups having structures different chemicals) In some embodiments, targeting groups are linked to the ANGPTL3 RNAi agents described here without the use of an additional ligand. In some embodiments, the targeting group alone is designed to have a linker or other site to facilitate the easily present conjugation. In some embodiments, when two or more ANGPTL3 RNAi agents are included in a single one, each of the RNAi agents can use the same ligand or different ligands (i.e., ligands having different chemical structures).
[00204] [00204] "Any of the ANGPTL3 RNAi agent nucleotide sequences listed in tables 2, 3, or 4, whether modified or unmodified, may contain targeting group (s) or 3 'and linker group (s) and / or 5 '. Any of the ANGPTL3 RNAi agent sequences listed in Table 3 or 4, or is otherwise described here, which contains a targeting group or linking group 3 'or 5', may alternatively contain none of a targeting group or linking group 3 'or 5', or may contain a different targeting group or linking group 3 'or 5' including, but not limited to, those described in Table 6. Any of the ANGPTL3 RNAi agent duplexes listed in Table 5, whether modified or unmodified, can also comprise a targeting group or linking group, including, but not limited to those described in Table 6, and the targeting group or linking group can be linked to the 3 'or 5 terminal 'sense tape or antiseptic tape from ANGPTL3 RNAi agent duplex.
[00205] [00205] “Examples of targeting groups and linking groups are provided in Table 6. Table 4 provides several modalities of the ANGPTL3 RNAi sense agent strands having a targeting group or linking group attached to the 5 'or 3' end. Table 6. Structures Representing Various Modified Nucleotides, Targeting Groups, and Liaison Groups o isit A NH: LAS Yv oo,! A o ”o o NH, o A 2º Fx Nx and E vpdT 5Me-Gf o | the XT the
[00206] [00206] In each of the structures above in Table 6, NAG comprises an N-acetyl-galactosamine or another galactose derivative, as would be understood by a person skilled in the art to be attached in view of the structures above and the description provided here. For example, in some embodiments, NAG in the structures provided in Table 6 is represented by the following structure: oro "OS de (N-acetyl-galactosamine).
[00207] [00207] Each (NAGx) can be linked to an ANGPTL3 RNAi agent via a phosphate group (as in (NAG25), (NAG30), and (NAG31)), or a phosphorothioate group, (as is (NAG25 ) s, (NAG29) s, (NAG30) s, (NAG31) s, or (NAG37) s), or another linking group. rot rot o S Phosphate Group Phosphorothioate Group
[00208] [00208] Other linking groups known in the art can be used.
[00209] [00209] In some embodiments, the delivery vehicle can be used to deliver an RNAi agent to a cell or tissue. The delivery vehicle is a compound that improves the release of the RNAi agent to a cell or tissue. The delivery vehicle may include, or consist of, but is not limited to: a polymer, such as an amphipathic polymer, an active membrane polymer, a peptide, a melitin peptide, a melitin-like peptide (MLP), a lipid , a reversibly modified polymer or peptide, or a reversibly modified membrane active polyamine.
[00210] [00210] In some embodiments, RNAi agents can be combined with lipids, nanoparticles, polymers, liposomes, micelles, DPCs or other delivery systems available in the art. RNAi agents can also be chemically conjugated to targeting groups, lipids (including, but not limited to, cholesterol and cholesteryl derivatives), nanoparticles, polymers, liposomes, micelles, DPCs (see, for example, WO 2000/053722, WO 2008/0022309, WO 2011/104169, and WO 2012/083185, WO 2013/032829, WO 2013/158141, each of which is incorporated herein by reference), or other delivery systems available in the art. Pharmaceutical Compositions and Formulations
[00211] [00211] The ANGPTL3 RNAi agents described herein can be prepared as pharmaceutical compositions or formulations (also referred to herein as "medicaments") In some embodiments, pharmaceutical compositions include at least one ANGPTL3 RNAi agent. These pharmaceutical compositions are particularly useful in inhibiting expression of the target mRNA in a target cell, group of cells, tissue, or organism. The pharmaceutical compositions can be used to treat an individual having a disease, disorder or condition that would benefit from a reduction in the level of the target MRNA, or inhibition in the expression of the target gene. The pharmaceutical combinations can be used to treat an individual at risk of developing a disease, disorder or condition that would benefit from a reduction in the level of the target MRNA or an inhibition in the expression of the target gene. In one embodiment, the method includes administering an ANGPTL3 RNAi agent linked to a targeting ligand as described herein, to an individual to be treated. In some embodiments, one or more excipients - pharmaceutically - * acceptable (including vehicles, carriers, diluents, and / or release polymers) are added to pharmaceutical compositions that include an ANGPTL3 RNAi agent, thereby forming a pharmaceutical or drug formulation suitable for in vivo release to an individual, including a human.
[00212] [00212] The pharmaceutical compositions that include an ANGPTL3 RNAi agent and methods described herein decrease the level of target MRNA in a cell, group of cells, group of cells, tissue, organ, or individual, including by administering to the individual a therapeutically amount efficacy of an ANGPTL3 RNAi agent described herein, thereby inhibiting the expression of ANGPTL3 MRNA in the individual. In some embodiments, the individual was previously identified or diagnosed as having over-pathogenic regulation of the target gene in the targeted cell or tissue. In some modalities, the individual was previously identified or diagnosed as having high triglyceride (TG) and / or high cholesterol levels or some other dyslipidemia. In some modalities, the individual was previously diagnosed with one or more cardiometabolic diseases such as hypertriglyceridemia, obesity, hyperlipidemia, abnormal cholesterol and / or lipid metabolism, atherosclerosis, atherosclerosis, type II diabetes mellitus, cardiovascular disease, coronary artery disease, non-alcoholic steatohepatitis, non-alcoholic fatty liver disease, homozygous and heterozygous familial hypercholesterolemia, statin-resistant hypercholesterolemia and other related metabolic disorders and diseases. In some embodiments, the individual was suffering from symptoms associated with one or more cardiometabolic diseases that are associated with or caused by elevated or increased levels of TG, elevated or increased cholesterol levels, or liver steatosis.
[00213] [00213] In some embodiments, the pharmaceutical compositions described including an ANGPTL3 RNAi agent are used for the treatment or control of clinical presentations associated with elevated TG levels, elevated cholesterol levels, hepatic steatosis, and / or mMRNA overexpression of ANGPTL3 in an individual. In some embodiments, a therapeutically (including prophylactically) effective amount of one or more pharmaceutical compositions is administered to an individual in need of such treatment. In some embodiments, administration of any of the ANGPTL3 RNAi agents described can be used to decrease the number, severity, and / or frequency of symptoms of a disease in an individual.
[00214] [00214] The described pharmaceutical compositions that include an ANGPTL3 RNAi agent can be used to treat at least one symptom in an individual having a disease or disorder that would benefit from the reduction or inhibition of ANGPTL3 mMRNA expression. In some embodiments, the individual is administered a therapeutically effective amount of one or more pharmaceutical compositions that include an ANGPTL3 RNAi agent, thereby treating the symptom. In other embodiments, the individual is administered a prophylactically effective amount of one or more ANGPTL3 RNAi agents, thereby preventing or inhibiting at least one symptom.
[00215] [00215] Aviade administration is the route by which an ANGPTL3 RNAi agent is placed in contact with the body. In general, methods of administering drugs and oligonucleotides and nucleic acids for the treatment of a mammal are well known in the art and can be applied to the administration of the compositions described herein. The ANGPTL3 RNAi agents described herein can be administered by any suitable route in the preparation appropriately adjusted for the particular route. Accordingly, the pharmaceutical compositions described herein can be administered by injection, for example, intravenously, intramuscularly, intracutaneously, - subcutaneously, intra-articularly, or intraperitoneally. In some embodiments, the pharmaceutical compositions described here are administered via subcutaneous injection.
[00216] [00216] Pharmaceutical combinations including an ANGPTL3 RNAi agent described herein can be delivered to a cell, group of cells, tissue, or individual using oligonucleotide delivery technologies known in the art. In general, any suitable method known in the art for releasing a nucleic acid molecule (in vitro or in vivo) can be adapted for use with the compositions described herein. For example, delivery can be by local administration, (for example, direct injection, implantation, or topical administration), systemic, or subcutaneous, intravenous, —intraperitoneal, or parenteral routes, including intracranial administration - (for example, intraventricular , intraparenchymal and intrathecal), intramuscular, transdermal, airway (aerosol), nasal, oral, rectal, or topical (including buccal and sublingual). In certain embodiments, the combinations are administered by subcutaneous or intravenous infusion or injection.
[00217] [00217] In some embodiments, the pharmaceutical combinations described - here “comprise one or more pharmaceutically acceptable excipients. The pharmaceutical combinations are described herein formulated for administration to an individual.
[00218] [00218] As used herein, a pharmaceutical composition or medicament includes a pharmacologically effective amount of at least one of the described therapeutic compounds and one or more pharmaceutically acceptable excipients. Pharmaceutically acceptable excipients (excipients) are substances other than the Active Pharmaceutical Ingredient (API, therapeutic product, for example, ANGPTL3 RNAi agent) that are intentionally included in the drug delivery system. Excipients do not have or are not intended to have a therapeutic effect on the intended dosage. Excipients can act to a) assist in processing the drug delivery system during manufacture, b) protect, support or enhance the API patient's stability, bioavailability or acceptability, c) assist in product identification, and / or d) highlight any other attributes of global security, effectiveness, API release during storage or use. A pharmaceutically acceptable excipient may or may not be an inert substance.
[00219] [00219] - Excipients include, but are not limited to: absorption enhancers, nonstick, antifoaming agents, antioxidants, binders, buffering agents, carriers, coating agents, dyes, release enhancers, release polymers, detergents, dextran, dextrose , thinners, disintegrants, emulsifiers, extenders, fillers, flavorings, glidants, humectants, lubricants, oils, polymers, preservatives, saline, salts, solvents, sugars, surfactants, suspending agents, extended release matrices, sweeteners, thickening agents, agents tonicity, vehicles, water-repellent agents, and wetting agents.
[00220] [00220] “Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where soluble in water) or sterile dispersions and powders for the extemporaneous preparation of dispersion or sterile injectable solutions. For intravenous administration, suitable vehicles include physiological saline, bacteriostatic water, CcCremophor & ELTM (BASF, Parsippany, NJ) or phosphate buffered saline (PBS). Suitable vehicles must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The solvent can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol), and suitable mixtures thereof. Adequate fluidity can be maintained, for example, by using a coating such as lecithin, by maintaining the required particle size, in the case of dispersion, and by using surfactants. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, and sodium chloride in the composition. Prolonged absorption of the injectable compositions can be carried out by including in the composition a reagent that delays absorption, for example, aluminum monostearate and gelatin.
[00221] [00221] Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients listed above, as required, followed by sterilizing the filter. Generally, dispersions are prepared by incorporating the active compound in a sterile vehicle, which contains a basic dispersion medium and the other necessary ingredients from those listed above. In the case of sterile powders for the preparation of sterile injectable solutions, the preparation methods include vacuum drying and lyophilization, which produces a powder of the active ingredient plus any desired additional ingredient from a previously sterile filtered solution thereof.
[00222] [00222] - “Formulations suitable for intra-articular administration can be in the form of a sterile aqueous drug preparation that can be in microcrystalline form, for example, in the form of an aqueous microcrystalline suspension. Liposomal formulations or biodegradable polymer systems can also be used to present the drug for both intra-articular and ophthalmic administration.
[00223] [00223] The active compounds can be prepared with vehicles that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including microencapsulated implants and delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparing such formulations will be evident to those skilled in the art. Liposomal suspensions can also be used as pharmaceutically acceptable vehicles. These can be prepared according to methods known to those skilled in the art, for example, as described in United States Patent No. 4,522,811.
[00224] [00224] ANGPTL3 RNAide agents can be formulated into unit dosage form compositions for ease of administration and uniformity of dosage. The dosage unit form refers to physically discrete units suitable as unitary dosages for the individual to be treated; each unit contains a predetermined amount of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the unit dosage forms of the invention is dictated by and directly dependent on the unique characteristics of the active compound and the therapeutic effect to be achieved, and the limitations inherent in the technique of composing such an active compound for the treatment of individuals.
[00225] [00225] A pharmaceutical composition can contain other additional components commonly found in pharmaceutical compositions. Such additional components include, but are not limited to: antipruritic, astringent, local anesthetics, analgesics, antihistamines or anti-inflammatory agents (eg, acetaminophen, NSAIDs, diphenhydramine, etc.). It is also envisaged that isolated cells, tissues or organs that express or comprise the RNAi agents defined herein can be used as "pharmaceutical compositions." As used herein, "pharmacologically effective amount," "therapeutically effective amount," or simply "effective amount" refers to that amount of an RNAi agent to produce a pharmacological, therapeutic or preventive result.
[00226] [00226] In some embodiments, the methods described here also comprise the step of administering a second therapeutic or treatment in addition to administering an RNAi agent described here. In some embodiments, the second therapeutic is another ANGPTL3 RNAi agent (for example, an ANGPTL3 RNAi agent that targets a different sequence within the target ANGPTL3). In other embodiments, the second therapeutic may be a small molecule drug, an antibody, an antibody fragment, or an aptamer.
[00227] [00227] Generally, an effective amount of an active compound will be in the range of about 0.1 to about 100 mg / kg of body weight / day, for example, from about 1.0 to about 50 mg / kg body weight / day. In some embodiments, an effective amount of an active compound will be in the range of about 0.25 to about 5 mg / kg of body weight per dose. In some embodiments, an effective amount of an active ingredient will be in the range of about 0.5 to about 4 mg / kg of body weight per dose. The amount administered will also likely depend on such variables as the patient's overall health status, the relative biological efficacy of the released compound, the formulation of the drug, the presence and types of excipients in the formulation, and the route of administration. In addition, it should be understood that the initial dosage administered can be increased beyond the upper level above to quickly reach the desired blood level or tissue level, or the initial dosage may be less than ideal.
[00228] [00228] For treatment of disease or for the formation of a drug or composition for treatment of a disease, the pharmaceutical combinations described here including an ANGPTL3 RNAi agent can be combined with an excipient or with a second therapeutic agent or treatment including, however not limited to: a second or other RNAi agent, a small molecule drug, an antibody, an antibody fragment, peptide and / or an aptamer.
[00229] [00229] The described ANGPTL3 RNAi agents, when added to pharmaceutically acceptable excipients or adjuvants, can be packaged in kits, containers, packages or applicators. The pharmaceutical combinations described here can be packaged in pre-filled syringes or vials. Methods of Treatment and Inhibition of Expression
[00230] [00230] The ANGPTL3 RNAi agents described herein can be used to treat an individual (e.g., a human or other mammal) having a disease or disorder that would benefit from the administration of the RNAi agent. In some embodiments, the RNAi agents described here can be used to treat an individual (e.g., a human) who would benefit from the reduction and / or inhibition in the expression of ANGPTL3 MRNA levels and / or ANGPTL3 protein, for example , an individual who was diagnosed with hypertriglyceridemia, obesity, hyperlipidemia, abnormal cholesterol and / or lipid metabolism, atherosclerosis, type 1 diabetes mellitus, cardiovascular disease, coronary artery disease, non-alcoholic steatohepatitis, non-alcoholic fatty liver disease, hypercholesterolemia - familial - homozygous = and - heterozygous, statin-resistant hypercholesterolemia and other related metabolic disorders and diseases.
[00231] [00231] In some embodiments, the individual is administered a therapeutically effective amount of any one or more ANGPTL3 RNAi agents. Treatment of an individual may include therapeutic and / or prophylactic treatment. The subject is administered a therapeutically effective amount of any one or more ANGPTL3 RNAi agents described herein. The individual can be a human, patient, or human patient. The individual can be an adult, teenager, child or baby. The administration of a pharmaceutical composition described herein can be to a human or animal.
[00232] [00232] The ANGPTL3 RNAi agents described here can be used to treat at least one symptom in an individual having an ANGPTL3-related disorder or disease, or having a disease or disorder that is mediated at least in part by the expression of the ANGPTL3 gene. . In some embodiments, ANGPTL3 RNAi agents are used to treat or control a clinical presentation of an individual with an ANGPTL3-related disorder or disease. The subject is administered a therapeutically effective amount of one or more of the ANGTL3 RNAi agents or composition containing ANGPTL3 RNAi agents described here. In some embodiments, the methods described here comprise administering a composition comprising an ANGPTL3 RNAi agent described here. to an individual to be treated. In some embodiments, the individual is administered a prophylactically effective amount of any one or more of the ANGPTL3 RNAi agents described, thereby treating the individual by preventing or inhibiting at least one symptom.
[00233] [00233] In certain embodiments, the present invention provides methods for treating diseases, disorders, conditions, or pathological conditions mediated at least in part by the expression of the ANGPTL3 gene, in a patient in need thereof, wherein the methods include administering to the any of the ANGTL3 RNAi agents described here.
[00234] [00234] In some embodiments, the level of gene expression and / or MRNA level of an ANGPTL3 gene in an individual to which a described ANGPTL3 RNAi agent is administered, is reduced by at least about 30%, 35% , 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 95%, 96%, 97%, 98%, 99%, or more than 99% with respect to the individual before the ANGPTL3 RNAi agent is administered or to an individual who does not receive the ANGPTL3 RNAi agent. The level of gene expression and / or mMRNA level in the individual can be reduced in an individual cell, group of cells, and / or tissue.
[00235] [00235] In some embodiments, the level of ANGPTL3 protein in an individual to which a described ANGPTL3 RNAi agent has been administered is reduced by at least about 30%, 35%, 40%, 45%, 50%, 55 %, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more than 99% with respect to the individual before the ANGPTL3 RNAi agent be administered or to an individual who does not receive the ANGPTL3 RNAi agent. The level of protein in the individual can be reduced in a cell, group of cells, tissue, blood, and / or other fluid in the individual.
[00236] [00236] In some embodiments, the triglyceride (TG) levels in an individual to which a described ANGPTL3 RNAi agent has been administered are reduced by at least about 10%, 20%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more than 99 % with respect to the individual before the ANGPTL3 RNAi agent was administered or to an individual who does not receive the ANGPTL3 RNAi agent. The level of TG in the individual can be reduced in a cell, group of cells, tissue, blood, and / or other fluid in the individual.
[00237] [00237] In some embodiments, the total cholesterol levels in an individual to which a described ANGPTL3 RNAi agent has been administered are reduced by at least about 10%, 20%, 30%, 35%, 40%, 45% , 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more than 99% with relation to the individual before the ANGPTL3 RNAi agent is administered or to an individual who does not receive the ANGPTL3 RNAi agent. In some embodiments, the levels of low-density lipoprotein (LDL) cholesterol in an individual to whom a described ANGPTL3 RNAi agent has been administered have been reduced by at least about 10%, 20%, 30%, 35%, 40 %, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more than than 99% with respect to the individual before the ANGPTL3 RNAi agent is administered or to an individual who does not receive the ANGPTL3 RNAi agent. The total cholesterol levels and / or LDL cholesterol levels in the individual can be reduced in an individual's cell, group of cells, tissue, blood, and / or other fluid.
[00238] [00238] A reduction in ANGPTLB3 MRNA levels, ANGPTL3 protein levels, TG levels, cholesterol levels, and LDL cholesterol levels can be assessed by any methods known in the art. As used herein, a reduction or decrease in the ANGPTL3 MRNA level and / or protein level is collectively referred to herein as a reduction or decrease in ANGPTL3 or inhibition or reduction of ANGPTL3 expression. The examples set forth here illustrate known methods for assessing inhibition of ANGPTL3 gene expression. Cell, Tissues, Organs, and Non-Human Organisms
[00239] [00239] Cells, tissues, organs, and non-human organisms that include at least one of the ANGTL3 RNAi agents are described herein. The non-human cell, tissue, organ, or organism is prepared by releasing the RNAi agent to the non-human cell, tissue, organ, or organism.
[00240] [00240] The modalities and items provided above are now illustrated with the following non-limited examples.
[00241] [00241] ANGPTL3 RNAi agent duplexes shown in Table 5, above, were synthesized according to the following general procedures: A. Synthesis. The sense or antisense strands of the RNAi agents were synthesized according to solid phase phosphoramidite technology used in oligonucleotide synthesis. Depending on the scale, a MerMade96EO (Bioautomation), a MerMade1280 (Bioautomation), or an OP Pilot 100 (GE Healthcare) was used. The syntheses were performed on a solid support made of controlled pore glass (CPG, 500 À or 600À, obtained from Prime S Synthesis, Aston, PA, USA). All RNA and modified 2-RNA phosphoramidites were purchased from Thermo Fisher Scientific (Milwaukee, WI, USA) or Hongene Biotech (Shanghai, PRC). The 2'-O-methyl phosphoramidites included the following: (5'-O-dimethoxytrityl-No.- (benzoyl) -2'-O-methyl-adenosine-3'-O- (2-cyanoethyl-N N-di- isopropylamino) phosphoramidite, 5-O-dimethoxy-trityl-No.- (acetyl) -2-O-methyl-cytidine-3'-O- (2-cyanoethyl-N, N-diisopropyl-amino) phosphoramidite, (5 "-O-dimethoxytrityl-N2- (isobutyryl) -2'-O-
[00242] [00242] Phosphoramidites containing targeting ligand were dissolved in anhydrous dichloromethane or anhydrous acetonitrile (50 mM), while all other amidites were dissolved in anhydrous acetonitrile (50 mM), or anhydrous dimethylformamide and molecular sieves (3À). 5-Benzyl-1H-tetrazole (BTT, 250 mM in acetonitrile) or 5-Ethyl-1H-tetrazole (ETT, 250 MM in acetonitrile) was used as an activating solution. The coupling times were 12 min (RNA), 15 min (targeting ligand), 90 sec (2 / OMe), and 60 sec (2'F). In order to introduce phosphorothioate bonds, a 100% solution of 3-phenyl 1,2,4-dithiazoline-5-one (POS, obtained from PoliOrg, Inc., Leominster, MA, USA) in anhydrous acetonitrile was used. Unless specifically identified a "naked" RNAi agent having no targeting ligand present, each of the ANGPTL3 RNAi agent duplexes sintered and tested in the following Examples used N-acetyl-galactosamine as "NAG" in the chemical structures of targeting binder represented in Table 6.
[00243] [00243] To assess the in vivo activity of ANGPTL3 RNAi agents that are designed to target different positions in the ANGPTL3 gene, female C57bl / 6 mice from six to eight weeks of age were used. Pre-dose serum samples were taken at -1 after a four-hour fast. On day 1, each mouse was given a single subcutaneous administration of 200 µl containing 3 mg / kg (mpk) of an ANGPTL3 RNAi agent in D5W (dextrose in 5% water), or control (DSW) without any RNAi, according to the dosing groups recited in Table 7. Table 7. Dosing Groups of Example 2 [E stmaraaeAT incanieção da da 7 [E peeeaS - mmerssns: |
[00244] [00244] Each of the RNAi agents included a modified sequence and a targeting linker containing N-acetyl-galactosaamine conjugated to the 5 'terminal end of the sense strand. (See tables 3, 4, and 5 for modified sequence structures and targeting linker). The injections were performed between the skin and the muscle (ie, subcutaneous injections) in the loose skin over the neck and shoulder area. Three (3) mice in each group were tested (n = 3).
[00245] [00245] ANGPTL3 protein levels, triglyceride levels, HDL levels, and total cholesterol levels for each animal have been normalized. For normalization, the protein level of ANGPTL3, triglyceride, HDL, and cholesterol! total, respectively, for each animal at a time point, was divided by the pre-treatment level of expression in that animal (in this case on day -1) to determine the expression ratio "normalized to pre-treatment." The expression, at a specific point in time, was then normalized for the DSW control group by dividing the "normalized for pretreatment" ratio for an individual animal by the average "normalized for pretreatment" ratio of all mice in the group D5W control panel. This resulted in the expression for each time point normalized to that in the control group.
[00246] [00246] The data from the study mentioned in this Example are shown in the following Tables 8 to 11: FAITH
[00247] The ANGPTL3 RNAi agents ADO5342 and ADO5343 (Groups 2 and 3) included nucleotide sequences that were designed to inhibit the expression of an ANGPTL3 gene at position 743 of the gene; ANGPTL3 RNAi agent ADO5344 (Group 4) included nucleotide sequences designed to inhibit the expression of an ANGPTL3 gene at position 744 of the gene; ANGPTL3 RNAi agents ADO5306 and ADO5S307 (Groups 5 and 6) included nucleotide sequences designed to inhibit the expression of an ANGPTL3 gene at position 921 of the gene; ANGPTL3 RNAi agents ADO5308 and ADO5309 (Groups 7 and 8) included nucleotide sequences designed to inhibit the expression of an ANGPTL3 gene at position 922 of the gene; ANGPTL3 RNAi agents ADO5310 and ADO5311 (Groups 9 and 10) included nucleotide sequences designed to inhibit the expression of an ANGPTL3 gene at position 1302 of the gene; and ANGPTL3 ADO5312 RNAi agents (Group 11) included nucleotide sequences designed to inhibit the expression of an ANGPTL3 gene at position 1304 of the gene. (see SEQ ID NO: 1 for the referenced ANGPTL3 gene sequence).
[00248] [00248] As shown in Table 8, above, each of the RNAi agents in at least Groups 5, 6, 7, 8, 9, 10, and 11 showed inhibition of ANGPTL3. For example, on day 29, Group 7 (ANGPTL3 RNAi agent ADOS5308), which included nucleotide sequences designed to target the position 922 of the ANGPTL3 gene, showed an approximately 91% (0.088) reduction in ANGPTL3 protein compared to the control. Similarly, both Group 5 (ANGPTL3 RNAi agent ADOS5306) and Group 6 (ANGPTL3 ADO5307 RNAi agent), which were designed to target position 921 of the ANGPTL3 gene, showed more than 75% reduction in ANGPTL3 protein on day 29 (i.e., 0.240 and 0.206).
[00249] [00249] To assess the in vivo activity of ANGPTL3 RNAi agents that are designed to target positions 921 and 922 in the ANGPTL3 gene, female C57bl / 6 mice from six to eight weeks of age were used. Pre-dose serum samples were taken on day -1 after a four-hour fast. On day 1, each mouse was given a 200 µl administration containing 1 mg / kg (mpk) of an ANGPTL3 RNAi agent in D5W (dextrose in 5% water), or control (DSW) with no RNAi agent , according to the dosing groups listed in Table 12. Table 12. Dosing Groups of Example 3 [E [straight [mma in [E msKes ADS radar ncia | [AA ren
[00250] [00250] Each of the RNAi agents included a modified sequence and a targeting linker containing N-acetyl-galactosaamine conjugated to the 5 'terminal end of the sense strand. (See tables 3, 4, and 5 for modified sequence structures and targeting linker). The injections were performed between the skin and the muscle (ie, subcutaneous injections) in the loose skin over the neck and shoulder area. Three (3) mice in each group were tested (n = 3). Serum was collected on days 9, 15, 22, and 29. The mice were fasted for four hours before each collection. The levels of ANGPTL3 protein in serum were measured by an ELISA assay (R&D Systems), according to the manufacturer's recommendations. Triglycerides, high density lipoprotein (HDL), and total serum cholesterol were measured in a Cobas € O Integra 400 (Roche Diagnostics), according to the manufacturer's recommendations.
[00251] [00251] ANGPTL3 protein levels, triglyceride levels, HDL levels, and total cholesterol levels for each animal have been normalized. For normalization, the protein level of ANGPTL3, triglyceride, HDL, and cholesterol! total, respectively, for each animal at a time point, was divided by the pre-treatment level of expression in that animal (in this case on day -1) to determine the expression ratio "normalized to pre-treatment." The expression, at a specific point in time, was then normalized for the DSW control group by dividing the "normalized for pretreatment" ratio for an individual animal by the average "normalized for pretreatment" ratio of all mice in the group D5W control panel. This resulted in the expression for each time point normalized to that in the control group.
[00252] [00252] The data of the study mentioned in this Example are shown in the following Tables 13 to 16:
[00253] [00253] While having different sequence and modification patterns, the ANGPTL3 RNAi agents in Groups 2 to 11 included nucleotide sequences that were each designed to inhibit the expression of an ANGPTL3 gene at position 921 of the gene; and the ANGPTL3 RNAi agents in Groups 12 to 19 included nucleotide sequences that were each designed to inhibit the expression of an ANGPTL3 gene at position 922 of the gene. (See SEQ ID NO: 1 for the referenced ANGPTL3 gene sequence). As shown in Table 12 above, each of the RNAi agents obtained inhibition of ANGPTL3 as compared to the control. For example, Group 12 (ANGPTL3 RNAi agent ADOS5308) achieved approximately an 80% reduction in ANGPTL3 protein levels compared to the control (0.209) on day 22. Example 4. In Vivo Testing of ANGPTL3 RNAi Agents in Mice.
[00254] [00254] To assess the in vivo activity of ANGPTL3 RNAi agents that are designed to target additional positions in the ANGPTL3 gene, female C57bl / 6 mice from six to eight weeks of age were used. Pre-dose serum samples were taken on day -1 after a four-hour fast. On day 1, each mouse was given 200 μl containing 1 mg / kg (mpk) or 0.5 mg / kg (mpk) of an ANGPTL3 RNAi agent in D5W (dextrose in 5% water), or control (DSW) with no RNAi agent, according to the dosing groups listed in Table 17. Table 17. Example 4 Dosing Groups
[00255] [00255] Each of the RNAi agents included a modified sequence and a targeting linker containing N-acetyl-galactosaamine conjugated to the 5 'terminal end of the sense strand. (See tables 3, 4, and 5 for modified sequence structures and targeting linker). The injections were performed between the skin and the muscle (ie, subcutaneous injections) in the loose skin over the neck and shoulder area. Three (3) mice in each group were tested (n = 3). Serum was collected on days 8, 15, 22, 29, and day 43 (Groups 1-3, 9, and 11-13 only). The mice were fasted for four hours before each collection. The levels of ANGPTL3 protein in serum were measured by an ELISA assay (R&D Systems), according to the manufacturer's recommendations. Triglycerides, high density lipoprotein (HDL), and total serum cholesterol were measured on a Cobas & Integra 400 (Roche Diagnostics),) according to the manufacturer's recommendations.
[00256] [00256] ANGPTL3 protein levels, triglyceride levels, HDL levels, and total cholesterol levels for each animal have been normalized. For normalization, the protein level of ANGPTL3, triglyceride, HDL, and cholesterol! total, respectively, for each animal at a time point, was divided by the pre-treatment level of expression in that animal (in this case on day -1) to determine the expression ratio "normalized to pre-treatment." The expression, at a specific point in time, was then normalized for the DSW control group by dividing the "normalized for pretreatment" ratio for an individual animal by the average "normalized for pretreatment" ratio of all mice in the group of control D5W .. This resulted in the expression for each time point normalized to that in the control group.
[00257] [00257] The data of the study mentioned in this Example are shown in the following Tables 18 to 22:
[00258] The ANGPTL3 RNAi agents ADOS5487 and ADO5488 (Groups 2 and 3) included nucleotide sequences that were designed to inhibit the expression of an ANGPTL3 gene at position 304 of the gene; ANGPTL3 RNAi agent ADO5489 and ADO5490 (Groups 4 and 5) included nucleotide sequences designed to inhibit the expression of an ANGPTL3 gene at position 172 of the gene; ANGPTL3 RNAi agents ADO5491 and ADO5492 (Groups 6 and 7) included nucleotide sequences designed to inhibit the expression of an ANGPTL3 gene at position 1008 of the gene; ANGPTL3 RNAi agent ADO593 (Group 8) included nucleotide sequences designed to inhibit the expression of an ANGPTL3 gene at position 1009 of the gene; ANGPTL3 RNAi agents ADOS494, ADO5495, and ADO5308 (Groups 9, 10, 11, and 12) included nucleotide sequences designed to inhibit the expression of an ANGPTL3 gene at position 1302 of the gene; and ANGPTL3 RNAi agents ADO5418 (Group 13) included nucleotide sequences designed to inhibit the expression of an ANGPTL3 gene at position 921 of the gene. (see SEQ ID NO: 1 for the referenced ANGPTL3 gene sequence).
[00259] [00259] As shown in Table 18 above, while most RNAi agents achieved a reduction in ANGPTL3 protein levels at almost all measured time points, ANGPTL3 RNAi agents in Group 2 (ADO5487) and Group 3 (ADO5488), each of which included nucleotide sequences designed to inhibit ANGPTL3 gene expression at position 304 of the gene, outperformed the other groups in this study. For example, on days 15 and 22, the ANGPTL3 RNAi agent ADOS5488 (Group 3) obtained more than 90% ANGPTL3 protein block (i.e., 0.070 on day 15 and 0.092 on day 22). Similarly, the ANGPTL3 RNAi agent ADO5487 (Group 2) obtained nearly 75% block on days 15 and 22 (i.e., 0.170 on day 15 and 0.138 on day 22). In addition, the same trends were observed through additional measured parameters including TG, total cholesterol, and LDL, as both Group 2 (ADO5487) and Group 3 (ADO5488) generally outperformed the other RNAi agents tested (see tables 19- 22). For example, For Groups 2 and 3, on day 29, triglyceride levels were reduced by at least 28% (ie, 0.556 or 0.721), cholesterol! total was reduced by at least 31% (ie, 0.560 or 0.683), and LDL levels were reduced by almost 20% (0.744 or 0.801). Example 5. Testing / Live n of ANGPTL3 RNAi Agents in Macacosccinomolgos.
[00260] [00260] ANGPTL3 RNAi agents were evaluated in cynomolgus monkeys. On day 1, primates cynomolgus macaque (Macaca fascicularis) (also referred to here as "girdles") were administered with a single subcutaneous injection of 0.3 mL / kg (approximately 2-3 mL in volume, depending on the animal's mass) containing 3.0 mg / kg of ANGPTL3 RNAi agent ADO5308 or ADO05418, formulated in saline. Each of the ANGTL3 RNAi agents contained modified nucleotides and included N-acetyl-galactosamine targeting ligands conjugated to the 5 'terminal end of the sense strand, as shown in Tables 3, 4, and 5.
[00261] [00261] Two (2) cinos in each group were tested (n = 2). Blood samples were taken and serum samples were analyzed on days -37 (pre-dose), -15 (pre-dose), and -1 (pre-dose), 8, 16, 23, 30, and
[00263] [00263] Each of the cynomolgus monkeys dosed with ADO5308 or ADO5418 showed a reduction in ANGPTL3 protein compared to pretreatment measurements across all measured time points. For example, for individual animals, on day 16, the hips dosed with ADO5418 showed a reduction of approximately 64% (0.358 normalized protein level) or 69% (0.309 normalized protein level) in the ANGPTL3 protein. In addition, even on day 37, the Group 2 (ADO5418) shanks showed an average reduction of approximately 73% (0.270) in the levels of ANGPTL protein. Example 6. In Vivo Testing of ANGPTL3 RNAi Agents in Mice.
[00264] [00264] To assess the in vivo activity of additional ANGPTL3 RNAi agents that are designed to target the 304 position in the ANGPTL3 gene, female C57bl / 6 mice from six to eight weeks of age were used. Pre-dose serum samples were taken on day -1 after a four-hour fast. On day 1, each mouse was given a 200 µl administration containing 0.5 mg / kg (mpk) of an ANGPTL3 RNAi agent in D5W (dextrose in 5% water), or control (DSW) without agent RNAi, according to the dosing groups listed in Table 25. Table 25. Example 6 Dosing Groups
[00265] [00265] Each of the RNAi agents included a modified sequence and a targeting linker containing N-acetyl-galactosaamine conjugated to the 5 'terminal end of the sense strand. (See tables 3, 4, and 5 for modified sequence structures and targeting linker). The injections were performed between the skin and the muscle (ie, subcutaneous injections) in the loose skin over the neck and shoulder area. Three (3) mice in each group were tested (n = 3). Serum was collected on days 8, 15, 22, 30, and day 43 for certain groups (ie Groups 1, 2, 5, and 10 only). The mice were fasted for four hours before each collection. The levels of ANGPTL3 protein in serum were measured by an ELISA assay (R&D Systems), according to the manufacturer's recommendations. Triglycerides, cholesterol! Total, high density lipoprotein (HDL), and low density lipoprotein (LDL) in serum were measured on a Cobas & Integra 400 (Roche Diagnostics), according to the manufacturer's recommendations.
[00266] [00266] ANGPTL3 protein levels, triglyceride levels, total cholesterol levels, HDL levels, and LDL levels for each animal have been normalized. For normalization, the protein level of ANGPTL3, triglyceride, HDL, and cholesterol! total, respectively, for each animal at a time point, was divided by the level of pretreatment of expression in that animal (in this case on day -1) to determine the expression ratio "normalized for pretreatment." The expression, at a specific point in time, was then normalized for the DSW control group by dividing the "normalized for pretreatment" ratio for an individual animal by the average "normalized for pretreatment" ratio of all mice in the group D5W control panel. This resulted in the expression for each time point normalized to that in the control group.
[00267] [00267] The data of the study mentioned in this Example are shown in the following Tables:
[00268] [00268] Each of the tested ANGTL3 RNAi agents (i.e., ADO5S488, ADO5652, ADO5653, ADO5654, ADOS5655, ADO5656, ADOS5657, ADO5658, ADOS66O0, ADOS5661, and ADOS662) each contained a specific sequence of genes ANGPTL3 at position 304 (see, for example, SEQ ID NO: 1). As shown above, each of the RNAi agents showed a substantial reduction in ANGPTL3 protein levels on at least day 22. Reductions in TG levels and total cholesterol were also observed. Example 7. In Vivo Testing of ANGPTL3 RNAi Agents in Mice.
[00269] [00269] To also evaluate the in vivo activity of additional ANGPTL3 RNAi agents that are designed to target position 304 in the ANGPTL3 gene, female C57bl / 6 mice from six to eight weeks of age were used. Pre-dose serum samples were taken on day -1 after a four-hour fast. On day 1, each mouse was given a 200 µl administration containing 0.5 mg / kg (mpk) of an ANGPTL3 RNAi agent in D5W (dextrose in 5% water), or control (DSW) without agent RNAi, according to the dosing groups listed in Table 31. Table 31. Example Dosing Groups 7 [9 osmeeseaDost once neção wheel 1 [E [es aAES - [immense |
[00270] [00270] Each of the RNAi agents included a modified sequence and a targeting linker containing N-acetyl-galactosaamine conjugated to the 5 'terminal end of the sense strand. (See tables 3, 4, and 5 for modified sequence structures and targeting linker). The injections were performed between the skin and the muscle (ie, subcutaneous injections) in the loose skin over the neck and shoulder area. Three (3) mice in each group were tested (n = 3). Serum was collected on days 8, 15, 22, and 29. The mice were fasted for four hours before each collection. The levels of ANGPTL3 protein in serum were measured by an ELISA assay (R&D Systems), according to the manufacturer's recommendations. Triglycerides, cholesterol! Total, high density lipoprotein (HDL), and low density lipoprotein (LDL) in serum were measured on a Cobas & Integra 400 (Roche Diagnostics), according to the manufacturer's recommendations.
[00271] [00271] ANGPTL3 protein levels, triglyceride levels, total cholesterol levels, HDL levels, and LDL levels for each animal have been normalized. For normalization, the protein level of ANGPTL3, triglyceride, HDL, and cholesterol! total, respectively, for each animal at a time point, was divided by the level of pretreatment of expression in that animal (in this case on day -1) to determine the expression ratio "normalized for pretreatment." The expression, at a specific point in time, was then normalized for the DSW control group by dividing the "normalized for pretreatment" ratio for an individual animal by the average "normalized for pretreatment" ratio of all mice in the group DSW control This resulted in the expression for each time point normalized to that in the control group.
[00272] [00272] The data from the study mentioned in this Example are shown in the following Tables 32-36:
[00273] [00273] Additional ANGPTL3 RNAi agents were evaluated in cynomolgus monkeys. On day 1, primates cynomolgus macaque (Macaca fascicularis) (also referred to here as "girdles") were administered with a single subcutaneous injection of 0.3 mL / kg (approximately 1 to 2 mL in volume, depending on the mass of the animal) containing 3.0 mg / kg of one of the ANGPTL3 RNAi agents ADOS5577, ADOS53SO07, ADOS488, ADO5654, or ADO5659, each formulated in saline. Each of the ANGTL3 RNAi agents contained modified nucleotides and included N-acetyl-galactosamine targeting ligands conjugated to the 5 'terminal end of the sense strand, as shown in Tables 3, 4, and 5.
[00274] [00274] Two (2) five in each group were tested (n = 2). Blood samples were taken and serum samples were analyzed on days -8 (pre-dose), 1 (pre-dose), 8, 15, 22, 29, and 36. The hips were fasted overnight before each collection. The levels of ANGPTL3 protein in serum were measured by an ELISA assay (R&D Systems), according to the manufacturer's recommendations. Triglycerides, total cholesterol, high density lipoprotein (HDL), and low density lipoprotein (LDL) in serum were measured in a Cobas € Integra 400 (Roche Diagnostics), according to the manufacturer's recommendations.
[00275] [00275] ANGPTL3 protein levels, triglyceride levels, total cholesterol levels, HDL levels, and LDL levels for each animal have been normalized. For normalization, the protein level of ANGPTL3, triglyceride, HDL, and cholesterol! total, respectively, for each animal at a time point, was divided by the average pretreatment level of expression in that animal (in this case on days 8 and 1 for pre-treatment. "
[00277] [00277] Each of the cynomolgus monkeys dosed with either ADO5577, ADO5307, ADOS5488, ADO5654, or ADO5659 showed a reduction in ANGPTL3 protein compared to pretreatment measurements across all measured time points. Example 9. In Vivo Testing of ANGPTL3 RNAi Agents in Cinomolgos Monkeys.
[00278] [00278] Additional ANGPTL3 RNAi agents were evaluated in cynomolgus monkeys. On day 1, primates cynomolgus macaque (Macaca fascicularis) (also referred to here as "girdles") were administered with a single subcutaneous injection of 0.3 mL / Kkg (approximately 2 to 3 mL in volume, depending on the animal's mass) containing 2.0 mg / kg of an ANGPTL3 RNAi agent, which included ADOS488, ADO5743, ADO5775, or ADO5841, each formulated in saline. Each of the ANGTL3 RNAi agents contained modified nucleotides and included N-acetyl-galactosamine targeting ligands conjugated to the 5 'terminal end of the sense strand, as shown in tables 3, 4, and 5. ANGPTL3 ADO5488 RNAi agents, ADO5743, and ADO5775 included nucleotide sequences designed to target the position 304 of the ANGPTL3 gene. ANGPTL3 RNAi agent ADOS5841 included nucleotide sequences designed to target position 1035 of the ANGPTL3 gene.
[00279] [00279] Three (3) cinos in each group were tested (n = 3). Blood samples were taken and serum samples were analyzed on days -14 (pre-dose), -7 (pre-dose), 1 (pre-dose), 8, 15, 22, 29, and 35. The hips were fasted overnight before each collection. The levels of ANGPTL3 protein in serum were measured by an ELISA assay (R&D Systems), according to the manufacturer's recommendations. Triglycerides, total cholesterol, high density lipoprotein (HDL), and low density lipoprotein (LDL) in serum were measured on a Cobas & Integra 400 (Roche Diagnostics), according to the manufacturer's recommendations.
[00280] [00280] ANGPTL3 protein levels, triglyceride levels, total cholesterol levels, HDL levels, and LDL levels for each animal have been normalized. For normalization, the protein level of ANGPTL3, triglyceride, HDL, and cholesterol! total, respectively, for each animal at a time point, was divided by the average pretreatment level of expression in that animal (in this case on days - 14, -7, and 1) to determine the expression ratio "normalized to -treatment."
[00281] [00281] The data of the study mentioned in this Example are shown in the following Tables 42 to 45:
[3] [3] = 3 S õ => i: PO "º í: 8::: = S:; oo: ww = à: w oo S>. o F" o O Ss z $, 3 os: so 2 Es) 8 PB É ê ã 8 P3ERZS o = Fr a> SS 2 BB 3 3 SSSESSESseSE ã; É 2 SS Be: B is SS is SS is Ss S SE PE SP: eRX5 e: E <:
[00282] [00282] Each of the cynomolgus monkeys dosed with any of ADOS5488, ADO5743, ADO5775, and ADO5841, each at dosage levels of 2.0 mg / kg, showed a reduction in ANGPTL3 protein compared to pre-treatment measurements in each of the measured time points. Example 10. In Vivo Testing of Additional ANGPTL3 RNAi Agents in Mice.
[00283] [00283] To assess the in vivo activity of other ANGPTL3 RNAi agents that are designed to target position 304 in the ANGPTL3 gene, female C57bl / 6 mice from six to eight weeks of age were used. Pre-dose serum samples were taken on day -1 after a four-hour fast. On day 1, each mouse was given a 200 µl administration containing 0.5 mg / Kkg (mpk) of an ANGPTL3 RNAi agent in D5W (5% water dextrose), or control (DSW) without RNAi agent, according to the dosing groups listed in Table 47. Table 47. Example 10 Dosing Groups [6 Crushes Samples on Turning On And Now AS Mena 9 will be ADA close to
[00284] [00284] Each of the RNAi agents included a modified sequence and a targeting linker containing N-acetyl-galactosaamine conjugated to the 5 'terminal end of the sense strand. (See tables 3, 4, and 5 for modified sequence structures and targeting linker). As noted above, each of the ANGTL3 RNAi agents measured in this study included nucleotide sequences designed to target the ANGPTL3 gene at the
[00285] [00285] ANGPTL3 protein levels, triglyceride levels, total cholesterol levels, HDL levels, and LDL levels for each animal have been normalized. For normalization, the protein level of ANGPTL3, triglyceride, HDL, and cholesterol! total, respectively, for each animal at a time point, was divided by the level of pretreatment of expression in that animal (in this case on day -1) to determine the expression ratio "normalized for pretreatment." The expression, at a specific point in time, was then normalized for the DSW control group by dividing the "normalized for pretreatment" ratio for an individual animal by the average "normalized for pretreatment" ratio of all mice in the group DS5W control panel. This resulted in the expression for each time point normalized to that in the control group.
[00286] [00286] The data of the study mentioned in this Example are shown in the following Tables 48-52:
[3] [3] "= | e 28 [28 he hehe | = sz EP je | Jg P jr | & Re ã ao = = = = = sz ao qe so s = so qe sr ã Ss 3: Po So Ro Ro jo lo É
[00287] [00287] “As indicated in Table 48 above, each of the ANGTL3 RNAi agents tested showed a significant reduction in ANGPTL3 protein at all time points, and similar trends are observed with respect to reductions in TG levels, levels of total cholesterol, and LDL levels. Example 11. In Vivo Testing of ANGPTL3 RNAi Agents in Mice.
[00288] [00288] To assess the dose response of ANGPTL3 ADOS5488 RNAi agent, female C57bl / 6 mice from six to eight weeks of age were used. Pre-dose serum samples were taken on day -1 after a four-hour fast. On day 1, each mouse was given an administration of 200 ul containing the respective mg / kg dose of an ANGPTL3 RNAi agent in D5W (dextrose in 5% water), or control (DSW) without an RNAi agent, according to with the dosing groups listed in Table 53: Table 53. Example Dosing Groups 11 with EA ren
[00289] The tested RNA agent (ADO5488) included a modified sequence and a targeting linker containing Nr-acetyl-galactosamine conjugated to the 5 'terminal end of the sense strand. (See tables 3, 4, and 5 for modified sequence structures and targeting linker). The injections were performed between the skin and the muscle (ie, subcutaneous injections) in the loose skin over the neck and shoulder area. Four (4) mice in each group were tested (n = 4). Serum was collected on days 8, 15, 22, and 29. The mice were fasted for four hours before each collection. The levels of ANGPTL3 protein in serum were measured by an ELISA assay (R&D Systems), according to the manufacturer's recommendations. Triglycerides, cholesterol! Total, high density lipoprotein (HDL), and low density lipoprotein (LDL) in serum were measured on a Cobas & Integra 400 (Roche Diagnostics), according to the manufacturer's recommendations.
[00290] [00290] ANGPTL3 protein levels, triglyceride levels, total cholesterol levels, HDL levels, and LDL levels for each animal have been normalized. For normalization, the protein level of ANGPTLS3, triglyceride, HDL, and cholesterol! total, respectively, for each animal at a time point, was divided by the level of pretreatment of expression in that animal (in this case on day -1) to determine the expression ratio "normalized for pretreatment." The expression, at a specific point in time, was then normalized for the DSW control group by dividing the "normalized for pretreatment" ratio for an individual animal by the average "normalized for pretreatment" ratio of all mice in the group DSW control This resulted in the expression for each time point normalized to that in the control group.
[00291] [00291] The data from the study mentioned in this Example are shown in the following Tables 54-58:
[00292] [00292] - Additionally, the MRPT levels of ANGPTL3 were also evaluated. All mice in each respective group were sacrificed on day 29 after serum collection, livers were collected, and approximately 100 mg of liver samples were collected and frozen in liquid nitrogen for RNA isolation. The MRPT levels of ANGPTL3 in the mouse livers were then measured by RT-qPCR, the results of which are set out in the following Table 59: Table 59. ANGPTL3 Mean mMRNA level on day 29, Normalized for Example 11 Control
[00293] [00293] As shown, among other things, in Tables 54 and 59, administration of ANGPTL3 RNAi agent ADO5488 showed a reduction in both ANGPTL3 protein and ANGPTLS3 MRNA. Example 12. In Vivo Testing of ANGPTL3 RNAi Agents in
[00294] [00294] To assess the effect of RNAi agent administration on a disease model, mice having a genetic mutation for the LDL receptor (referred to herein as LDLR KO mice) were commercially obtained (The Jackson Laboratory). LDLR KO mice are homozygous for the Ldlrimiter mutation, and have high serum cholesterol levels, particularly when placed on a high-fat diet. For three weeks before the study began, thirty-nine (39) LDLR KO mice were placed on a high-fat diet (Teklad Custom Diets TD.88137). An additional eight (8) LDLR KO mice were placed on a normal food diet during the same three-week period. Pre-dose serum samples were taken on day -15 and day -1 after a four-hour fast. On day 1, each mouse was given an administration of 200 μl / 30 g of the animal's body containing the respective mg / kg dose of an ANGPTL3 RNAi agent in D5W (dextrose in 5% water), control (DSW) no RNAi agent, or a control RNAi agent that included the nucleotide sequence designed to target the hepatitis B virus (HBV) genome. A second injection of the same formulation was administered to the animals on day 29. The dosage regimen for the study is recited in the following Table 60:
[00295] [00295] “Each mouse remained on their respective diet for the duration of the study. The tested RNAi agent (ADO5488) included a modified sequence and a targeting linker containing N-acetyl-galactosamine conjugated to the 5 'terminal end of the sense strand. (See tables 3, 4, and 5 for modified sequence structures and targeting linker). The injections were performed between the skin and the muscle (ie, subcutaneous injections) in the loose skin over the neck and shoulder area. Serum was collected on days 8, 15, 22, 29 (second pre-dose), 36, 43, 50, and 57. LDLR KO mice were fasted for four hours before each collection. On day 15, four (4) LDLR KO mice from Groups 1, 2, and 3 (ie, the groups being fed the "Western" high fat diet) were sacrificed after serum collection, and on day 29, plus four (4) LDLR KO mice from Groups 1, 2, and 3 were sacrificed after serum collection, for the purpose of performing mMRNA evaluations.
[00296] [00296] Protein levels of ANGPTL3 in serum were measured by ELISA assay (R&D Systems), according to the manufacturer's recommendations. Triglycerides, total cholesterol, high density lipoprotein (HDL), and low density lipoprotein (LDL) in serum were measured in a Cobas € Integra 400 (Roche Diagnostics), according to the manufacturer's recommendations.
[00297] [00297] ANGPTL3 protein levels, triglyceride levels, total cholesterol levels, HDL levels, and LDL levels for each animal have been normalized. For normalization, the respective protein levels of ANGPTL3, TG, cholesterol! total, HDL, or LDL for each animal at a time point was divided by the average pretreatment level of expression in that animal (in this case, the average of day -15 and day -1) to determine the "normalized expression ratio" for pre-treatment. "
[00298] [00298] The expression, at a specific point in time, was then normalized for the DSW control group that was administered the same diet (ie, either the "Western" high-fat diet or the normal food diet) dividing the "normalized to pretreatment" ratio for an individual animal by the average "normalized to pretreatment" ratio of all mice in the DSW control group in the respective group, resulting in expression for each time point normalized to that in the group of control.
[00299] [00299] The data of the study mentioned in this Example are shown in the following Tables 61 to 65:
[00300] [00300] “As shown in Tables 61 to 65, the groups dosed with 3.0 mg / kg of ANGPTL3 RNAi agent ADO5488 (ie Groups 2 and 5) showed significant reductions in ANGPTL3 protein levels, at levels of TG, and total cholesterol in this model. LDLR KO mice on a "Western" high-fat diet showed particularly low levels, with an approximately 99% reduction in ANGPTL3 protein levels on day 57 (0.007) compared to the control of two 3 mg doses. / kg of ANGPTL3 ADO5488 RNAi agent. It is also noted that Group 3, which included a control RNAi agent that included nucleotide sequences designed to target an HBV mMRNA, performed as expected and showed essentially no inhibition of ANGPTL3.
[00301] [00301] Additionally, MRPT levels of ANGPTL3 were also assessed. On day 15, four (4) mice were sacrificed from each of Groups 1, 2, and 3. On day 29, four (4) more mice were sacrificed from each of Groups 1,2, e3. On day 57, all remaining animals in all Groups were sacrificed. At sacrifice, livers were harvested, and approximately 100 mg of liver samples from the middle lobes were collected and frozen in liquid nitrogen for RNA isolation. The levels of MRPT of ANGPTL3 in the livers of mice were then measured by RT-gGPCR, and normalized to the levels of mRNA in the mice in Group 1 (Western high-fat diet; DSW administration; day 15, sacrifice), the results of which are set out in the following Table 66:
[00302] [00302] Administration of ANGPTL3 RNAi agent ADO5488 showed a significant reduction in the levels of MRPT of ANGPTL3 both in animals on the "Western" high-fat diet and in animals on the normal food diet. Example 13. In Vivo Testing of ANGPTL3 RNAi Agents in Rhesus Monkeys Fed Diet with High Fructose Corn Syrup (HFCS).
[00303] [00303] ANGPTL3 RNAi agent ADO5488 was also evaluated in Rhesus monkeys fed a high fructose corn syrup (HFCS) diet. Rhesus monkeys were placed on a HFCS diet 37 days before dosing. These animals were known to develop plasma triglycerides increased by more than 180 mg / dL in the HFCS diet. On day 1 and again on day 29, four (4) rhesus monkeys were administered with a subcutaneous injection containing 4.0 mg / kg of ANGPTL3 ADOS488 RNAi agent formulated in saline (n = 4). Two more rhesus monkeys were administered with normal saline control. The ANGPTL3 RNAi agent ADOS5488 contained modified nucleotides and included N-acetyl-galactosamine targeting ligands conjugated to the 5 'terminal end of the sense strand, as shown in Tables 3, 4, and 5.
[00304] [00304] Fasting blood samples were taken for analysis, and serum samples were analyzed on days -8 (pre-dose), 8, 15, 21, 29, and 36. The expression levels of ANGPTLS, triglycerides, colestero | Total, high density lipoprotein (HDL), and low density lipoprotein (LDL) in serum were measured on a Cobas € & Integra 400 (Roche Diagnostics), according to the manufacturer's recommendations.
[00305] [00305] ANGPTL3 protein levels, triglyceride levels, total cholesterol levels, HDL levels, and LDL levels for each animal have been normalized. For normalization, the protein level of
[00306] [00306] The data of the study mentioned in this Example are shown in the following Tables 67 to 71:
[00307] [00307] Reso monkeys dosed with ADO5488 at dosage levels of 4.0 mg / kg showed a significant reduction in ANGPTL3 protein compared to pretreatment measurements at each of the measured time points. In addition, reductions in triglyceride and cholesterol levels! total were evident. Example 14. In Vivo Testing of ANGPTL3 RNAi Agents and Statins in LDL Receptor Knockout (LDLR) Mice.
[00308] [00308] To evaluate the effect of co-administration of RNAi agents and statins on a disease model, LDLR KO mice were commercially obtained (The Jackson Laboratory). For three weeks before the start of the study, forty-one (41) male LDLR KO mice aged 7 to 8 weeks were placed on a high-fat (Western) diet (Teklad Custom Diets TD.88137), and kept on such a diet for the duration of the study. Pre-dose serum samples were taken on day 1 of the study after a four-hour fast. The Dosage regimen for the study is recited in the following Table 72: Table 72. Example Dosing Groups 14 Group | Dosing regimen and | Dosing regimen | Mice dose of atorvastatin and dose of | LDL KO (n =) Oral gavage of | DSW (without daily agent - starting | 23 on day 1 N / A Single injection of 2.5 2 mg / kg of ADO5488 | 7 en, | Po a mem nr am | oral atorvastatin | mg / kg of ADO5488 administered in day 23 daily - starting on day 1 20 mg / kg * oral gavage | Single injection of 2.5 atorvastatin / mg / kg of ADO5488 4 administered on day 23 6 daily - starting on day 1 10 mg / kg of gavage N / Atorvastatin oral administered 7 daily - starting
[00309] [00309] The vehicle used for oral gavage in the study was a 1: 1 mixture of Ora-Plus &: Ora-SweetO solution, which was purchased commercially. For the preparation of oral gavage administrations of atorvastatin, the respective desired dose of atorvastatin was first dissolved in sterile water (0.3 ml of water per 1 ml of the desired temperature) and vortexed until it became homogeneous by adding a 1: 1 mixture of Ora-Plus &: Ora-SweetO (0.7 mL vehicle per 1 mL of desired formulation) and vortexed. On day 1 and for each day thereafter, an oral gavage dose was administered to each of the Groups, except for Group 2. On day 23, Groups 1, 2, 3, and 4 received a single subcutaneous dose 2.5 mg / kg (31.25 ug / mL solution) of an ANGPTL3 RNAi agent in D5W (dextrose in 5% water), or vehicle control (DSW) without RNAi agent.
[00310] The tested RNA agent (ADO5488) included a modified sequence and a targeting linker containing Nr-acetyl-galactosamine conjugated to the 5 'terminal end of the sense strand. (See tables 3, 4, and 5 for modified sequence structures and targeting linker). The injections were performed between the skin and the muscle (ie, subcutaneous injections) in the loose skin over the neck and shoulder area. Serum was collected on days 8, 15, 22 (pre-RNAi injection Agent), 29, 36, 43, and 50. LDLR KO mice were fasted for four hours before each collection.
[00311] [00311] The levels of ANGPTL3 protein in serum were measured by ELISA assay (R&D Systems), according to the manufacturer's recommendations. Among other biomarkers, triglycerides, total cholesterol, and low density lipoprotein (LDL) in serum were measured on a Cobas & O Integra 400 (Roche Diagnostics), according to the manufacturer's recommendations.
[00312] [00312] ANGPTL3 protein levels, triglyceride levels, total cholesterol levels, HDL levels, and LDL levels for each animal have been normalized. For normalization, the respective protein levels of ANGPTL3, TG, cholesterol! total, or LDL for each animal at a time point were divided by the pre-treatment level of expression in that animal (in this case, pre-dose levels on day 1) to determine the "normalized expression for pre-treatment ratio. " The data for the study mentioned in this Example are shown in the following Tables 73 to 76:
[00313] [00313] Mice administered daily with atorvastatin showed approximately 40 to 60% reduction in triglycerides, approximately 23 to 40% reduction in total cholesterol, and approximately 30 to 45% reduction in LDL, respectively. Mice treated with higher doses of atorvastatin typically provided deeper reductions.
[00314] [00314] RNAi agent administration of ANGPTL3 ADOS5488 with co-administration of atorvastatin (ie Groups 3 and 4) showed additive effects on lipid parameters. For example, for groups that involved co-administration of atorvastatin and RNAi agent, total reductions in triglycerides, total cholesterol, and LDL, were 95%, 70%, and -80%, respectively. The profile of global lipid parameters with the co-administration of atorvastatin was slightly better than the administration of ANGPTL3 ADO5488 RNAi agent alone. In addition, Groups with ANGPTL3 RNAi agent ADOS488 showed a clear reduction in the levels of ANGPTL3 protein, while no reduction in the ANGPTL3 protein was observed in the groups that did not involve the administration of an ANGPTL3 RNAi agent. OTHER MODALITIES
[00315] [00315] It should be understood that while the invention has been described in conjunction with the detailed description thereof, the previous description is intended to illustrate and not to limit the scope of the invention, which is defined by the appended claims. Other aspects, advantages and modifications are in the scope of the following claims.

权利要求:
Claims (60)
[1]
1. RNAi agent for inhibiting the expression of an ANGPTL3 gene, characterized by the fact that it comprises: an antisense strip comprising at least 17 contiguous nucleotides that differ in O or 1 nucleotide from any of the sequences provided in Table 2 or Table 3 ; and a sense strand comprising the nucleotide sequence that is at least partially complementary to the antisense strand.
[2]
2. RNAi agent according to claim 1, characterized in that the antisense strip comprises nucleotides 2 to 18 of any of the sequences provided in Table 2 or Table 3.
[3]
RNAi agent according to claim 1 or 2, characterized in that the sense strand comprises the nucleotide sequence of at least 17 contiguous nucleotides that differ in O or 1 nucleotide from any of the sense strand sequences provided in Table 2 or Table 4, and where the sense tape has a region of at least 85% complementarity over the 17 nucleotides contiguous to the antisense tape.
[4]
RNAi agent according to any one of claims 1 to 3, characterized in that at least one RNAi agent nucleotide is a modified nucleotide or includes a modified internucleoside bond.
[5]
An RNAi agent according to any one of claims 1 to 3, characterized in that all or substantially all nucleotides of the RNAi agent sense and / or antisense strand are modified nucleotides.
[6]
An RNAi agent according to any one of claims 4 and 5, characterized in that the modified nucleotide is selected from the group consisting of: 2 "nucleotide -
O-methyl, 2'-fluorine nucleotide, 2'-deoxy nucleotide, 2 'mimic, 3-dry nucleotide, blocked nucleotide, 2'-F-arabino nucleotide, 2'-methoxyethyl nucleotide, abasic nucleotide, ribitol, inverted nucleotide, inverted 2'-O-methyl nucleotide, inverted 2'-deoxy nucleotide, modified 2'-amino nucleotide, modified 2'-alkyl nucleotide, morpholino nucleotide, vinyl phosphonate deoxyribonucleotide, and 3'-O-methyl nucleotide.
[7]
RNAi agent according to claim 5, characterized by the fact that all or substantially all of the modified nucleotides are 2'-O-methyl nucleotides and 2'-fluorine nucleotides.
[8]
An RNAi agent according to any one of claims 1 to 7, characterized in that the antisense strip comprises the nucleotide sequence of any of the modified antisense strip sequences provided in Table 3.
[9]
RNAi agent according to any one of claims 1 to 8, characterized in that the sense strand comprises the nucleotide sequence of any of the modified sense strand sequences provided in Table 4.
[10]
10. RNAi agent according to claim 1, characterized in that the antisense strip comprises the nucleotide sequence of any of the modified sequences provided in Table 3 and the sense strip comprises the nucleotide sequence of any of the modified sequences provided in Table 4.
[11]
11. RNAi agent according to any one of claims 1 to 10, characterized in that the RNAi agent is linked to a targeting linker.
[12]
12. RNAi agent according to claim 11, characterized in that the targeting linker comprises n-acetyl-galactosamine.
[13]
13. RNAi agent according to claim 11 or 12, characterized in that the targeting ligand comprises a structure selected from the group consisting of: (NAG13), (NAG13) s, (NAG18), (NAG18) s , (NAG24), (NAG24) s, (NAG25), (NAG25) s, (NAG26), (NAG26) s, (NAG27), (NAG27) s, (NAG28), (NAG28) s, (NAG29), (NAG29) s, (NAG30), (NAG30) s, (NAG31), (NAG31) s, (NAG32), (NAG32) s, (NAG33), (NAG33) s, (NAG34), (NAG34) s, (NAG35), (NAG35) s, (NAG36), (NAG36) s, (NAG37), (NAG37) s, (NAG38), (NAG38) s, (NAG39), (NAG39) s.
[14]
14. RNAi agent according to claim 13, characterized in that the targeting ligand comprises the structure of (NAG37) or (NAG37) s.
[15]
15. RNAi agent according to any one of claims 11 to 14, characterized in that the targeting ligand is attached to the sense strand.
[16]
16. RNAi agent according to claim 15, characterized in that the targeting ligand is attached to the 5 'terminal end of the sense strand.
[17]
17. RNAi agent according to any one of claims 1 to 16, characterized in that the sense strand is between 18 and 30 nucleotides in length, and the antisense strand is between 18 and 30 nucleotides in length.
[18]
18. RNAi agent according to claim 17, characterized by the fact that the sense tape and the antisense tape are each between 18 and 27 nucleotides in length.
[19]
19. RNAi agent according to claim 18, characterized in that the sense and antisense strips are each between 18 and 24 nucleotides in length.
[20]
20. RNAi agent according to claim 19,
characterized by the fact that the sense tape and the antisense tape are each 21 nucleotides in length.
[21]
21. RNAi agent according to any one of claims 17 to 20, characterized in that the RNAi agent has two blunt ends.
[22]
22. RNAi agent according to any one of claims 1 to 21, characterized in that the sense strand comprises one or two terminal plugs.
[23]
23. RNAi agent according to any one of claims 1 to 22, characterized in that the sense strand comprises one or two inverted abasic residues.
[24]
24. RNAi agent according to claim 1, characterized in that the RNAi agent is comprised of a sense tape and an antisense tape that form a duplex having the structure of any of the duplexes in Table 5.
[25]
25. An RNAi agent according to claim 1, characterized in that it comprises an antisense strip consisting of, consists essentially of, or comprises a nucleotide sequence that differs in O or 1 nucleotide from one of the following nucleotide sequences ( 5 '> 3 "): UACUGAUCAAAUAUGUUGAGC (SEQ ID NO: 3); UACUGAUCAAAUAUGUUGAGU (SEQ ID NO: 6); UUUGAAUUAAUGUCCAUGGGC (SEQ ID NO: 8); UUUGAAUUAAUGUCCAUGGGA (SEA ID: NO; ), or ACAUCGUCUAACAUAGCAACC (SEQ | D NO: 15).
[26]
26. RNAi agent according to claim 25, characterized in that the sense strand consists of, consists essentially of, or comprises a nucleotide sequence that differs in O or 1 nucleotide from one of the following nucleotide sequences (5 '3 3 '): GCUCAACAUAUUUGAUCAGUA (SEQ ID NO: 17); GCUCAACAU (A PNJUUUGAUCAGUA (SEQ ID NO: 19), where (A N) represents a 2-aminoadenosine nucleotide; GCUCAAC (APN) JU (APNJUUUGAUCAGUA (SEQ ID NO: 21), where (AN) represents a 2-aminoadenosine nucleotide; ACUCAACAUAUUUGAUCAGUA (SEQ | D NO: 24); GCCCAUGGACAUUVAAUUCAAA (SEQ ID NO: 26); ACCCAUGGACAUUAAUUCAAA (SEQ ID NO: 28); UCCAUGGACAUU (SEA ID: 30) 32).
[27]
27. An RNAi agent according to claim 25 or 26, characterized in that all or substantially all nucleotides are modified nucleotides.
[28]
28. RNAi agent according to claim 25 or 26, characterized in that the sense stripe further includes abasic residues inverted at the 3 'terminal end of the nucleotide sequence, at the 5' end of the nucleotide sequence, or both.
[29]
29. An RNAi agent according to claim 1, characterized in that it comprises an antisense strip comprising, consisting of, or consisting essentially of a modified nucleotide sequence that differs in O or 1 nucleotide from one of the following nucleotide sequences (5 '> 3'): usAfscsUfgAfuCfaAfaUfaUufgUufuGfaGfsc (SEQ ID NO: 2); usAfscUfgAfuCfaAfaUfaUfgufuGfasGfsc (SEQ ID NO: 4); usAfscsUfgAfuCfaAfaUfaUfgufuGfaGfsu (SEQ ID NO: 5); usUfsusGfaAfuUfaAfuGfuCfcAfuGfggsc (SEQ ID NO: 7); usUfsusGfaAfuUfaAfuGfuCfcAfuGfgGfsu (SEQ ID NO: 9); usGfsusugaauuaaUfgUufcCfaUfgGfsa (SEQ ID NO: 11);
usGfsusUfgAfaUfuAfaUfgUfcCfaUfgGisa (SEQ ID NO: 13); or asCfsasUfcGfucuaaCfaUfaGfcAfaCfsc (SEQ ID NO: 14); wherein a, c, g, and u represent 2'-O-methyl adenosine, cytidine, guanosine, or uridine, respectively; Af, Cf, Gf, and Uf represent 2 "” - fluorine adenosine, cytidine, y guanosine, or uridine, respectively; s represents a phosphorothioate bond; and where all or substantially all of the nucleotides in the sense strand are modified nucleotides.
[30]
30. An RNAi agent according to claim 32, characterized in that the sense strand comprises, consists of, or consists essentially of a modified nucleotide sequence that differs in O or 1 nucleotide from one of the following nucleotide sequences (5 '> 3 "): gcucaacaUfAfUfuugaucagua (SEQ ID NO: 16); gcucaacaUfa 2NUfuugaucagua (SEQ ID NO: 18); gcucaaca 2NUfa 2NUfuugaucagua (SEQ ID NO: 20); geUfcAfaCfaUfAfUfuugaucagua (SEQ IDU: 22); : 23); gccecauggAfCfAfuuaauucaaa (SEQ ID NO: 25); acccauggAfCfAfuuaauucaaa (SEQ ID NO: 27); uccauggaCfAfUfuaauucaaca (SEQ ID NO: 29); or gguugcuaUfGfUfuagacugu (NO, g; represent 2'-O-methyl adenosine, cytidine, guanosine, or uridine, respectively; Af, Cf, Gf, and Uf represent 2 "'- fluorine adenosine, cytidine, y guanosine, or uridine, respectively; s represents a phosphorothioate bond; 2N represents 2'-O-methyl-2-aminoadenosine; and wherein all or substantially all of the nucleotides in the sense strand are modified nucleotides.
TIN
[31]
31. An RNAi agent according to any one of claims 25 to 30, characterized in that the sense stripe further includes abasic residues inverted at the 3 'end of the nucleotide sequence, at the 5' end of the nucleotide sequence, or in both.
[32]
32. RNAi agent according to any one of claims 25 to 31, characterized in that the RNAi agent sense strand is attached to a targeting ligand.
[33]
33. RNAi agent according to claim 32, characterized by the fact that the targeting ligand has affinity for the asialoglycoprotein receptor.
[34]
34. The RNAi agent according to claim 33, characterized in that the targeting linker comprises N-acetyl-galactosamine.
[35]
35. RNAi agent according to claim 1, characterized in that the RNAi agent has the duplex structure selected from the group consisting of: ADOS488 (SEQ ID NOs: 2 and 300) and ADO5775 (SEQ ID NOs: 2 and 334); ADO5791 (SEQ ID NOs: 4 and 300); ADOS5777 (SEQ ID NOs: 2 and 336); ADO5743 (SEQ ID NOs: 2 and 326); ADOS487 (SEQ ID NOs: 5 and 299); ADO5307 (SEQ ID NOs: 7 and 278); ADOS5418 (SEQ ID NOs: 9 and 292); ADOS5577 (SEQ ID NOs: 11 and 279); ADOS5308 (SEQ ID NOs: 13 and 279); and ADOS5840 (SEQ ID NOs: 15 and 357).
[36]
36. RNAi agent according to claim 35, characterized in that the RNAi agent has the duplex structure selected from the group consisting of: ADOS488 (SEQ ID NOs: 2 and 300) and ADO5775 (SEQ ID NOs: 2 and 334).
[37]
37. Composition, characterized by the fact that it comprises RNAi agent as defined in any one of claims 1 to 36, wherein the composition comprises a pharmaceutically acceptable excipient.
[38]
38. Composition according to claim 37, characterized in that it further comprises a second RNAi agent for inhibiting ANGPTL3 expression.
[39]
39. Composition according to claim 37 or 38, characterized in that it further comprises one or more additional therapies.
[40]
40. Method for inhibiting the expression of an ANGPTL3 gene in a cell, characterized in that the method comprises introducing into an cell an effective amount of an RNAi agent as defined in any of claims 1 to 36 or composition as defined in any of claims 37 to 39.
[41]
41. Method according to claim 40, characterized by the fact that the cell is within an individual.
[42]
42. Method according to claim 41, characterized by the fact that the individual is a human individual.
[43]
43. The method of any one of claims 40 to 42, characterized in that the expression of the ANGPTL3 gene is inhibited by at least about 30%.
[44]
44. Method of treating an ANGPTL3-related disorder or disease, characterized in that the method comprises administering to a human subject in need thereof a therapeutically effective amount of the composition as defined in any of claims 37 to 39.
[45]
45. Method according to claim 44, characterized by the fact that the disease is a cardiometabolic disease.
[46]
46. Method according to claim 44, characterized by the fact that the disease is hypertriglyceridemia, obesity, hyperlipidemia, abnormal cholesterol and / or lipid metabolism, atherosclerosis, type II diabetes mellitus, cardiovascular disease, coronary artery disease, steato- non-alcoholic hepatitis, non-alcoholic fatty liver disease, homozygous and heterozygous familial hypercholesterolemia, or statin-resistant hypercholesterolemia.
[47]
47. Method according to any of claims 40 to 46, characterized in that the RNAi agent is administered in a dose of about 0.05 mg / kg to about 5.0 mg / kg of the individual's body weight human.
[48]
48. Method according to any one of claims 40 to 47, characterized in that the RNAi agent is administered in two or more doses.
[49]
49. A method of decreasing triglyceride levels in an individual, characterized in that it comprises administering to the individual an effective amount of a composition as defined in any one of claims 37 to 39.
[50]
50. A method of decreasing cholesterol levels in an individual, characterized in that the method comprises administering to the individual an effective amount of a composition as defined in any of claims 37 to 39.
[51]
51. A method of decreasing low density lipoprotein (LDL) levels in an individual, characterized in that the method comprises administering to the individual an effective amount of a composition as defined in any of claims 37 to 39.
[52]
52. Method according to any one of claims 44 to 51, characterized in that the method further comprises the administration of a statin.
[53]
53. Method according to claim 52, characterized by the fact that the statin is selected from the group consisting of: atorvastatin, fluvastatin, pravastatin, pitavastatin, rosuvastatin, and simvastatin.
[54]
54. Use of an RNAi agent as defined in any one of claims 1 to 36 or a composition as defined in any one of claims 37 to 39, for the treatment of a disease, disorder or symptom that is mediated at least in part by expression of ANGPTL3 gene.
[55]
55. Use according to claim 54, characterized by the fact that the symptom is elevated triglyceride levels and / or elevated cholesterol levels.
[56]
56. Use of an RNAi agent as defined in any of claims 1 to 36 or composition as defined in any of claims 37 to 39, characterized in that it is for the preparation of pharmaceutical compositions for the treatment of a disease, disorder or symptom that is mediated at least in part by the expression of the ANGPTL3 gene.
[57]
57. Use according to any of claims 54 to 56, characterized in that the disease is hypertriglyceridemia, obesity, hyperlipidemia, abnormal cholesterol and / or lipid metabolism, atherosclerosis, type 1 diabetes mellitus, cardiovascular disease, coronary artery, non-alcoholic steatohepatitis, non-alcoholic fatty liver disease, homozygous and heterozygous familial hypercholesterolemia, or statin-resistant hypercholesterolemia.
[58]
58. Use according to any one of claims 54 to 56, characterized by the fact that the disease is a cardiometabolic disease.
[59]
59. Use according to any of claims 54 to 58, characterized in that the RNAi agent is administered in a dose of about 0.05 mg / kg to about 5.0 mg / kg of the individual's body weight human.
[60]
60. Use according to any of claims 54 to 59, characterized in that the levels of triglycerides, cholesterol levels, and / or levels of low density lipoprotein (LDL) in the individual are decreased.

类似技术:

---

公开号 | 公开日 | 专利标题

---

BR112020003126A2|2020-10-13|rnai agents and compositions for inhibiting the expression of angiopoietin type 3 |, and methods of use

---

US10662427B2|2020-05-26|Compositions and methods for inhibiting gene expression of LPA

---

US20160272970A1|2016-09-22|RNA Interference Agents

---

US11214801B2|2022-01-04|RNAi agents and compositions for inhibiting expression of apolipoprotein C-III |

---

CN110268060A|2019-09-20|α -1 antitrypsin | RNAi substance, composition and application method comprising AAT RNAi substance

---

CN110234326A|2019-09-13|Composition and method for inhibiting factor XII gene expression

---

KR20210061380A|2021-05-27|RNAi agents for inhibiting the expression of 17beta-HSD type 13- |, compositions thereof, and methods of use

---

US20130210903A1|2013-08-15|Aptamers to glycoprotein vi

---

JP2020537653A|2020-12-24|RNAi agents and compositions for inhibiting the expression of asialoglycoprotein receptor 1

---

JP2020526192A|2020-08-31|RNAi agents for inhibiting the expression of alpha-ENaC and how to use them

---

Hartmann et al.0|view abstracts from the meeting-Oligonucleotide Therapeutics...

---

Corey et al.0|view abstracts from the meeting-Oligonucleotide Therapeutics...

同族专利:

---

公开号 | 公开日

---

ECSP20018305A|2020-06-30|

---

EP3681513A4|2021-09-22|

---

CO2020001740A2|2020-05-29|

---

CA3074320A1|2019-03-21|

---

TW201922264A|2019-06-16|

---

CN111343994A|2020-06-26|

---

US10995335B2|2021-05-04|

---

AU2018331383A1|2020-04-23|

---

KR20200044837A|2020-04-29|

---

JOP20200050A1|2019-03-14|

---

SG11201912188RA|2020-01-30|

---

IL273173D0|2020-04-30|

---

WO2019055633A1|2019-03-21|

---

PE20201287A1|2020-11-24|

---

JP2020534268A|2020-11-26|

---

US20190078089A1|2019-03-14|

---

CL2020000666A1|2020-08-14|

---

PH12020500309A1|2021-01-25|

---

UY37881A|2019-03-29|

---

EP3681513A1|2020-07-22|

---

US20210238602A1|2021-08-05|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

US4522811A|1982-07-08|1985-06-11|Syntex Inc.|Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides|

---

NL9201440A|1992-08-11|1994-03-01|Univ Leiden|Triantennary cluster glycosides, their preparation and application.|

---

US5998203A|1996-04-16|1999-12-07|Ribozyme Pharmaceuticals, Inc.|Enzymatic nucleic acids containing 5'-and/or 3'-cap structures|

---

MXPA01009073A|1999-03-10|2002-05-06|Phogen Ltd|Delivery of substances to cells.|

---

CZ20021853A3|1999-12-09|2002-11-13|Sankyo Company, Limited|method of testing effect of a substance, polynucleotide, DNA, antibody, kit for testing, use of the polynucleotide, use of a polypeptide, use of the antibody, RNA and therapeutic agent|

---

KR20100029861A|2001-11-16|2010-03-17|제넨테크, 인크.|Composition comprising and method of using angiopoietin-like protein 3 angptl3|

---

JP2006507841A|2002-11-14|2006-03-09|ダーマコン，インコーポレイテッド|Functional and ultrafunctional siRNA|

---

WO2006006948A2|2002-11-14|2006-01-19|Dharmacon, Inc.|METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY|

---

US20040198640A1|2003-04-02|2004-10-07|Dharmacon, Inc.|Stabilized polynucleotides for use in RNA interference|

---

US20040224405A1|2003-05-06|2004-11-11|Dharmacon Inc.|siRNA induced systemic gene silencing in mammalian systems|

---

MX2009001207A|2006-08-18|2009-02-11|Hoffmann La Roche|Polyconjugates for in vivo delivery of polynucleotides.|

---

JP5519523B2|2007-12-04|2014-06-11|アルニラムファーマスーティカルズインコーポレイテッド|Carbohydrate conjugates as oligonucleotide delivery agents|

---

AU2010324658A1|2009-11-26|2012-05-03|Quark Pharmaceuticals, Inc.|siRNA compounds comprising terminal substitutions|

---

CA2786071C|2010-01-08|2021-01-12|Isis Pharmaceuticals, Inc.|Modulation of angiopoietin-like 3 expression|

---

KR101956623B1|2010-02-24|2019-03-12|애로우헤드 파마슈티컬스 인코포레이티드|Compositions for Targeted Delivery of siRNA|

---

DK2632472T3|2010-10-29|2018-03-19|Sirna Therapeutics Inc|RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS |

---

US8501930B2|2010-12-17|2013-08-06|Arrowhead Madison Inc.|Peptide-based in vivo siRNA delivery system|

---

EP3656860A1|2011-06-21|2020-05-27|Alnylam Pharmaceuticals, Inc.|Angiopoietin-like 3 irna compositions and methods of use thereof|

---

KR20140051357A|2011-08-26|2014-04-30|애로우헤드 리서치 코오포레이션|Poly polymers for in vivo nucleic acid delivery|

---

US9796974B2|2011-11-18|2017-10-24|Alnylam Pharmaceuticals, Inc.|Modified RNAi agents|

---

AU2012377385A1|2012-04-18|2014-01-23|Arrowhead Research Corporation|Poly polymers for in vivo nucleic acid delivery|

---

EP3919620A1|2012-05-02|2021-12-08|Sirna Therapeutics, Inc.|Short interfering nucleic acid compositions|

---

US20170037409A1|2013-12-24|2017-02-09|Ionis Pharmaceuticals, Inc.|Modulation of angiopoietin-like 3 expression|

---

DK3137605T3|2014-05-01|2020-12-14|Ionis Pharmaceuticals Inc|COMPOSITIONS AND METHODS FOR MODULATING ANGIOPOIETIN-LIKE-3 EXPRESSION|

---

SG11201701166UA|2014-08-20|2017-03-30|Alnylam Pharmaceuticals Inc|Modified double-stranded rna agents|

---

CA2979998A1|2015-03-20|2016-09-29|Protiva Biotherapeutics, Inc.|Compositions and methods for treating hypertriglyceridemia|

---

KR20170135932A|2015-04-13|2017-12-08|알닐람 파마슈티칼스 인코포레이티드|Angiopoietin-like 3 IRNA compositions and methods for their use|

---

MA43347A|2015-10-01|2018-08-08|Arrowhead Pharmaceuticals Inc|COMPOSITIONS AND METHODS TO INHIBIT LPA GENE EXPRESSION|

---

WO2017156012A1|2016-03-07|2017-09-14|Arrowhead Pharmaceuticals, Inc.|Targeting ligands for therapeutic compounds|

---

MA45340A|2016-04-01|2019-02-06|Avidity Biosciences Llc|ANDROGEN RECEPTOR NUCLEIC ACIDS AND THEIR USES|

---

WO2018044350A1|2016-09-02|2018-03-08|Arrowhead Pharmaceuticals, Inc|Targeting ligands|WO2018044350A1|2016-09-02|2018-03-08|Arrowhead Pharmaceuticals, Inc|Targeting ligands|

---

WO2021030522A1|2019-08-13|2021-02-18|Alnylam Pharmaceuticals, Inc.|SMALL RIBOSOMAL PROTEIN SUBUNIT 25iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF|

---

TW202132567A|2019-11-01|2021-09-01|美商阿尼拉製藥公司|Huntingtinirna agent compositions and methods of use thereof|

---

TW202132568A|2019-11-13|2021-09-01|美商阿尼拉製藥公司|Methods and compositions for treating an angiotensinogen-associated disorder|

---

WO2021119226A1|2019-12-13|2021-06-17|Alnylam Pharmaceuticals, Inc.|Human chromosome 9 open reading frame 72irna agent compositions and methods of use thereof|

---

TW202138559A|2019-12-16|2021-10-16|美商阿尼拉製藥公司|Patatin-like phospholipase domain containing 3irna compositions and methods of use thereof|

---

WO2021167841A1|2020-02-18|2021-08-26|Alnylam Pharmaceuticals, Inc.|Apolipoprotein c3irna compositions and methods of use thereof|

---

WO2021178607A1|2020-03-05|2021-09-10|Alnylam Pharmaceuticals, Inc.|Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases|

---

WO2021178736A1|2020-03-06|2021-09-10|Alnylam Pharmaceuticals, Inc.|KETOHEXOKINASEiRNA COMPOSITIONS AND METHODS OF USE THEREOF|

---

WO2021188611A1|2020-03-18|2021-09-23|Alnylam Pharmaceuticals, Inc.|Compositions and methods for treating subjects having a heterozygous alanine-glyoxylate aminotransferase genevariant|

---

WO2021188795A1|2020-03-18|2021-09-23|Dicerna Pharmaceuticals, Inc.|Compositions and methods for inhibiting angptl3 expression|

---

WO2021195307A1|2020-03-26|2021-09-30|Alnylam Pharmaceuticals, Inc.|Coronavirus irna compositions and methods of use thereof|

---

WO2021206922A1|2020-04-07|2021-10-14|Alnylam Pharmaceuticals, Inc.|Transmembrane serine protease 2irna compositions and methods of use thereof|

---

WO2021206917A1|2020-04-07|2021-10-14|Alnylam Pharmaceuticals, Inc.|ANGIOTENSIN-CONVERTING ENZYME 2iRNA COMPOSITIONS AND METHODS OF USE THEREOF|

---

WO2021222065A1|2020-04-27|2021-11-04|Alnylam Pharmaceuticals, Inc.|Apolipoprotein eirna agent compositions and methods of use thereof|

---

WO2021222549A1|2020-04-30|2021-11-04|Alnylam Pharmaceuticals, Inc.|Complement factor birna compositions and methods of use thereof|

---

WO2021252557A1|2020-06-09|2021-12-16|Alnylam Pharmaceuticals, Inc.|Rnai compositions and methods of use thereof for delivery by inhalation|

---

WO2021257782A1|2020-06-18|2021-12-23|Alnylam Pharmaceuticals, Inc.|XANTHINE DEHYDROGENASEiRNA COMPOSITIONS AND METHODS OF USE THEREOF|

法律状态:
2021-11-23| B350| Update of information on the portal [chapter 15.35 patent gazette]|

优先权:

---

申请号 | 申请日 | 专利标题

---

US201762558819P| true| 2017-09-14|2017-09-14|

---

US62/558,819|2017-09-14|

---

US201762583919P| true| 2017-11-09|2017-11-09|

---

US62/583,919|2017-11-09|

---

US201862651284P| true| 2018-04-02|2018-04-02|

---

US62/651,284|2018-04-02|

---

US201862694976P| true| 2018-07-07|2018-07-07|

---

US62/694,976|2018-07-07|

---

PCT/US2018/050848|WO2019055633A1|2017-09-14|2018-09-13|Rnai agents and compositions for inhibiting expression of angiopoietin-like 3 , and methods of use|

---